metoclopramide has been researched along with Nausea in 534 studies
Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.
metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.
Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the clinical efficacy of prophylactic metoclopramide in reducing the incidence of nausea and vomiting in emergency department (ED) patients with acute pain who were treated with intravenous tramadol." | 9.69 | The efficacy of prophylactic metoclopramide in preventing nausea and vomiting in patients with acute pain treated with intravenous tramadol: a randomized double-blinded, placebo-controlled trial. ( Lokeskrawee, T; Patumanond, J; Phinyo, P; Sriwiset, H; Wongyikul, P, 2023) |
| "To assess and confirm the effect of ondansetron on behavior suggestive of nausea in dogs with vestibular syndrome." | 9.51 | Ondansetron in dogs with nausea associated with vestibular disease: A double-blinded, randomized placebo-controlled crossover study. ( Charalambous, M; Elliott, J; Foth, S; Henze, L; Kenward, H; Meller, S; Pelligand, L; Twele, F; Volk, HA, 2022) |
| " The EMPOWER (EMesis in Pregnancy – Ondansetron With mEtoClopRamide) trial aimed to compare the clinical effectiveness and cost-effectiveness of two anti-sickness drugs [metoclopramide (metoclopramide hydrochloride, Actavis UK Ltd, Barnstable, UK; IV Ratiopharm GmbH, Ulm, Germany) and ondansetron (ondansetron hydrochloride dehydrate, Wockhardt UK Ltd, Wrexham, UK; IV Hameln Pharma plus GmbH, Hameln)] for the treatment of nausea and vomiting in pregnancy." | 9.41 | Ondansetron and metoclopramide as second-line antiemetics in women with nausea and vomiting in pregnancy: the EMPOWER pilot factorial RCT. ( Campbell, I; Fernandez-Garcia, C; Goudie, N; Graham, R; Howel, D; Lie, M; McColl, E; McParlin, C; Mossop, H; Nadeem, A; Nelson-Piercy, C; O'Hara, ME; Phillipson, J; Robson, S; Shehmar, M; Simpson, N; Steel, A; Ternent, L; Tuffnell, D; Williams, R, 2021) |
| " Maropitant (MRP) and metoclopramide (MCP) prevent emesis attributable to the opioid agent apomorphine in dogs." | 9.24 | A comparison between maropitant and metoclopramide for the prevention of morphine-induced nausea and vomiting in dogs. ( Himelfarb, MA; Invaldi, SH; Litterio, NJ; Lorenzutti, AM; Martín-Flores, M; Zarazaga, MP, 2017) |
| " The aim of this study was to verify if A + D is superior to metoclopramide plus dexamethasone (M + D) in preventing delayed emesis in cancer patients receiving the same prophylaxis for acute emesis." | 9.20 | Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study. ( Angelelli, L; Ballatori, E; Caserta, C; Cavanna, L; Ciuffreda, L; Colantonio, I; Fasola, G; Fatigoni, S; Fava, S; Ionta, MT; Licitra, L; Massidda, B; Mirabile, A; Palladino, MA; Roila, F; Ruggeri, B; Tocci, A; Zerilli, F, 2015) |
| "We compare efficacy of ondansetron and metoclopramide with placebo for adults with undifferentiated emergency department (ED) nausea and vomiting." | 9.19 | Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo. ( Braitberg, G; Egerton-Warburton, D; Mee, MJ; Meek, R, 2014) |
| " The granisetron group indicated a higher complete response rate in acute emesis (adjusted OR: 0." | 9.17 | Can granisetron injection used as primary prophylaxis improve the control of nausea and vomiting with low- emetogenic chemotherapy? ( Abdul Kassim, MS; Keat, CH; Phua, G; Poh, WK; Sriraman, M, 2013) |
| "During the 72-h observation period, 39 out of 56 (70%) patients receiving olanzapine had no emesis compared to 16 out of 52 (31%) patients with no emesis for patients receiving metoclopramide (p < 0." | 9.17 | The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. ( Gray, SE; Nagy, CK; Navari, RM, 2013) |
| "To compare the effects of metoclopramide infusion in emergency department (ED) patients complaining of nausea to determine the changes in its therapeutic effect and prevention of side effects such as akathisia and sedation." | 9.16 | Slow infusion metoclopramide does not affect the improvement rate of nausea while reducing akathisia and sedation incidence. ( Aydin, B; Erdur, B; Parlak, I; Tura, P; Turkcuer, I, 2012) |
| "To compare the efficacy of acupressure wrist bands, ondansetron, metoclopramide and placebo in the prevention of vomiting and nausea after strabismus surgery." | 9.15 | Comparing the efficacy of prophylactic p6 acupressure, ondansetron, metoclopramide and placebo in the prevention of vomiting and nausea after strabismus surgery. ( Arbabi, S; Ebrahim Soltani, AR; Goudarzi, M; Mohammadinasab, A; Mohammadinasab, F; Mohammadinasab, H; Samimi, M, 2011) |
| "We aimed to compare the relative efficacy of tropisetron and metoclopramide in treating nausea/vomiting in undifferentiated ED patients." | 9.15 | Tropisetron versus metoclopramide for the treatment of nausea and vomiting in the emergency department: A randomized, double-blinded, clinical trial. ( Chae, J; Frauman, AG; Taylor, DM, 2011) |
| "This study assesses the effects of ginger on nausea and vomiting caused by pregnancy and compares it with metoclopramide medicine." | 9.15 | Comparing the effects of ginger and metoclopramide on the treatment of pregnancy nausea. ( Farhadifar, F; Mohammadbeigi, R; Rezaiie, M; Shahgeibi, S; Soufizadeh, N, 2011) |
| " Patients who presented to our emergency department with a primary or secondary chief complaint of nausea were randomized to one of the following 4 groups: (1) metoclopramide 10 mg+diphenhydramine 25 mg; (2) metoclopramide 10 mg+placebo; (3) metoclopramide 20 mg+diphenhydramine 25 mg; (4) metoclopramide 20 mg+placebo." | 9.14 | A randomized trial of diphenhydramine as prophylaxis against metoclopramide-induced akathisia in nauseated emergency department patients. ( Bender, B; Bijur, P; Davitt, M; Esses, D; Friedman, BW; Gallagher, EJ; Paternoster, J; Solorzano, C, 2009) |
| "Of the 380 patients evaluated, significantly fewer ondansetron 4 mg treated patients (89/189; 47%) experienced postoperative nausea and/or vomiting compared with metoclopramide treated patients (115/ 191; 60%) during the study period (p = 0." | 9.13 | Ondansetron vs. metoclopramide for the prevention of nausea and vomiting after gynecologic surgery. ( Diregpoke, S; Krobbuaban, B; Pitakpol, S, 2008) |
| "The aim of this study was to compare the incidence of nausea and vomiting in patients with acute pain treated with morphine along with prophylactic metoclopramide or placebo." | 9.12 | Use of a prophylactic antiemetic with morphine in acute pain: randomised controlled trial. ( Bradshaw, M; Sen, A, 2006) |
| "This study demonstrates that betamethasone does not prevent nausea, vomiting and increase of vasopressin induced by apomorphine, whereas metoclopramide prevents apomorphine-induced emesis." | 9.12 | Betamethasone does not prevent nausea and vomiting induced by the dopamine-agonist apomorphine. ( Axelsson, P; Lövqvist, A; Thörn, SE; Wattwil, L; Wattwil, M, 2006) |
| "A prospective randomized study was performed to assess the value of some individual risk factors for postoperative nausea and vomiting (PONV), and to compare the efficacy of ondansetron, metoclopramide, dexamethason, and combinations of these antiemetics in preventing PONV in patients after laparoscopic cholecystectomy." | 9.12 | Ondansetron, metoclopramid, dexamethason, and their combinations compared for the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: a prospective randomized study. ( Leksowski, K; Peryga, P; Szyca, R, 2006) |
| "To determine whether intermediate dose metoclopramide is more effective than standard dose metoclopramide for patients who present to the ED with nausea and vomiting." | 9.11 | Intermediate dose metoclopramide is not more effective than standard dose metoclopramide for patients who present to the emergency department with nausea and vomiting: a pilot study. ( Basire, M; Cham, S; Kelly, AM, 2004) |
| "Aim of this study was to demonstrate that intravenous metoclopramide can reduce pain, nausea and discomfort during nasogastric tube (NGT) insertion in ED." | 9.11 | Effectiveness of pre-emptive metoclopramide infusion in alleviating pain, discomfort and nausea associated with nasogastric tube insertion: a randomised, double-blind, placebo-controlled trial. ( Karaca, MA; Ozucelik, DN; Sivri, B, 2005) |
| "Metoclopramide pretreatment provided protection against nausea and cramping associated with estrogen/progestin emergency contraception." | 9.10 | Metoclopramide pretreatment attenuates emergency contraceptive-associated nausea. ( Buck, HW; Ragan, RE; Rock, RW, 2003) |
| " The number of patients who were emesis free (no nausea, retching, or vomiting) was significantly higher in patients who received granisetron (88% [2225]) than in those who received droperidol (64% [1625]; P = 0." | 9.10 | A comparison of granisetron, droperidol, and metoclopramide in the treatment of established nausea and vomiting after breast surgery: a double-blind, randomized, controlled trial. ( Fujii, Y; Kawasaki, T; Tanaka, H, 2003) |
| "The results obtained showed that ondansetron was more effective in controlling nausea and vomiting than metoclopramide, either objectively (2." | 9.10 | Comparison of ondansetron with metoclopramide in the symptomatic relief of uremia-induced nausea and vomiting. ( Bagatin, J; Hozo, I; Ljutić, D; Perković, D; Pivac, N; Rumboldt, Z, 2002) |
| "Several studies have confirmed the efficacy of high-dose metoclopramide and, more recently, serotonin antagonists, with and without dexamethasone, in the prophylaxis of cisplatin-induced nausea and vomiting." | 9.09 | Prospective randomized comparison of tropisetron with and without dexamethasone against high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. ( Hussain, M; Khan, Z; Malik, I; Moid, I, 1999) |
| ") doses of ondansetron 8 mg, ondansetron 16 mg and metoclopramide 10 mg in the treatment of opioid-induced emesis." | 9.09 | Ondansetron is more effective than metoclopramide for the treatment of opioid-induced emesis in post-surgical adult patients. Ondansetron OIE Post-Surgical Study Group. ( Alahuta, S; Chung, F; Curtis, P; Duvaldestin, P; Jacka, M; Lane, R; Luttropp, HH; McQuade, B; Rocherieux, S; Roy, M; Spraggs, C, 1999) |
| "Complete control of established postoperative nausea and vomiting, defined as no emesis and no need for another rescue antiemetic medication, was more frequent among the patients who had received granisetron (88%) than among those who had received droperidol (55%) or metoclopramide (50%) (P <." | 9.09 | Granisetron, droperidol, and metoclopramide for the treatment of established postoperative nausea and vomiting in women undergoing gynecologic surgery. ( Fujii, Y; Somekawa, Y; Tanaka, H, 2000) |
| "The serotonin (5HT3) antagonist ondansetron was compared in a randomised study with metoclopramide and dexamethasone for the prevention of chemotherapy induced emesis." | 9.08 | Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis. ( Dick, GS; Meller, ST; Pinkerton, CR, 1995) |
| "Metoclopramide was significantly more effective at preventing both nausea and vomiting (20/44 (45%) compared with 32/47 (68%), p < 0." | 9.08 | Prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy. A prospective randomized study of metoclopramide and transdermal hyoscine. ( Appelgren, L; Haglind, E; Thune, A, 1995) |
| "Successful control of vomiting was achieved in the first 24 hours, in 74% of the cycles containing cisplatin and 82% of the cycles without cisplatin, if ondansetron was used." | 9.08 | Ondansetron in chemotherapy-induced emesis. Our experience. ( Bandiera, AF; Fiorelli, C; Framarino dei Malatesta, M; Marzetti, L; Toccaceli Blasi, MR; Veneziano, M; Yacoub, M, 1995) |
| "To determine whether postoperative pain and nausea after laparoscopic sterilization can be reduced with a combination of bupivacaine, metoclopramide, scopolamine, ketorolac, and gastric suctioning." | 9.08 | Reduction of pain and nausea after laparoscopic sterilization with bupivacaine, metoclopramide, scopolamine, ketorolac, and gastric suctioning. ( Bradford, TH; Meeks, GR; Norman, PF; Robertson, K, 1995) |
| "To compare the efficacy of oral droperidol versus oral metoclopramide, or both oral droperidol and metoclopramide, on postoperative vomiting when used as a premedicant for strabismus surgery." | 9.08 | The effects of oral droperidol versus oral metoclopramide versus both oral droperidol and metoclopramide on postoperative vomiting when used as a premedicant for strabismus surgery. ( Brown, RE; Jones, E; Kymer, PJ; Lawhorn, CD; Pearce, L, 1995) |
| "This randomized, double-blind, multicentre, parallel-group study compared the efficacy and safety of an intravenous dose of ondansetron 4 mg for the prevention of postoperative nausea and vomiting (PONV) with metoclopramide 10 mg and placebo in patients undergoing major gynaecological surgery." | 9.08 | [Intravenous administration of ondansetron vs. metoclopramide for the prophylaxis of postoperative nausea and vomiting]. ( Rust, M, 1995) |
| "We have compared the efficacy of ondansetron, metoclopramide, droperidol and placebo in the prevention of postoperative nausea and vomiting in 118 day stay patients undergoing laparoscopic gynaecological procedures." | 9.08 | Prevention of nausea and vomiting after day case gynaecological laparoscopy. A comparison of ondansetron, droperidol, metoclopramide and placebo. ( McKay, AC; Mirakhur, RK; Paxton, LD, 1995) |
| " We compared the efficacy, toxicity, and patients' preference for tropisetron, a new 5-hydroxytryptamine3 (HT3) receptor antagonist, with those of a combination of high-dose metoclopramide, dexamethasone, diphenhydramine, and lorazepam (metoclopramide cocktail) in a randomized crossover study for the control of nausea and vomiting during cisplatin-containing chemotherapy." | 9.08 | Comparison of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis. ( Chang, TC; Cheng, HH; Hsieh, F; Lai, CH; Li, CL; Michael, BJ; Soong, YK; Tseng, CJ, 1996) |
| "Of the patients treated with metoclopramide plus methylprednisolone (n = 92), 53% had complete protection from delayed emesis, 16% a major response, 15% a minor response, and 15% no response." | 9.08 | Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial. ( Cannata, G; Gebbia, N; Gebbia, V; Testa, A; Tirrito, ML; Valenza, R, 1995) |
| "The aim of the present study was to compare the antiemetic efficacy of ondansetron (OND) with metoclopramide (MCP), both combined with corticosteroid (CS) in patients with malignant lymphoma." | 9.08 | Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy. ( Jørgensen, M; Victor, MA, 1996) |
| " The recurrence of retching or vomiting was higher with propofol (58%) than with droperidol (4%) or metoclopramide (24%) (P < 0." | 9.08 | Treatment of postoperative nausea and vomiting: comparison of propofol, droperidol and metoclopramide. ( Lacroix, G; Lessard, MR; Trépanier, CA, 1996) |
| "The purpose of this retrospective study is to assess the frequency and intensity of chronic nausea in patients admitted to the Palliative Care Unit and the results of a metoclopramide-based treatment regimen." | 9.08 | Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen. ( Babul, N; Bruera, E; Darke, A; Harsanyi, Z; Seifert, L; Suarez-Almazor, M; Watanabe, S, 1996) |
| "The efficacy of ondansetron 4 mg was compared with metoclopramide 10 mg for the prevention of post-operative nausea and vomiting in patients after major gynaecological abdominal surgery." | 9.08 | Comparison of ondansetron and metoclopramide for the prevention of post-operative nausea and vomiting after major gynaecological surgery. ( Chen, PP; Chui, PT; Gin, T, 1996) |
| "The potent serotonin receptor (5-HT3) antagonists are new highly selective agents for the prevention and control of chemotherapy-induced nausea and vomiting that have been shown to be comparable to or more effective than traditional metoclopramide regimens." | 9.08 | A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy. ( Bastit, P; Cals, L; Cappelaere, P; Catimel, G; Chevallier, B; Claverie, N; Fabbro, M; Giovannini, M; Khayat, D; Splinter, T; Wendling, JL, 1997) |
| "A double-blind, randomised, placebo-controlled trial was conducted to compare the efficacy of metoclopramide with the 5-HT3 antagonist, ondansetron, for the prevention of postoperative emesis in children undergoing elective strabismus surgery." | 9.08 | Efficacy of ondansetron and metoclopramide for preventing postoperative emesis following strabismus surgery in children. ( Mandal, NG; Shende, D, 1997) |
| "To compare the efficacy of oral ondansetron with oral metoclopramide for the prevention of postoperative vomiting and nausea in children undergoing strabismus surgery." | 9.08 | [Does oral ondansetron reduce the incidence of nausea and vomiting after surgery for strabismus in children?]. ( Amraoui, A; Benaguida, M; el Harrar, N; Idali, B; Laouissi, F; Mjahed, K, 1996) |
| "In a randomised, double-blind study, we have compared the incidence of postoperative nausea and vomitting in 124 patients undergoing major lower limb orthopaedic surgery following oral premedication with temazapam and ondansetron 8 mg, metoclopramide 10 mg or placebo." | 9.08 | Comparison of ondansetron, metoclopramide and placebo as premedicants to reduce nausea and vomiting after major surgery. ( Alexander, R; Fennelly, M, 1997) |
| " This difference was still significant when controlling for age, body weight, history of motion sickness, previous PONV episodes, duration of anesthesia, and intraoperative fentanyl consumption using a logistic model." | 9.08 | Ondansetron versus metoclopramide in the treatment of postoperative nausea and vomiting. ( Finco, G; Gottin, L; Grosso, S; Ischia, S; Mosaner, W; Pinaroli, AM; Polati, E; Verlato, G, 1997) |
| "Granisetron is a better prophylactic antiemetic than droperidol or metoclopramide in female patients with a history of motion sickness undergoing major gynaecological surgery." | 9.08 | Prevention of PONV with granisetron, droperidol and metoclopramide in female patients with history of motion sickness. ( Fujii, Y; Tanaka, H; Toyooka, H, 1997) |
| " After experiencing at least one nausea and/or one emetic episode in the 6 h after recovery from anaesthesia, patients received either ondansetron 4 mg i." | 9.08 | Ondansetron compared with metoclopramide in the treatment of established postoperative nausea and vomiting. The French Ondansetron Study Group. ( Clyti, N; Conseiller, C; Diemunsch, P; Mamet, JP, 1997) |
| "Seminoma stage I patients on tropisetron experienced less nausea and vomiting during abdominal radiotherapy than patients receiving metoclopramide." | 9.08 | Prophylactic use of tropisetron or metoclopramide during adjuvant abdominal radiotherapy of seminoma stage I: a randomised, open trial in 23 patients. ( Aass, N; Fosså, SD; Håtun, DE; Thoresen, M, 1997) |
| "Granisetron is more effective than droperidol or metoclopramide in preventing PONV in female patients with a history of postoperative emesis." | 9.08 | Prevention of PONV with granisetron, droperidol or metoclopramide in patients with postoperative emesis. ( Fujii, Y; Saitoh, Y; Tanaka, H; Toyooka, H, 1998) |
| "Ondansetron 4 mg was compared with metoclopramide 10 mg for prevention of post-operative nausea and emesis in in-patients undergoing major gynaecological surgery in this double-blind, randomized, placebo-controlled, multicentre study." | 9.08 | International, multicentre, placebo-controlled study to evaluate the effectiveness of ondansetron vs. metoclopramide in the prevention of post-operative nausea and vomiting. ( Aune, H; Cohen, LA; Feiss, P; Hanson, A; Hasselstrøm, L; Maltby, JR; Morris, RW; Rocke, DA; Rozenberg, B; Rust, M, 1998) |
| "This study evaluates the prophylactic anti-emetic efficacy of granisetron, droperidol and metoclopramide, for the prevention of post-operative nausea and vomiting in female patients undergoing elective laparoscopic cholecystectomy." | 9.08 | Anti-emetic efficacy of prophylactic granisetron, droperidol and metoclopramide in the prevention of nausea and vomiting after laparoscopic cholecystectomy: a randomized, double-blind, placebo-controlled trial. ( Fujii, Y; Saitoh, Y; Tanaka, H; Toyooka, H, 1998) |
| "A single institution, prospective, randomized trial was performed in terminal cancer patients to compare tropisetron (TRO), metoclopramide (MET), and chlorpromazine (CHL) in the management of nausea and emesis." | 9.08 | Comparison of the efficacy and safety of tropisetron, metoclopramide, and chlorpromazine in the treatment of emesis associated with far advanced cancer. ( Befon, S; Liossi, C; Mystakidou, K; Vlachos, L, 1998) |
| "Ondansetron appeared to be superior to metoclopramide-diphenhydramine in the control of emesis induced by chemotherapy regimens containing cisplatin." | 9.08 | Comparison of the efficacy and side-effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy: a prospective randomized study. ( Atay, AA; Köseoglu, V; Kürekçi, AE; Ozcan, O; Sarici, U; Sorici, U, 1998) |
| "To determine the contribution of metoclopramide to the efficacy of ondansetron in control of cisplatin-induced emesis, ondansetron was compared with ondansetron plus metoclopramide for antiemetic efficacy in a randomized double-blind trial." | 9.07 | Ondansetron compared with ondansetron plus metoclopramide in the prevention of cisplatin-induced emesis. ( Cho, GY; Kim, SH; Kim, SW; Lee, CW; Lee, JS; Lee, KH; Suh, CW, 1994) |
| "The mechanism of ioxaglate-induced nausea has not been fully elucidated." | 9.07 | [The mechanism producing nausea during ventriculography performed with ioxaglate: the implications of a randomized study]. ( Barthe, JE; Catarino, C; Cequier, A; Esplugas, E; Gómez-Hospital, JA; Jara, F; Mauri, J; Sabaté, M; Sala, J; Valerio, L, 1994) |
| "Lignocaine has been shown to reduce the incidence of pain on injection of propofol." | 9.07 | Propofol injection pain: comparing the addition of lignocaine or metoclopramide. ( Mecklem, DW, 1994) |
| "Oral metoclopramide may be given as a premedicant to reduce post-operative nausea and vomiting, but there is little evidence that it is effective." | 9.07 | Sustained release metoclopramide for prophylaxis of post-operative nausea and vomiting. ( Curran, JP; Elliott, RH; Graham, SG, 1994) |
| "The clinical efficacy and tolerability of a new nasal spray formulation of metoclopramide (MTC) was evaluated in terms of its ability to prevent the nausea and vomiting induced by a moderately emetic chemotherapy (cisplatin 20 mg/m2 weekly as radioenhancer+radiotherapy for a fractionated total of 60 Gy) in 12 patients with non-small-cell lung cancer, stage IIIB." | 9.07 | Efficacy and tolerability of nasally administered compared to parenterally administered metoclopramide in the symptomatic treatment of chemotherapy-induced emesis in cancer outpatients. A controlled clinical study. ( Confalonieri, M; Dimaiuta, M; Scanni, A; Tomirotti, M, 1994) |
| "In a prospective, double-blind study, we have examined the effect of preoperative nabilone on postoperative nausea and vomiting (PONV)." | 9.07 | Effect of nabilone on nausea and vomiting after total abdominal hysterectomy. ( Barrowcliffe, MP; Campbell, DN; Lewis, IH, 1994) |
| "The short elimination half-life of metoclopramide necessitates frequent administration for optimal relief of nausea." | 9.07 | Comparison of the efficacy, safety, and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer. ( Babul, N; Bruera, ED; Darke, AC; Harsanyi, Z; LeGatt, DF; MacDonald, RN; MacEachern, TJ; Spachynski, KA, 1994) |
| " Oral granisetron alone was as effective as met/dex in control of acute emesis in all parameters examined." | 9.07 | Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group. ( Cedar, E; Cunningham, J; Goedhals, L; Heron, JF; Jordaan, JP, 1994) |
| " A sample of 43 patients with breast cancer was accrued from September to November 1992 in a phase II study to assess the efficacy of granisetron in patients receiving FEC (5-FU, epirubicin, cyclophosphamide)." | 9.07 | Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide. ( Ang, PT; Khoo, KS; Tan, EH, 1994) |
| "We studied the preventive effect on postoperative nausea and vomiting (PONV) of ondansetron, metoclopramide and placebo associated with epidural anaesthesia." | 9.07 | [Effects of ondansetron and metoclopramide on postoperative nausea and vomiting after epidural anesthesia in children]. ( Andreuccetti, T; Busoni, P; Calamandrei, M; Crescioli, M; Messeri, A; Sarti, A; Sestini, G, 1994) |
| "Metoclopramide is an active antiemetic against cisplatin-induced acute emesis." | 9.07 | Continuous infusion versus intermittent short infusion of metoclopramide for cisplatin-induced acute emesis. ( Kajita, M; Niimi, T; Saito, H; Shimokata, K; Yamori, S, 1994) |
| "We have compared the incidence of postoperative nausea and vomiting up to 48 h after day-case gynaecological laparoscopy after oral premedication with ondansetron 4 mg, metoclopramide 10 mg or a placebo allocated randomly and assessed blindly." | 9.07 | Nausea and vomiting after gynaecological laparoscopy: comparison of premedication with oral ondansetron, metoclopramide and placebo. ( Cooper, GM; Field, JM; Malins, AF; Nesling, PM, 1994) |
| "We have compared the efficacy of ondansetron with droperidol and saline in the prevention of postoperative nausea and vomiting (PONV) in 120 ASA I and II patients undergoing hip and knee replacements and femoral resections." | 9.07 | Double-blind comparison of ondansetron, droperidol and saline in the prevention of postoperative nausea and vomiting. ( Collis, R; Gan, TJ; Hetreed, M, 1994) |
| "We investigated the usefulness of concurrent therapy of granisetron with methylprednisolone sodium for on nausea, vomiting and anorexia induced by chemotherapy, including cisplatin, in patients with oral cancer." | 9.07 | [Clinical effects of granisetron and methylprednisolone against nausea, vomiting and anorexia induced by cisplatin]. ( Kawashima, T; Miyata, K; Morita, N; Ohmata, T; Sakamoto, T; Wada, T, 1993) |
| ") was compared with a metoclopramide cocktail for the prevention of nausea and emesis." | 9.07 | An open, randomized study to compare the efficacy and tolerability of tropisetron with that of a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. ( Frankendal, B; Hallén, C; Sorbe, B, 1994) |
| ", Basel, Switzerland), a new 5-HT3 receptor antagonist, was compared in a randomized multicenter trial with a high-dose metoclopramide-dexamethasone cocktail for the prevention of nausea and emesis during cisplatin-containing chemotherapy." | 9.07 | A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. ( de Bruijn, KM; Glimelius, B; Hansen, O; Högberg, T; Räisänen, I; Schmidt, M; Sorbe, BG; Sörensen, BT; van Oosterom, AT; Wernstedt, L, 1994) |
| "Ondansetron is a serotonin antagonist that recently has been introduced as a preventive agent for chemotherapy-induced nausea and vomiting." | 9.07 | Comparison of intermittent ondansetron versus continuous infusion metoclopramide used with standard combination antiemetics in control of acute nausea induced by cisplatin chemotherapy. ( Kilgore, JR; Navari, RM; Perrine, GM; Province, WS, 1993) |
| "The usefulness of alprazolam (minor tranquilizer) used in combination with metoclopramide plus methylprednisolone for the prevention and control of emesis induced by chemotherapies, including 5-day continuous intravenous infusion of cisplatin (25 mg/m2/day) for advanced lung cancer, was evaluated using a double-blind randomized crossover design." | 9.07 | Antiemetic efficacy of alprazolam in the combination of metoclopramide plus methylprednisolone. Double-blind randomized crossover study in patients with cisplatin-induced emesis. ( Mori, K; Saito, Y; Tominaga, K, 1993) |
| " To address its use with a widely used but less emetogenic regimen, we performed a double-blind, randomized clinical trial comparing ondansetron with dexamethasone and metoclopramide in patients with breast cancer receiving chemotherapy with cyclophosphamide, methotrexate, and fluorouracil." | 9.07 | Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. ( Latreille, J; Levitt, M; Lofters, WS; Perrault, DJ; Potvin, M; Rayner, HL; Warner, E; Warr, D; Wilson, KS; Yelle, L, 1993) |
| "This report of a double-blind, randomized study performed to evaluate the comparative antiemetic efficacy of tropisetron (Navoban; Sandoz Pharma Ltd, Basel, Switzerland), a new 5-hydroxytryptamine receptor antagonist, focuses on treatment during stages of chemotherapy when nausea and vomiting are particularly severe." | 9.07 | A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis. ( Krzakowski, M; Lasota, W; Madej, G; Pawinski, A; Rogowski, W; Skoneczna, I, 1994) |
| "The efficacy and tolerability of tropisetron in preventing cisplatin-induced nausea and vomiting was studied in 2 open trials and compared with the efficacy and tolerability of metoclopramide plus lorazepam in a randomised crossover trial." | 9.07 | Three years' experience with tropisetron in the control of nausea and vomiting in cisplatin-treated patients. ( Antonacci, RA; Berruti, A; Dogliotti, L; Faggiuolo, R; Ortega, C; Pazè, E, 1992) |
| "Sixty patients were studied in a randomized, double-blind manner to determine whether metoclopramide added to droperidol decreased further the incidence of emetic symptoms (nausea, retching, vomiting) in outpatients receiving alfentanil anaesthesia for nasal surgery." | 9.07 | Metoclopramide does not decrease the incidence of nausea and vomiting after alfentanil for outpatient anaesthesia. ( AlHaddad, S; Furgerson, C; Khalil, I; Maurer, W; Whalley, DG, 1991) |
| " In this randomized, single-blind, multicenter, parallel group study, we compared the efficacy and safety of intravenous (IV) ondansetron with IV metoclopramide in the prevention of nausea and vomiting associated with high-dose (greater than or equal to 100 mg/m2) cisplatin chemotherapy." | 9.07 | A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. ( Gandara, D; Hainsworth, J; Harker, G; Harvey, W; Hesketh, P; Kasimis, B; Khojasteh, A; Monaghan, G; Oblon, D; Pendergrass, K, 1991) |
| "Ondansetron was compared with metoclopramide for antiemetic efficacy in a randomised double-blind trial in 122 patients with advanced breast cancer." | 9.07 | Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. ( Adler, M; Christmann, D; Fenzl, E; Marschner, NW; Nagel, GA; Upadhyaya, B, 1991) |
| "To prevent delayed emesis induced by cisplatin (mean dose 90 mg/m2), 120 consecutive patients were randomized to receive, in a 7-day crossover design, oral metoclopramide (20 mg q." | 9.07 | Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. ( Ballatori, E; Basurto, C; Boschetti, E; Bracarda, S; Patoia, L; Penza, O; Picciafuoco, M; Roila, F; Santi, E; Tonato, M, 1991) |
| "Ondansetron is a 5-hydroxytryptamine 3-receptor antagonist which has shown activity in the prevention of cytotoxic-induced emesis." | 9.06 | Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation. ( Adams, M; Collis, CH; Lucraft, H; Priestman, S; Priestman, TJ; Roberts, JT; Upadhyaya, BK, 1990) |
| "To compare ondansetron (GR 38032F), a 5-hydroxytryptamine3-receptor antagonist, with metoclopramide in the prophylaxis of acute cisplatin-induced emesis, we conducted a double-blind crossover study in 97 patients scheduled to receive cisplatin (80 to 100 mg per square meter of body-surface area) for treatment of cancer." | 9.06 | Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. ( Azab, M; Bons, J; Brion, N; Droz, JP; Marty, M; Paes, D; Paule, B; Pouillart, P; Pujade-Lauraine, E; Scholl, S, 1990) |
| "Seventy-five breast cancer patients scheduled to receive a first course (in a new cycle) of cyclophosphamide, fluorouracil, and doxorubicin (FAC) or epirubicin (FEC) participated in a double-blind crossover study to compare the antiemetic efficacy and safety of ondansetron (GR38032), a 5-hydroxytryptamine3 (5-HT3) receptor antagonist, and metoclopramide." | 9.06 | A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. ( Bonneterre, J; Bons, J; Chevallier, B; Fargeot, P; Metz, R; Paes, D; Pujade-Lauraine, E; Spielmann, M; Tubiana-Hulin, M, 1990) |
| "The efficacy of ondansetron was compared with metoclopramide in the prophylaxis of nausea and vomiting induced by cyclophosphamide greater than or equal to 500 mg/m2 in combination with doxorubicin greater than or equal to 40 mg/m2 or epirubicin greater than or equal to 40 mg/m2." | 9.06 | A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group. ( Carruthers, L; Dicato, MA; Huys, JV; Kaasa, S; Kvaløy, S; Ries, F; Royer, E, 1990) |
| "To compare the efficacy and side effects of ondansetron with those of high-dose metoclopramide in treating acute and delayed cisplatin-induced nausea and vomiting." | 9.06 | Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. ( Allman, EL; Beranek, P; De Mulder, PH; Mols-Jevdevic, S; Seynaeve, C; van Liessum, PA; Vermorken, JB; Verweij, J, 1990) |
| " All patients received intravenous (IV) metoclopramide, dexamethasone, and lorazepam for the control of acute emesis during the period from 0 to 24 hours after cisplatin." | 9.06 | Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. ( Cirrincione, C; Clark, RA; Gralla, RJ; Groshen, S; Kris, MG; Tyson, LB, 1989) |
| "In a randomized, double-blind study, we compared the efficacy of metoclopramide hydrochloride with that of low-dose droperidol for prevention of nausea and vomiting during and after elective cesarean section with epidural anesthesia." | 9.06 | Metoclopramide versus droperidol for prevention of nausea and vomiting during epidural anesthesia for cesarean section. ( Bates, JN; Chestnut, DH; Choi, WW; Geiger, M; Ostman, PL; Owen, CL, 1989) |
| " CMF were included in a double-blind comparative study aimed at evaluating the efficacy of 3 different drugs (methylprednisolone (MP), metoclopramide (MTC), and domperidone (DMP) in preventing chemotherapy-induced nausea and vomiting." | 9.06 | Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF. ( Ballatori, E; Basurto, C; del Favero, A; Minotti, V; Roila, F; Tonato, M, 1987) |
| "Forty patients with advanced lung cancer who had received chemotherapy containing cisplatin (80 mg/m2) were accrued for a randomized controlled trial to evaluate the additional effect of prochlorperazine on the combination of high-dose metoclopramide and dexamethasone for the treatment of acute cisplatin-induced emesis." | 9.06 | [A randomized controlled trial of acute and delayed cisplatin-induced emesis with metoclopramide, dexamethasone and prochlorperazine]. ( Eguchi, K; Inoue, I; Nino, S; Saijo, N; Sakurai, M; Sasaki, Y; Shinkai, T; Suemasu, K; Tamura, T; Umehara, H, 1987) |
| "The antiemetic efficacy and toxicity of methylprednisolone (MP) and metoclopramide (MTC) in prevention of nausea and vomiting in breast cancer patients receiving intravenous cyclophosphamide methotrexate 5-fluorouracil (CMF) chemotherapy has been evaluated in a double-blind trial." | 9.06 | Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized study. ( Ballatori, E; Basurto, C; Del Favero, A; Minotti, V; Roila, F; Tonato, M, 1988) |
| "Methylprednisolone sodium succinate and metoclopramide were compared for their efficacy, tolerance, and safety in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy in patients with cancer." | 9.06 | Superiority of methylprednisolone sodium succinate over low dose metoclopramide hydrochloride in the prevention of nausea and vomiting produced by cancer chemotherapy. ( Erlichman, C; Levitt, M; Osoba, D; Pater, JL; Willan, AR, 1986) |
| "A randomized cross-over study on the effects of methylprednisolone (MP), metoclopramide (MT) and droperidol (DP) on the control of nausea and vomiting associated with cis-platinum chemotherapy was performed." | 9.06 | [Randomized cross-over study on the effects of methylprednisolone, metoclopramide and droperidol on the control of nausea and vomiting associated with cis-platinum chemotherapy]. ( Akaza, H; Aso, Y; Fujita, K; Isurugi, K; Kawabe, K; Kinoshita, K; Koiso, K; Kondo, Y; Niijima, T; Yokoyama, M, 1986) |
| "Thirty three untreated patients being given cisplatin received metoclopramide (7 mg/kg) for antiemesis by either continuous or intermittent infusion in a random order." | 9.06 | Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin. ( Allan, SG; Cornbleet, MA; Leonard, RC; MacPherson, JS; Smyth, JF; Warrington, PS, 1986) |
| "One hundred and two patients with advanced solid tumors receiving chemotherapy were treated with metoclopramide (MCP; 100 mg) to prevent emesis." | 9.05 | Improved control of chemotherapy-induced emesis by the addition of dexamethasone to metoclopramide in patients resistant to metoclopramide. ( Bruera, ED; Cedaro, L; Chacón, R; Estévez, R; Roca, E, 1983) |
| " Compared to metoclopramide, alizapride caused a faster regression of inappetence and of the frequency of daily vomiting." | 9.05 | [Alizapride in a double-blind trial with metoclopramide in nausea and vomiting caused by radiotherapy]. ( Budach, V; Krüger, K, 1983) |
| "A double-blind comparison of metoclopramide versus placebo was performed on 8 cirrhotic patients with nausea (8 cases) and heartburn (3 of the 8 cases) plus mild portal-systemic encephalopathy." | 9.05 | Successful administration of metoclopramide for the treatment of nausea in patients with advanced liver disease. A double-blind controlled trial. ( Ballesteros, A; Briones, A; Garcia Ramos, G; Garza, J; Rosales, J; Strauss, R; Uribe, M; Villalobos, A, 1985) |
| "The effect of high-dose metoclopramide (2 mg/kg, 4 times every 2 hours) on the emesis of patients treated with CDDP (80 mg/m2) was examined by randomized control trial." | 9.05 | [Randomized control study of high-dose metoclopramide in the prevention of CDDP-induced emesis]. ( Eguchi, K; Fujita, J; Funaki, Y; Futami, H; Sakurai, M; Sasaki, Y; Sawamura, N; Takahashi, S; Yokoyama, S; Yoshioka, S, 1985) |
| "We tested the safety and antiemetic effectiveness of intravenous (IV) dexamethasone (DXM) as an adjunct to high-dose IV metoclopramide (MCP) to prevent nausea and vomiting induced by high-dose cisplatin chemotherapy." | 9.05 | High-dose intravenous metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind crossover comparison of antiemetic efficacy. ( Liponi, DF; McDermed, JE; Strum, SB, 1985) |
| "In a double-blind trial in 60 children suffering from gastroenteritis complicated by vomiting, it was found that suppositories of domperidone (30 mg) were more effective than either metoclopramide (10 mg) or placebo in reducing the severity of vomiting, nausea and other symptomatic parameters." | 9.04 | A double-blind comparison of domperidone and metoclopramide suppositories in the treatment of nausea and vomiting in children. ( Ameryckx, L; Dhondt, F; Heck, E; Van Eygen, M; Van Ravensteyn, H, 1979) |
| "Forty-seven infants and children suffering from chronic vomiting or regurgitation, participated in a two-week double-blind trial comparing 1% drops of domperidone, 1% metoclopramide drops or placebo." | 9.04 | Domperidone drops in the symptomatic treatment of chronic paediatric vomiting and regurgitation. A comparison with metoclopramide. ( Ameryckx, L; De Loore, I; Van Ravensteyn, H, 1979) |
| "One hundred and ninety-five female patients of child-bearing age were assessed for postoperative vomiting in a double-blind trial using domperidone, metoclopramide and placebo." | 9.04 | Prevention of postoperative nausea and vomiting by domperidone: A double-blind randomized study using domperidone, metoclopramide and a placebo. ( Ball, RW; Comyn, DJ; Cooke, RD, 1979) |
| "To assess the efficacy and safety of olanzapine when used as an antiemetic in the prevention and treatment of nausea and vomiting related to cancer in adults." | 8.98 | Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. ( Burton, MJ; Head, K; Naessens, K; Plugge, E; Sutherland, A; Ware, L; Wee, B, 2018) |
| "To examine the medical evidence regarding the clinical efficacy and cost-effectiveness of the application of continuous subcutaneous metoclopramide and ondansetron to treat nausea and vomiting during pregnancy." | 8.88 | Reviewing the evidence for using continuous subcutaneous metoclopramide and ondansetron to treat nausea & vomiting during pregnancy. ( Kirkbride, MS; Reichmann, JP, 2012) |
| "8 mg/kg was superior to metoclopramide in preventing emesis induced by high dose cisplatin or by moderately emetogenic chemotherapy in high risk subgroups." | 8.79 | Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. ( Balfour, JA; Goa, KL, 1997) |
| "Monosodium glutamate induces behaviors thought to reflect headache and nausea in rats." | 8.12 | Peripheral N-methyl-D-aspartate receptor activation contributes to monosodium glutamate-induced headache but not nausea behaviours in rats. ( Benbow, T; Cairns, BE; Exposto, FG; Sheikhi, A; Svensson, P; Teja, F, 2022) |
| "The objective of the study was to evaluate the rate of major congenital anomalies after first trimester exposure to ondansetron for nausea and vomiting of pregnancy (NVP)." | 8.02 | Pregnancy outcome following in-utero exposure to ondansetron: A prospective comparative observational study. ( Arnon, J; Diav-Citrin, O; Sakran, R; Shechtman, S, 2021) |
| "This study aimed to compare the therapeutic efficacy of dimenhydrinate and metoclopramide in patients with nausea and vertigo." | 8.02 | Comparison of efficacy dimenhydrinate and metoclopramide in the treatment of nausea due to vertigo; a randomized study. ( Ercin, D; Erdur, B; Ozen, M; Seyit, M; Turkcuer, I; Yilmaz, A; Zincir Ercin, DO, 2021) |
| " Delayed emesis following Cycle 1 of carboplatin was observed in 30% of patients." | 7.83 | Delayed nausea and vomiting from carboplatin doublet chemotherapy. ( Baggstrom, MQ; Chitneni, P; Gao, F; Govindan, R; Mann, J; Morgensztern, D; Waqar, MA; Waqar, SN; Williams, K, 2016) |
| "Patients with cancer frequently report gastrointestinal symptoms such as anorexia, early satiety, nausea, vomiting, and bloating." | 7.80 | Long-term safety and clinical effectiveness of controlled-release metoclopramide in cancer-associated dyspepsia syndrome: a multicentre evaluation. ( Chow, W; Darke, A; Harsanyi, Z; Marshall, D; Pearen, S; Plourde, JY; Wilson, J; Yoshida, S, 2002) |
| "We aimed to determine the potential of various doses of metoclopramide (MCP, a dopamine antagonist) to reduce lithium chloride (LiCl)-induced conditioned gaping (a nausea-induced behaviour) in rats, using the taste reactivity test." | 7.79 | Suppression of lithium chloride-induced conditioned gaping (a model of nausea-induced behaviour) in rats (using the taste reactivity test) with metoclopramide is enhanced by cannabidiolic acid. ( Parker, LA; Rock, EM, 2013) |
| "Ondansetron was superior to placebo in Study 1; complete control of emesis (0 emetic episodes) over 15 days was achieved in 62% of ondansetron-treated patients compared to 34% of placebo-treated patients (P = 0." | 7.77 | Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review. ( Marschner, N, 1991) |
| "The aim of the study was to evaluate the role of ramosetron for the prevention of chemoradiotherapy-induced nausea and vomiting (CRINV) in patients receiving upper abdominal irradiation with concurrent 5-fluorouracil chemotherapy." | 7.75 | Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer. ( Bang, YJ; Chie, EK; Ha, SW; Im, SA; Jang, JY; Kim, K; Kim, SW; Kim, TY; Oh, DY, 2009) |
| "In various countries, metoclopramide is the antiemetic drug of choice in pregnant women, but insufficient information exists regarding its safety in pregnancy." | 7.75 | The safety of metoclopramide use in the first trimester of pregnancy. ( Gorodischer, R; Koren, G; Levy, A; Matok, I; Sheiner, E; Wiznitzer, A, 2009) |
| "A patient who was given metoclopramide for vomiting and diarrhoea developed circulatory collapse with his blood pressure dropping to 50/20 mm Hg." | 7.75 | Circulatory collapse in a patient with gastrinoma after metoclopramide administration. ( Chan, AY; Chan, KW; Ching, CK; Lam, AW; Lau, KK; Lee, HH; Li, SM; Lo, J; Lok, CM; Luk, WF; Mak, CM, 2009) |
| "To assess the effectiveness of ondansetron in relieving symptoms of nausea and vomiting which were refractory to metoclopramide and cyclizine, in a patient receiving iloprost infusions." | 7.71 | Pre-emptive metoclopramide and ondansetron for nausea and vomiting associated with iloprost infusions. ( Roome, C; Thompson, J, 2001) |
| "A prospective trial was performed to better assess the risk of nausea and vomiting and the rescue value of tropisetron (TRO), a 5-HT3 receptor antagonist, in 88 patients undergoing fractionated radiotherapy to the abdomen or to large supradiaphragmatic fields and failing a first anti-emetic trial with metoclopramide (MET)." | 7.69 | Nausea and vomiting in fractionated radiotherapy: a prospective on-demand trial of tropisetron rescue for non-responders to metoclopramide. ( Behrouz, F; Blazek, N; Coucke, P; Gebhard, S; Melliger, M; Miralbell, R; Philipp, S; Rosset, A; Schwabb, T; Wickenhauser, R, 1995) |
| "Although buprenorphine sometimes causes severe emesis, its relation to the menstrual cycle has not been reported." | 7.69 | Menstrual stage influences postoperative nausea and vomiting following epidural buprenorphine. ( Kamiyama, M; Kitamura, A; Kon, T; Ogawa, R, 1996) |
| "Fifty-one patients who received their first course of chemotherapy were studied to compare the respective efficacy and safety of granisetron and metoclopramide plus dexamethasone in the prevention of nausea and vomiting induced by emetogenic cytotoxic drugs." | 7.69 | Comparison of intravenous granisetron with metoclopramide plus dexamethasone in the prevention of nausea and vomiting associated with emetogenic cytotoxic chemotherapy. ( Chang, CS; Chen, LT; Chen, TP; Huang, SM; Lin, SF; Liu, TC; Wei, TC, 1997) |
| " The syndrome was associated with metoclopramide antiemetic therapy given for post-operative nausea and vomiting." | 7.68 | Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy. ( Bakri, YN; Kawi, Z; Khan, R; Subhi, J, 1992) |
| "To evaluate the efficacy of a combined therapy of prednisolone and alprazolam for controlling cisplatin-induced delayed emesis, a study involving 14 non-small cell lung cancer patients receiving cisplatin (80 mg/m2) was conducted." | 7.68 | [A combined anti-emesis therapy of oral prednisolone and alprazolam for cisplatin-induced delayed emesis]. ( Horio, Y; Iwahara, T; Minami, H; Sakai, S; Shibagaki, T; Shimokata, K; Watanabe, A, 1990) |
| "Nabilone is a cannabinoid anti-emetic which has been extensively evaluated in control of chemotherapy-induced vomiting." | 7.67 | An initial evaluation of Nabilone in the control of radiotherapy-induced nausea and vomiting. ( Priestman, SG; Priestman, TJ, 1984) |
| "Repeated oral doses of metoclopramide (50 mg) and prednisone (25 mg) completely prevented nausea and vomiting (N + V) in approximately 50% and substantially reduced N + V in an additional 27%-36% of 56 chemotherapy courses in 30 consecutive cancer patients who were receiving primarily cisplatin." | 7.67 | Effective control of chemotherapy-induced nausea and vomiting with oral prednisone and metoclopramide. ( Bachmann-Mettler, I; Glaus, A; Senn, HJ, 1984) |
| "The authors tested the safety and efficacy of intravenous metoclopramide in the prevention of chemotherapy-induced nausea and vomiting." | 7.67 | Intravenous metoclopramide: prevention of chemotherapy-induced nausea and vomiting. A preliminary evaluation. ( McDermed, JE; Pileggi, J; Riech, LP; Strum, SB; Whitaker, H, 1984) |
| "Forty-six outpatients with breast cancer who had experienced severe emesis as a result of chemotherapy were evaluated for the antiemetic efficacy of high-dose metoclopramide (HD-MCP) and dexamethasone (DXM)." | 7.67 | High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second study. ( Ben-Baruch, N; Ben-Yosef, R; Biran, S; Brufman, G; Gez, E; Uziely, B; Warner-Efraty, E; Yitzhaki, N, 1987) |
| "Orally administered metoclopramide (REGLAN) at doses of 10 or 20 mg, 75 min prior to either stressful linear acceleration (parabolic flight) or cross-coupled accelerative semicircular canal stimulation in a rotating chair was evaluated for its ability to prevent emesis or nausea II, respectively." | 7.67 | Failure of metoclopramide to control emesis or nausea due to stressful angular or linear acceleration. ( Kohl, RL, 1987) |
| "The ergoline derivative, Metergoline, in a dosage of 4 to 24 mg/day, was administered for one to eight months to 42 patients with hyperprolactinemic amenorrhea." | 7.67 | Treatment of hyperprolactinemic amenorrhea with Metergoline. ( Bohnet, HG; Kato, K; Wolf, AS, 1986) |
| "Fourteen patients undergoing strongly emetic cancer chemotherapy received a total of 33 continuous infusions of high-dose metoclopramide to prevent nausea and vomiting." | 7.66 | Continuous infusion of high-dose metoclopramide for the prevention of nausea and vomiting in patients receiving cancer chemotherapy. ( Brunner, KW; Galeazzi, RL; Joss, RA, 1983) |
| "Nausea and emesis are common side effects of opioid drugs administered for pain relief in cancer patients." | 6.70 | A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. ( Albertsson, M; Chimontsi-Kypriou, V; Curtis, P; Daly, S; Hardy, J; McQuade, B; Stathopoulos, P, 2002) |
| "198 chemonaive patients with breast cancer, treated with a moderately emetogenic chemotherapy, were randomly assigned to receive either oral granisetron 1 mg twice a day on day 1, followed by metoclopramide, 60 mg on day 2 and 3, or ondansetron, 8 mg IV on day 1, followed by ondansetron 8 mg tablet twice a day on day 2 and 3." | 6.69 | [Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron]. ( Granisétron, PK; Mabro, M, 1999) |
| "Metoclopramide was ineffective." | 6.68 | The efficacy of prophylactic ondansetron, droperidol, perphenazine, and metoclopramide in the prevention of nausea and vomiting after major gynecologic surgery. ( Clark, K; Cronin, MK; Darvish, AH; Desilva, PH; McDonald, SM, 1995) |
| "Nausea and vomiting are extremely common and most distressing side effects of high-dose cisplatin therapy." | 6.68 | Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. ( Ata, E; Butt, A; Khan, MA; Khan, WA; Malik, IA; Qazilbash, M, 1995) |
| " We compared ondansetron and metoclopramide, both combined with dexamethasone, in cisplatin-treated patients." | 6.68 | Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research. ( , 1997) |
| "Tropisetron+dexamethasone was significantly superior to tropisetron alone both for acute (P = 0." | 6.68 | Comparison of three tropisetron-containing antiemetic regimens in the prophylaxis of acute and delayed chemotherapy-induced emesis and nausea. ( Bangerter, M; Bruntsch, U; Drechsler, S; Eggert, J; Faerber, L; Gallmeier, WM; Gosse, H; Grote-Kiehn, J; Imhoff, W; Mezger, J; Oehm, C; Ukena, D; Untch, M, 1997) |
| "Delayed emesis has not been seen during the antiemetic therapies." | 6.67 | [Nausea and vomiting in cytostatic therapy of melanoma patients with the use of metoclopramide and corticosteroid or ondansetron]. ( Baki, M; Czeglédi, F, 1994) |
| "Tropisetron is an effective and well-tolerated agent in the prevention of chemotherapy-induced vomiting." | 6.67 | Tropisetron compared with a metoclopramide-based regimen in the prevention of chemotherapy-induced nausea and vomiting. ( Anderson, H; de Bruijn, KM; Howell, A; Logan, K; Sage, T; Thatcher, N, 1994) |
| " Tropisetron in combination with dexamethasone produced the best control of both acute and delayed emesis." | 6.67 | Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents. ( Bruntsch, U; Drechsler, S; Eggert, J; Faerber, L; Gosse, H; Imhoff, W; Ukena, D, 1994) |
| "Emesis is one of the most frequent and distressing adverse effects of cytotoxic chemotherapy." | 6.67 | Prevention of emesis by tropisetron (Navoban) in children receiving cytotoxic therapy for solid malignancies. ( Balduck, N; Hachimi-Idrissi, S; Maurus, R; Otten, J, 1994) |
| "Acute nausea was prevented completely in 40% of patients in the tropisetron group and in 61% of the metoclopramide cocktail group during course 1 (P < ." | 6.67 | Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience. ( Sorbe, BG, 1994) |
| "Ondansetron was well tolerated in the dose and schedule used." | 6.67 | The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. ( Bryson, JC; Finn, AL; Gandara, DR; Harvey, WH; Hesketh, PJ; Monaghan, GG; Perez, EA; Stokes, C, 1992) |
| "At the end of the treatment period, nausea, vomiting and reflux symptoms, adverse events and a global assessment of patients' symptom control were recorded by the investigator." | 6.67 | A comparison of controlled release metoclopramide and domperidone in the treatment of nausea and vomiting. ( Miller, AJ; Patel, NH; Roy, P, 1991) |
| "Severe nausea was significantly less frequent with cinnarizine and 59% of the chemotherapy days were without nausea, compared to 46% of the days without cinnarizine (p less than 0." | 6.67 | Cinnarizine for prevention of nausea and vomiting during platin chemotherapy. ( Osterwalder, B; Schimke, J; Senn, HJ; Wilder-Smith, CH, 1991) |
| "Vomiting was not satisfactorily prevented by either treatment." | 6.67 | Betamethasone-dixyrazine versus betamethasone-metoclopramide as antiemetic treatment of cisplatin-doxorubicin-induced nausea in ovarian carcinoma patients. ( Hallén, C; Sorbe, B, 1991) |
| " We have, therefore, carried out a multicenter, double-blind randomized trial comparing a combination of high-dose metoclopramide (MTC) (1 mg/kg x 4) and methylprednisolone (P) (treatment A) with a shorter but higher single-dose schedule of metoclopramide (3 mg/kg x 2) combined with dexamethasone (DEX) and diphenhydramine (DIP) to prevent extrapyramidal reactions (treatment B)." | 6.66 | Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research ( Basurto, C; Bracarda, S; Di Costanzo, F; Donati, D; Malacarne, P; Monici, L; Patoia, L; Picciafuoco, M; Roila, F; Tonato, M, 1989) |
| "Droperidol was significantly more effective than domperidone, metoclopramide or placebo in reducing emetic sequelae." | 6.66 | Comparison of the use of domperidone, droperidol and metoclopramide in the prevention of nausea and vomiting following major gynaecological surgery. ( Madej, TH; Simpson, KH, 1986) |
| "In a randomized trial of 58 cancer patients receiving strongly emetogenic cytostatic drugs (cisplatin or comparable cytostatic agents, alone or in combination), the anti-emetic action of oral metoclopramide was tested, alone or combined with prednisone." | 6.66 | [Prevention of nausea and emesis during cytostatic therapy. Antiemetic efficacy of high-dosage oral metoclopramide without and with prednisone]. ( Bachmann-Mettler, I; Glaus, A; Köhler, M; Senn, HJ; Weigand, W, 1986) |
| "The metoclopramide-treated group demonstrated a statistically significant decrease in the incidence of nausea and vomiting." | 6.66 | Metoclopramide as prophylaxis for nausea and vomiting induced by fluorescein. ( Brown, RE; Drew, SJ; Sabates, R, 1987) |
| "Metoclopramide was given at a dosage of 2 mg/kg (H) or 1 mg/kg (M), intravenously, 30 minutes before and 2." | 6.66 | [Randomized controlled study of high-dose metoclopramide (2 mg/kg x 4:H) vs moderate-dose metoclopramide (1 mg/kg x 4:M) in the prevention of CDDP-induced emesis]. ( Dozono, H; Ohmi, K, 1986) |
| "Metoclopramide (MCP) was given i." | 6.65 | Randomized open cross-over trial between metoclopramide (MCP) and dexamethazone (DXM) for the prevention of cisplatin-induced nausea and vomiting. ( Carlini, P; Cognetti, F; Conti, EM; Cortese, M; Pinnarò, P; Pollera, CF, 1984) |
| "Metoclopramide was superior to placebo and to prochlorperazine in reducing the volume of emesis (P = 0." | 6.65 | Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. ( Bordin, LA; Braun, DW; Braun, TJ; Gralla, RJ; Itri, LM; Kelsen, DP; Pisko, SE; Squillante, AE; Young, CW, 1981) |
| " The importance of adequate dosage of metoclopramide and the role of IV metoclopramide are emphasized." | 6.65 | Metoclopramide in the reduction of nausea and vomiting associated with combined chemotherapy. ( Cox, R; Leyland, MJ; Newman, CE, 1982) |
| "Metoclopramide is a prokinetic agent reported to be safe in parturients." | 6.48 | Metoclopramide for nausea and vomiting prophylaxis during and after Caesarean delivery: a systematic review and meta-analysis. ( Habib, AS; Mishriky, BM, 2012) |
| " High-dose metoclopramide has demonstrated efficacy in small series of patients in the treatment of cisplatin-induced vomiting." | 6.15 | Advances in anti-emetic therapy. ( Bakowski, MT, 1984) |
| "To examine the clinical efficacy of prophylactic metoclopramide in reducing the incidence of nausea and vomiting in emergency department (ED) patients with acute pain who were treated with intravenous tramadol." | 5.69 | The efficacy of prophylactic metoclopramide in preventing nausea and vomiting in patients with acute pain treated with intravenous tramadol: a randomized double-blinded, placebo-controlled trial. ( Lokeskrawee, T; Patumanond, J; Phinyo, P; Sriwiset, H; Wongyikul, P, 2023) |
| "To assess and confirm the effect of ondansetron on behavior suggestive of nausea in dogs with vestibular syndrome." | 5.51 | Ondansetron in dogs with nausea associated with vestibular disease: A double-blinded, randomized placebo-controlled crossover study. ( Charalambous, M; Elliott, J; Foth, S; Henze, L; Kenward, H; Meller, S; Pelligand, L; Twele, F; Volk, HA, 2022) |
| "Metoclopramide (MCP) is a commonly used anti-emetic in the emergency department (ED)." | 5.48 | Metoclopramide induced pheochromocytoma crisis. ( Kim, HK; Leonard, JB; Munir, KM, 2018) |
| " The EMPOWER (EMesis in Pregnancy – Ondansetron With mEtoClopRamide) trial aimed to compare the clinical effectiveness and cost-effectiveness of two anti-sickness drugs [metoclopramide (metoclopramide hydrochloride, Actavis UK Ltd, Barnstable, UK; IV Ratiopharm GmbH, Ulm, Germany) and ondansetron (ondansetron hydrochloride dehydrate, Wockhardt UK Ltd, Wrexham, UK; IV Hameln Pharma plus GmbH, Hameln)] for the treatment of nausea and vomiting in pregnancy." | 5.41 | Ondansetron and metoclopramide as second-line antiemetics in women with nausea and vomiting in pregnancy: the EMPOWER pilot factorial RCT. ( Campbell, I; Fernandez-Garcia, C; Goudie, N; Graham, R; Howel, D; Lie, M; McColl, E; McParlin, C; Mossop, H; Nadeem, A; Nelson-Piercy, C; O'Hara, ME; Phillipson, J; Robson, S; Shehmar, M; Simpson, N; Steel, A; Ternent, L; Tuffnell, D; Williams, R, 2021) |
| " Compared to other active drugs, it only showed a lower significant effect compared with granisetron regarding headache change while it showed significantly higher effects only with placebo in both rescue medication needs and headache-free symptoms and valproate in only rescue medication need." | 5.41 | The efficacy and safety of metoclopramide in relieving acute migraine attacks compared with other anti-migraine drugs: a systematic review and network meta-analysis of randomized controlled trials. ( Abd-ElGawad, M; Abdelhay, HM; Abdelmonem, H; Abdelwadoud, GT; Ahmed, AE; Al-Dardery, NM; Alhosini, ANM; Kamel, MA; Mohamed, SW, 2023) |
| "Metoclopramide is a dopamine receptor blocking drug that is commonly used to treat nausea and vomiting." | 5.31 | Metoclopramide for nausea and vomiting of pregnancy: a prospective multicenter international study. ( Addis, A; Arnon, J; Berkovitch, M; Elbirt, D; Greenberg, R; Magee, L; Mazzota, P; Merlob, P; Moretti, M; Ornoy, A; Schuler-Faccini, L; Stahl, B, 2002) |
| "and metoclopramide 0." | 5.29 | Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study. ( Cannata, G; Gebbia, N; Gebbia, V; Testa, A, 1996) |
| "Metoclopramide is a very effective drug in preventing the acute emetic and nauseating effects of cisplatin." | 5.28 | Suitability of long-acting metoclopramide for prophylaxis of chemotherapy-induced delayed nausea and vomiting. ( Schimke, J; Senn, HJ; Vergin, H; Wilder-Smith, C, 1989) |
| " Metoclopramide and methylprednisolone, at the dosage and schedule used, were well tolerated and moderately active in preventing nausea and vomiting induced by cis-platin; their use in combination could further improve these results." | 5.27 | Comparison of methylprednisolone and metoclopramide in the prophylactic treatment of cis-platin-induced nausea and vomiting. ( Bertetto, O; Calciati, A; Ciuffreda, L; Clerico, M; Donadio, M; Ferrati, P; Giaccone, G; Musella, R, 1984) |
| "Metoclopramide was orally administered (10 or 20 mg) to 22 subjects, 75 min before parabolic flight." | 5.27 | Hormonal responses of metoclopramide-treated subjects experiencing nausea or emesis during parabolic flight. ( Kohl, RL, 1987) |
| "Diphenhydramine was administered intramuscularly 30 minutes before and 5 hours after chemotherapy." | 5.27 | [The prevention of CDDP-induced emesis with a combination regimen including metoclopramide, dexamethasone, droperidol and diphenhydramine]. ( Arihiro, T; Dozono, H; Morimoto, O; Ochiai, K; Sasaki, H; Takahashi, S; Terashima, Y; Tsuruoka, M; Yasuda, M; Yokoyama, S, 1987) |
| " Maropitant (MRP) and metoclopramide (MCP) prevent emesis attributable to the opioid agent apomorphine in dogs." | 5.24 | A comparison between maropitant and metoclopramide for the prevention of morphine-induced nausea and vomiting in dogs. ( Himelfarb, MA; Invaldi, SH; Litterio, NJ; Lorenzutti, AM; Martín-Flores, M; Zarazaga, MP, 2017) |
| "There was no evidence that prophylactic metoclopramide affected the risk of vomiting, nausea, or the need for rescue medication when provided prior to intravenous opioids in the acute care setting." | 5.22 | Prophylactic antiemetics for adults receiving intravenous opioids in the acute care setting. ( Carlson, JN; Gottlieb, M; Peksa, GD, 2022) |
| "To compare effectiveness of "oxygen alone" vs "metoclopramide plus oxygen" vs "metamizole plus oxygen" therapy in treating carbon monoxide-induced headache." | 5.22 | Treatment in carbon monoxide poisoning patients with headache: a prospective, multicenter, double-blind, controlled clinical trial. ( Basturk, M; Duran, A; Emet, M; Ocak, T; Serinken, M; Tekin, E, 2016) |
| " The aim of this study was to verify if A + D is superior to metoclopramide plus dexamethasone (M + D) in preventing delayed emesis in cancer patients receiving the same prophylaxis for acute emesis." | 5.20 | Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study. ( Angelelli, L; Ballatori, E; Caserta, C; Cavanna, L; Ciuffreda, L; Colantonio, I; Fasola, G; Fatigoni, S; Fava, S; Ionta, MT; Licitra, L; Massidda, B; Mirabile, A; Palladino, MA; Roila, F; Ruggeri, B; Tocci, A; Zerilli, F, 2015) |
| "We compare efficacy of ondansetron and metoclopramide with placebo for adults with undifferentiated emergency department (ED) nausea and vomiting." | 5.19 | Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo. ( Braitberg, G; Egerton-Warburton, D; Mee, MJ; Meek, R, 2014) |
| " The granisetron group indicated a higher complete response rate in acute emesis (adjusted OR: 0." | 5.17 | Can granisetron injection used as primary prophylaxis improve the control of nausea and vomiting with low- emetogenic chemotherapy? ( Abdul Kassim, MS; Keat, CH; Phua, G; Poh, WK; Sriraman, M, 2013) |
| "To estimate whether the addition of metoclopramide or its combination with ondansetron to a prophylactic phenylephrine infusion provides improved intraoperative nausea and vomiting prophylaxis compared with phenylephrine infusion alone." | 5.17 | Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial. ( Allen, TK; George, RB; Habib, AS; Ituk, US; McKeen, DM; Megalla, SA; White, WD, 2013) |
| "During the 72-h observation period, 39 out of 56 (70%) patients receiving olanzapine had no emesis compared to 16 out of 52 (31%) patients with no emesis for patients receiving metoclopramide (p < 0." | 5.17 | The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. ( Gray, SE; Nagy, CK; Navari, RM, 2013) |
| "To compare the effects of metoclopramide infusion in emergency department (ED) patients complaining of nausea to determine the changes in its therapeutic effect and prevention of side effects such as akathisia and sedation." | 5.16 | Slow infusion metoclopramide does not affect the improvement rate of nausea while reducing akathisia and sedation incidence. ( Aydin, B; Erdur, B; Parlak, I; Tura, P; Turkcuer, I, 2012) |
| "Several trials had independently noted that patients receiving megestrol acetate had less nausea and vomiting, but this antiemetic activity of megestrol acetate has not been reported separately in the literature." | 5.15 | Antiemetic activity of megestrol acetate in patients receiving chemotherapy. ( Bi, F; Cao, D; Gou, HF; Hou, M; Jiang, M; Luo, de Y; Qiu, M; Shen, Y; Wang, J; Xu, F; Yang, Y; Yi, C; Zang, J; Zhou, XJ, 2011) |
| "The objective of the study was to assess whether ondansetron has superior nausea reduction compared with metoclopramide, promethazine, or saline placebo in emergency department (ED) adults." | 5.15 | A randomized, placebo-controlled trial of ondansetron, metoclopramide, and promethazine in adults. ( Barrett, TW; DiPersio, DM; Jack, M; Jenkins, CA; Lee, P; McCoin, NS; Singleton, LM; Slovis, CM; Storrow, AB; Zhou, C, 2011) |
| "To compare the efficacy of acupressure wrist bands, ondansetron, metoclopramide and placebo in the prevention of vomiting and nausea after strabismus surgery." | 5.15 | Comparing the efficacy of prophylactic p6 acupressure, ondansetron, metoclopramide and placebo in the prevention of vomiting and nausea after strabismus surgery. ( Arbabi, S; Ebrahim Soltani, AR; Goudarzi, M; Mohammadinasab, A; Mohammadinasab, F; Mohammadinasab, H; Samimi, M, 2011) |
| "We aimed to compare the relative efficacy of tropisetron and metoclopramide in treating nausea/vomiting in undifferentiated ED patients." | 5.15 | Tropisetron versus metoclopramide for the treatment of nausea and vomiting in the emergency department: A randomized, double-blinded, clinical trial. ( Chae, J; Frauman, AG; Taylor, DM, 2011) |
| "This study assesses the effects of ginger on nausea and vomiting caused by pregnancy and compares it with metoclopramide medicine." | 5.15 | Comparing the effects of ginger and metoclopramide on the treatment of pregnancy nausea. ( Farhadifar, F; Mohammadbeigi, R; Rezaiie, M; Shahgeibi, S; Soufizadeh, N, 2011) |
| " Patients who presented to our emergency department with a primary or secondary chief complaint of nausea were randomized to one of the following 4 groups: (1) metoclopramide 10 mg+diphenhydramine 25 mg; (2) metoclopramide 10 mg+placebo; (3) metoclopramide 20 mg+diphenhydramine 25 mg; (4) metoclopramide 20 mg+placebo." | 5.14 | A randomized trial of diphenhydramine as prophylaxis against metoclopramide-induced akathisia in nauseated emergency department patients. ( Bender, B; Bijur, P; Davitt, M; Esses, D; Friedman, BW; Gallagher, EJ; Paternoster, J; Solorzano, C, 2009) |
| "Of the 380 patients evaluated, significantly fewer ondansetron 4 mg treated patients (89/189; 47%) experienced postoperative nausea and/or vomiting compared with metoclopramide treated patients (115/ 191; 60%) during the study period (p = 0." | 5.13 | Ondansetron vs. metoclopramide for the prevention of nausea and vomiting after gynecologic surgery. ( Diregpoke, S; Krobbuaban, B; Pitakpol, S, 2008) |
| "Metoclopramide use during first trimester of pregnancy was not associated with the risk of major congenital malformations." | 5.12 | Use of metoclopramide in the first trimester and risk of major congenital malformations: A systematic review and meta-analysis. ( Sun, L; Wen, X; Xi, Y; Zou, W, 2021) |
| "First-line antiemetics for nausea and vomiting in advanced cancer are metoclopramide and haloperidol, and second-line medications are methotrimeprazine and olanzapine." | 5.12 | MASCC antiemetics in advanced cancer updated guideline. ( Bruera, E; Capela, A; Davies, A; Davis, M; DeFeo, G; Del Fabbro, E; Hui, D; Ripamonti, C, 2021) |
| "The aim of this study was to compare the incidence of nausea and vomiting in patients with acute pain treated with morphine along with prophylactic metoclopramide or placebo." | 5.12 | Use of a prophylactic antiemetic with morphine in acute pain: randomised controlled trial. ( Bradshaw, M; Sen, A, 2006) |
| "This study demonstrates that betamethasone does not prevent nausea, vomiting and increase of vasopressin induced by apomorphine, whereas metoclopramide prevents apomorphine-induced emesis." | 5.12 | Betamethasone does not prevent nausea and vomiting induced by the dopamine-agonist apomorphine. ( Axelsson, P; Lövqvist, A; Thörn, SE; Wattwil, L; Wattwil, M, 2006) |
| "A prospective randomized study was performed to assess the value of some individual risk factors for postoperative nausea and vomiting (PONV), and to compare the efficacy of ondansetron, metoclopramide, dexamethason, and combinations of these antiemetics in preventing PONV in patients after laparoscopic cholecystectomy." | 5.12 | Ondansetron, metoclopramid, dexamethason, and their combinations compared for the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: a prospective randomized study. ( Leksowski, K; Peryga, P; Szyca, R, 2006) |
| "In children and adolescents with osteosarcoma, granisetron was safe and more efficient than metoclopramide plus dimenhydrinate for controlling chemotherapy-induced emesis and nausea." | 5.12 | Contribution to the treatment of nausea and emesis induced by chemotherapy in children and adolescents with osteosarcoma. ( Caran, EM; Luisi, FA; Petrilli, AS; Tanaka, C, 2006) |
| "To determine whether intermediate dose metoclopramide is more effective than standard dose metoclopramide for patients who present to the ED with nausea and vomiting." | 5.11 | Intermediate dose metoclopramide is not more effective than standard dose metoclopramide for patients who present to the emergency department with nausea and vomiting: a pilot study. ( Basire, M; Cham, S; Kelly, AM, 2004) |
| "Aim of this study was to demonstrate that intravenous metoclopramide can reduce pain, nausea and discomfort during nasogastric tube (NGT) insertion in ED." | 5.11 | Effectiveness of pre-emptive metoclopramide infusion in alleviating pain, discomfort and nausea associated with nasogastric tube insertion: a randomised, double-blind, placebo-controlled trial. ( Karaca, MA; Ozucelik, DN; Sivri, B, 2005) |
| "Metoclopramide pretreatment provided protection against nausea and cramping associated with estrogen/progestin emergency contraception." | 5.10 | Metoclopramide pretreatment attenuates emergency contraceptive-associated nausea. ( Buck, HW; Ragan, RE; Rock, RW, 2003) |
| " The number of patients who were emesis free (no nausea, retching, or vomiting) was significantly higher in patients who received granisetron (88% [2225]) than in those who received droperidol (64% [1625]; P = 0." | 5.10 | A comparison of granisetron, droperidol, and metoclopramide in the treatment of established nausea and vomiting after breast surgery: a double-blind, randomized, controlled trial. ( Fujii, Y; Kawasaki, T; Tanaka, H, 2003) |
| "This study compares pyridoxine-metoclopramide combination therapy to prochlorperazine and promethazine monotherapies in the outpatient treatment of nausea and vomiting in pregnancy." | 5.10 | Comparison of three outpatient regimens in the management of nausea and vomiting in pregnancy. ( Bsat, FA; Hoffman, DE; Seubert, DE, 2003) |
| "The results obtained showed that ondansetron was more effective in controlling nausea and vomiting than metoclopramide, either objectively (2." | 5.10 | Comparison of ondansetron with metoclopramide in the symptomatic relief of uremia-induced nausea and vomiting. ( Bagatin, J; Hozo, I; Ljutić, D; Perković, D; Pivac, N; Rumboldt, Z, 2002) |
| "Several studies have confirmed the efficacy of high-dose metoclopramide and, more recently, serotonin antagonists, with and without dexamethasone, in the prophylaxis of cisplatin-induced nausea and vomiting." | 5.09 | Prospective randomized comparison of tropisetron with and without dexamethasone against high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. ( Hussain, M; Khan, Z; Malik, I; Moid, I, 1999) |
| ") doses of ondansetron 8 mg, ondansetron 16 mg and metoclopramide 10 mg in the treatment of opioid-induced emesis." | 5.09 | Ondansetron is more effective than metoclopramide for the treatment of opioid-induced emesis in post-surgical adult patients. Ondansetron OIE Post-Surgical Study Group. ( Alahuta, S; Chung, F; Curtis, P; Duvaldestin, P; Jacka, M; Lane, R; Luttropp, HH; McQuade, B; Rocherieux, S; Roy, M; Spraggs, C, 1999) |
| "Complete control of established postoperative nausea and vomiting, defined as no emesis and no need for another rescue antiemetic medication, was more frequent among the patients who had received granisetron (88%) than among those who had received droperidol (55%) or metoclopramide (50%) (P <." | 5.09 | Granisetron, droperidol, and metoclopramide for the treatment of established postoperative nausea and vomiting in women undergoing gynecologic surgery. ( Fujii, Y; Somekawa, Y; Tanaka, H, 2000) |
| "The serotonin (5HT3) antagonist ondansetron was compared in a randomised study with metoclopramide and dexamethasone for the prevention of chemotherapy induced emesis." | 5.08 | Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis. ( Dick, GS; Meller, ST; Pinkerton, CR, 1995) |
| "Metoclopramide was significantly more effective at preventing both nausea and vomiting (20/44 (45%) compared with 32/47 (68%), p < 0." | 5.08 | Prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy. A prospective randomized study of metoclopramide and transdermal hyoscine. ( Appelgren, L; Haglind, E; Thune, A, 1995) |
| "Successful control of vomiting was achieved in the first 24 hours, in 74% of the cycles containing cisplatin and 82% of the cycles without cisplatin, if ondansetron was used." | 5.08 | Ondansetron in chemotherapy-induced emesis. Our experience. ( Bandiera, AF; Fiorelli, C; Framarino dei Malatesta, M; Marzetti, L; Toccaceli Blasi, MR; Veneziano, M; Yacoub, M, 1995) |
| "To determine whether postoperative pain and nausea after laparoscopic sterilization can be reduced with a combination of bupivacaine, metoclopramide, scopolamine, ketorolac, and gastric suctioning." | 5.08 | Reduction of pain and nausea after laparoscopic sterilization with bupivacaine, metoclopramide, scopolamine, ketorolac, and gastric suctioning. ( Bradford, TH; Meeks, GR; Norman, PF; Robertson, K, 1995) |
| "To compare the efficacy of oral droperidol versus oral metoclopramide, or both oral droperidol and metoclopramide, on postoperative vomiting when used as a premedicant for strabismus surgery." | 5.08 | The effects of oral droperidol versus oral metoclopramide versus both oral droperidol and metoclopramide on postoperative vomiting when used as a premedicant for strabismus surgery. ( Brown, RE; Jones, E; Kymer, PJ; Lawhorn, CD; Pearce, L, 1995) |
| "This randomized, double-blind, multicentre, parallel-group study compared the efficacy and safety of an intravenous dose of ondansetron 4 mg for the prevention of postoperative nausea and vomiting (PONV) with metoclopramide 10 mg and placebo in patients undergoing major gynaecological surgery." | 5.08 | [Intravenous administration of ondansetron vs. metoclopramide for the prophylaxis of postoperative nausea and vomiting]. ( Rust, M, 1995) |
| "We have compared the efficacy of ondansetron, metoclopramide, droperidol and placebo in the prevention of postoperative nausea and vomiting in 118 day stay patients undergoing laparoscopic gynaecological procedures." | 5.08 | Prevention of nausea and vomiting after day case gynaecological laparoscopy. A comparison of ondansetron, droperidol, metoclopramide and placebo. ( McKay, AC; Mirakhur, RK; Paxton, LD, 1995) |
| " We compared the efficacy, toxicity, and patients' preference for tropisetron, a new 5-hydroxytryptamine3 (HT3) receptor antagonist, with those of a combination of high-dose metoclopramide, dexamethasone, diphenhydramine, and lorazepam (metoclopramide cocktail) in a randomized crossover study for the control of nausea and vomiting during cisplatin-containing chemotherapy." | 5.08 | Comparison of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis. ( Chang, TC; Cheng, HH; Hsieh, F; Lai, CH; Li, CL; Michael, BJ; Soong, YK; Tseng, CJ, 1996) |
| "Of the patients treated with metoclopramide plus methylprednisolone (n = 92), 53% had complete protection from delayed emesis, 16% a major response, 15% a minor response, and 15% no response." | 5.08 | Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial. ( Cannata, G; Gebbia, N; Gebbia, V; Testa, A; Tirrito, ML; Valenza, R, 1995) |
| "Intravenous antiemetic combinations containing a 5-HT3 receptor antagonist (like metoclopramide, ondansetron, or granisetron) with dexamethasone have become the standard therapy for the treatment of acute chemotherapy-induced vomiting." | 5.08 | Oral combination antiemetics in patients with small cell lung cancer receiving cisplatin or cyclophosphamide plus doxorubicin. ( Clark, RA; Cleri, LB; Gralla, RJ; Kris, MG; Pisters, KM; Tyson, LB, 1995) |
| "Both metoclopramide and prochlorperazine in combination with lorazepam and diphenhydramine offer good control of nausea and vomiting although the sedation and low risk for cardiac toxicity limit the regimen to an inpatient setting with close monitoring." | 5.08 | Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation. ( Gilbert, CJ; Ohly, KV; Peters, WP; Rosner, G, 1995) |
| "The aim of the present study was to compare the antiemetic efficacy of ondansetron (OND) with metoclopramide (MCP), both combined with corticosteroid (CS) in patients with malignant lymphoma." | 5.08 | Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy. ( Jørgensen, M; Victor, MA, 1996) |
| " The recurrence of retching or vomiting was higher with propofol (58%) than with droperidol (4%) or metoclopramide (24%) (P < 0." | 5.08 | Treatment of postoperative nausea and vomiting: comparison of propofol, droperidol and metoclopramide. ( Lacroix, G; Lessard, MR; Trépanier, CA, 1996) |
| "The purpose of this retrospective study is to assess the frequency and intensity of chronic nausea in patients admitted to the Palliative Care Unit and the results of a metoclopramide-based treatment regimen." | 5.08 | Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen. ( Babul, N; Bruera, E; Darke, A; Harsanyi, Z; Seifert, L; Suarez-Almazor, M; Watanabe, S, 1996) |
| "The efficacy of ondansetron 4 mg was compared with metoclopramide 10 mg for the prevention of post-operative nausea and vomiting in patients after major gynaecological abdominal surgery." | 5.08 | Comparison of ondansetron and metoclopramide for the prevention of post-operative nausea and vomiting after major gynaecological surgery. ( Chen, PP; Chui, PT; Gin, T, 1996) |
| "This study determined the overall incidence of postoperative nausea and vomiting (PONV) in 38 patients undergoing laparoscopic gynaecological procedures who received a standardized propofol/isoflurane anaesthetic but no preoperative antiemetic." | 5.08 | A randomized double-blinded comparison of metoclopramide, ondansetron and cyclizine in day-case laparoscopy. ( Watts, SA, 1996) |
| "The potent serotonin receptor (5-HT3) antagonists are new highly selective agents for the prevention and control of chemotherapy-induced nausea and vomiting that have been shown to be comparable to or more effective than traditional metoclopramide regimens." | 5.08 | A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy. ( Bastit, P; Cals, L; Cappelaere, P; Catimel, G; Chevallier, B; Claverie, N; Fabbro, M; Giovannini, M; Khayat, D; Splinter, T; Wendling, JL, 1997) |
| "In a prospective, randomised, double-blind trial, we assessed the relative efficacy of prophylactic ondansetron and metoclopramide administration in the reduction of postoperative nausea and vomiting in 60 patients undergoing routine major neurosurgical procedures." | 5.08 | A comparison of prophylactic ondansetron and metoclopramide administration in patients undergoing major neurosurgical procedures. ( Barsoum, LZ; Jones, NC; Pugh, SC, 1996) |
| "A double-blind, randomised, placebo-controlled trial was conducted to compare the efficacy of metoclopramide with the 5-HT3 antagonist, ondansetron, for the prevention of postoperative emesis in children undergoing elective strabismus surgery." | 5.08 | Efficacy of ondansetron and metoclopramide for preventing postoperative emesis following strabismus surgery in children. ( Mandal, NG; Shende, D, 1997) |
| "To compare the efficacy of oral ondansetron with oral metoclopramide for the prevention of postoperative vomiting and nausea in children undergoing strabismus surgery." | 5.08 | [Does oral ondansetron reduce the incidence of nausea and vomiting after surgery for strabismus in children?]. ( Amraoui, A; Benaguida, M; el Harrar, N; Idali, B; Laouissi, F; Mjahed, K, 1996) |
| "In a randomised, double-blind study, we have compared the incidence of postoperative nausea and vomitting in 124 patients undergoing major lower limb orthopaedic surgery following oral premedication with temazapam and ondansetron 8 mg, metoclopramide 10 mg or placebo." | 5.08 | Comparison of ondansetron, metoclopramide and placebo as premedicants to reduce nausea and vomiting after major surgery. ( Alexander, R; Fennelly, M, 1997) |
| " This difference was still significant when controlling for age, body weight, history of motion sickness, previous PONV episodes, duration of anesthesia, and intraoperative fentanyl consumption using a logistic model." | 5.08 | Ondansetron versus metoclopramide in the treatment of postoperative nausea and vomiting. ( Finco, G; Gottin, L; Grosso, S; Ischia, S; Mosaner, W; Pinaroli, AM; Polati, E; Verlato, G, 1997) |
| "Granisetron is a better prophylactic antiemetic than droperidol or metoclopramide in female patients with a history of motion sickness undergoing major gynaecological surgery." | 5.08 | Prevention of PONV with granisetron, droperidol and metoclopramide in female patients with history of motion sickness. ( Fujii, Y; Tanaka, H; Toyooka, H, 1997) |
| " The purpose of this study was to compare the efficacy of ondansetron, a highly selective 5-hydroxytryptamine subtype-3 receptor antagonist, with that of metoclopramide for the prevention of postoperative emesis in patients undergoing cataract surgery." | 5.08 | Prophylactic intravenous ondansetron in patients undergoing cataract extraction under general anesthesia. ( Ascaso, FJ; Ayala, I; Carbonell, P; Castro, FJ; Palomar, A, 1997) |
| " After experiencing at least one nausea and/or one emetic episode in the 6 h after recovery from anaesthesia, patients received either ondansetron 4 mg i." | 5.08 | Ondansetron compared with metoclopramide in the treatment of established postoperative nausea and vomiting. The French Ondansetron Study Group. ( Clyti, N; Conseiller, C; Diemunsch, P; Mamet, JP, 1997) |
| "Seminoma stage I patients on tropisetron experienced less nausea and vomiting during abdominal radiotherapy than patients receiving metoclopramide." | 5.08 | Prophylactic use of tropisetron or metoclopramide during adjuvant abdominal radiotherapy of seminoma stage I: a randomised, open trial in 23 patients. ( Aass, N; Fosså, SD; Håtun, DE; Thoresen, M, 1997) |
| "To establish a dose-response relationship for ondansetron, and to evaluate any effects of oral premedication with metoclopramide in pediatric patients undergoing tonsillectomy and adenoidectomy and strabismus surgery." | 5.08 | Ondansetron dose response curve in high-risk pediatric patients. ( Kymer, PJ; Lawhorn, CD; Shirey, R; Stewart, FC; Stoner, JM; Volpe, P, 1997) |
| "Granisetron is more effective than droperidol or metoclopramide in preventing PONV in female patients with a history of postoperative emesis." | 5.08 | Prevention of PONV with granisetron, droperidol or metoclopramide in patients with postoperative emesis. ( Fujii, Y; Saitoh, Y; Tanaka, H; Toyooka, H, 1998) |
| "Ondansetron 4 mg was compared with metoclopramide 10 mg for prevention of post-operative nausea and emesis in in-patients undergoing major gynaecological surgery in this double-blind, randomized, placebo-controlled, multicentre study." | 5.08 | International, multicentre, placebo-controlled study to evaluate the effectiveness of ondansetron vs. metoclopramide in the prevention of post-operative nausea and vomiting. ( Aune, H; Cohen, LA; Feiss, P; Hanson, A; Hasselstrøm, L; Maltby, JR; Morris, RW; Rocke, DA; Rozenberg, B; Rust, M, 1998) |
| "This study evaluates the prophylactic anti-emetic efficacy of granisetron, droperidol and metoclopramide, for the prevention of post-operative nausea and vomiting in female patients undergoing elective laparoscopic cholecystectomy." | 5.08 | Anti-emetic efficacy of prophylactic granisetron, droperidol and metoclopramide in the prevention of nausea and vomiting after laparoscopic cholecystectomy: a randomized, double-blind, placebo-controlled trial. ( Fujii, Y; Saitoh, Y; Tanaka, H; Toyooka, H, 1998) |
| "A single institution, prospective, randomized trial was performed in terminal cancer patients to compare tropisetron (TRO), metoclopramide (MET), and chlorpromazine (CHL) in the management of nausea and emesis." | 5.08 | Comparison of the efficacy and safety of tropisetron, metoclopramide, and chlorpromazine in the treatment of emesis associated with far advanced cancer. ( Befon, S; Liossi, C; Mystakidou, K; Vlachos, L, 1998) |
| "To compare the prophylactic administration of ondansetron plus droperidol, droperidol plus metoclopramide, and perphenazine to determine effects on postoperative nausea, vomiting, and sedation after laparoscopic cholecystectomy." | 5.08 | Prophylactic antiemetics for laparoscopic cholecystectomy: a comparison of perphenazine, droperidol plus ondansetron, and droperidol plus metoclopramide. ( Freiberger, D; Gosnell, JL; Steinbrook, RA, 1998) |
| "Ondansetron appeared to be superior to metoclopramide-diphenhydramine in the control of emesis induced by chemotherapy regimens containing cisplatin." | 5.08 | Comparison of the efficacy and side-effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy: a prospective randomized study. ( Atay, AA; Köseoglu, V; Kürekçi, AE; Ozcan, O; Sarici, U; Sorici, U, 1998) |
| "To determine the contribution of metoclopramide to the efficacy of ondansetron in control of cisplatin-induced emesis, ondansetron was compared with ondansetron plus metoclopramide for antiemetic efficacy in a randomized double-blind trial." | 5.07 | Ondansetron compared with ondansetron plus metoclopramide in the prevention of cisplatin-induced emesis. ( Cho, GY; Kim, SH; Kim, SW; Lee, CW; Lee, JS; Lee, KH; Suh, CW, 1994) |
| "The mechanism of ioxaglate-induced nausea has not been fully elucidated." | 5.07 | [The mechanism producing nausea during ventriculography performed with ioxaglate: the implications of a randomized study]. ( Barthe, JE; Catarino, C; Cequier, A; Esplugas, E; Gómez-Hospital, JA; Jara, F; Mauri, J; Sabaté, M; Sala, J; Valerio, L, 1994) |
| "Lignocaine has been shown to reduce the incidence of pain on injection of propofol." | 5.07 | Propofol injection pain: comparing the addition of lignocaine or metoclopramide. ( Mecklem, DW, 1994) |
| "We carried out a randomized, single-blind, cross-over trial to compare the antiemetic effect, for both acute and delayed emesis, of granisetron plus dexamethasone (GRN+Dx) with that of high-dose metoclopramide plus dexamethasone (HDMP+Dx)." | 5.07 | A randomized cross-over study of high-dose metoclopramide plus dexamethasone versus granisetron plus dexamethasone in patients receiving chemotherapy with high-dose cisplatin. ( Arioka, H; Eguchi, K; Karato, A; Kunikane, H; Nakashima, H; Nisio, M; Ohe, Y; Ohmatsu, H; Shinkai, T; Tamura, T, 1994) |
| "Oral metoclopramide may be given as a premedicant to reduce post-operative nausea and vomiting, but there is little evidence that it is effective." | 5.07 | Sustained release metoclopramide for prophylaxis of post-operative nausea and vomiting. ( Curran, JP; Elliott, RH; Graham, SG, 1994) |
| "The clinical efficacy and tolerability of a new nasal spray formulation of metoclopramide (MTC) was evaluated in terms of its ability to prevent the nausea and vomiting induced by a moderately emetic chemotherapy (cisplatin 20 mg/m2 weekly as radioenhancer+radiotherapy for a fractionated total of 60 Gy) in 12 patients with non-small-cell lung cancer, stage IIIB." | 5.07 | Efficacy and tolerability of nasally administered compared to parenterally administered metoclopramide in the symptomatic treatment of chemotherapy-induced emesis in cancer outpatients. A controlled clinical study. ( Confalonieri, M; Dimaiuta, M; Scanni, A; Tomirotti, M, 1994) |
| "In a prospective, double-blind study, we have examined the effect of preoperative nabilone on postoperative nausea and vomiting (PONV)." | 5.07 | Effect of nabilone on nausea and vomiting after total abdominal hysterectomy. ( Barrowcliffe, MP; Campbell, DN; Lewis, IH, 1994) |
| " Acetaminophen and meperidine were given for postoperative pain." | 5.07 | Prophylactic antiemetic treatment with ondansetron in children undergoing tonsillectomy. ( Furst, SR; Rodarte, A, 1994) |
| "The short elimination half-life of metoclopramide necessitates frequent administration for optimal relief of nausea." | 5.07 | Comparison of the efficacy, safety, and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer. ( Babul, N; Bruera, ED; Darke, AC; Harsanyi, Z; LeGatt, DF; MacDonald, RN; MacEachern, TJ; Spachynski, KA, 1994) |
| " dexamethasone and oral metoclopramide) for delayed emesis, while they had received either i." | 5.07 | Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles. Italian Group for Antiemetic Research. ( , 1994) |
| " Oral granisetron alone was as effective as met/dex in control of acute emesis in all parameters examined." | 5.07 | Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group. ( Cedar, E; Cunningham, J; Goedhals, L; Heron, JF; Jordaan, JP, 1994) |
| " A sample of 43 patients with breast cancer was accrued from September to November 1992 in a phase II study to assess the efficacy of granisetron in patients receiving FEC (5-FU, epirubicin, cyclophosphamide)." | 5.07 | Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide. ( Ang, PT; Khoo, KS; Tan, EH, 1994) |
| "We studied the preventive effect on postoperative nausea and vomiting (PONV) of ondansetron, metoclopramide and placebo associated with epidural anaesthesia." | 5.07 | [Effects of ondansetron and metoclopramide on postoperative nausea and vomiting after epidural anesthesia in children]. ( Andreuccetti, T; Busoni, P; Calamandrei, M; Crescioli, M; Messeri, A; Sarti, A; Sestini, G, 1994) |
| "Metoclopramide is an active antiemetic against cisplatin-induced acute emesis." | 5.07 | Continuous infusion versus intermittent short infusion of metoclopramide for cisplatin-induced acute emesis. ( Kajita, M; Niimi, T; Saito, H; Shimokata, K; Yamori, S, 1994) |
| "We have compared the incidence of postoperative nausea and vomiting up to 48 h after day-case gynaecological laparoscopy after oral premedication with ondansetron 4 mg, metoclopramide 10 mg or a placebo allocated randomly and assessed blindly." | 5.07 | Nausea and vomiting after gynaecological laparoscopy: comparison of premedication with oral ondansetron, metoclopramide and placebo. ( Cooper, GM; Field, JM; Malins, AF; Nesling, PM, 1994) |
| "This placebo-controlled, randomized, double-blind trial was designed to evaluate the efficacy of three prophylactic antiemetic regimens on postoperative nausea and vomiting (PONV) during patient-controlled analgesia (PCA) with morphine." | 5.07 | Prophylactic antiemetic therapy with patient-controlled analgesia: a double-blind, placebo-controlled comparison of droperidol, metoclopramide, and tropisetron. ( Kaufmann, MA; Rosow, C; Schneider, M; Schnieper, P, 1994) |
| "We have compared the efficacy of ondansetron with droperidol and saline in the prevention of postoperative nausea and vomiting (PONV) in 120 ASA I and II patients undergoing hip and knee replacements and femoral resections." | 5.07 | Double-blind comparison of ondansetron, droperidol and saline in the prevention of postoperative nausea and vomiting. ( Collis, R; Gan, TJ; Hetreed, M, 1994) |
| "We investigated the usefulness of concurrent therapy of granisetron with methylprednisolone sodium for on nausea, vomiting and anorexia induced by chemotherapy, including cisplatin, in patients with oral cancer." | 5.07 | [Clinical effects of granisetron and methylprednisolone against nausea, vomiting and anorexia induced by cisplatin]. ( Kawashima, T; Miyata, K; Morita, N; Ohmata, T; Sakamoto, T; Wada, T, 1993) |
| ") was compared with a metoclopramide cocktail for the prevention of nausea and emesis." | 5.07 | An open, randomized study to compare the efficacy and tolerability of tropisetron with that of a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. ( Frankendal, B; Hallén, C; Sorbe, B, 1994) |
| ", Basel, Switzerland), a new 5-HT3 receptor antagonist, was compared in a randomized multicenter trial with a high-dose metoclopramide-dexamethasone cocktail for the prevention of nausea and emesis during cisplatin-containing chemotherapy." | 5.07 | A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. ( de Bruijn, KM; Glimelius, B; Hansen, O; Högberg, T; Räisänen, I; Schmidt, M; Sorbe, BG; Sörensen, BT; van Oosterom, AT; Wernstedt, L, 1994) |
| "Ondansetron is a serotonin antagonist that recently has been introduced as a preventive agent for chemotherapy-induced nausea and vomiting." | 5.07 | Comparison of intermittent ondansetron versus continuous infusion metoclopramide used with standard combination antiemetics in control of acute nausea induced by cisplatin chemotherapy. ( Kilgore, JR; Navari, RM; Perrine, GM; Province, WS, 1993) |
| "The usefulness of alprazolam (minor tranquilizer) used in combination with metoclopramide plus methylprednisolone for the prevention and control of emesis induced by chemotherapies, including 5-day continuous intravenous infusion of cisplatin (25 mg/m2/day) for advanced lung cancer, was evaluated using a double-blind randomized crossover design." | 5.07 | Antiemetic efficacy of alprazolam in the combination of metoclopramide plus methylprednisolone. Double-blind randomized crossover study in patients with cisplatin-induced emesis. ( Mori, K; Saito, Y; Tominaga, K, 1993) |
| "This pilot randomized study compared MDL 72,222, a highly selective 5-HT3 receptor antagonist, with a high-dose metoclopramide regimen (HDM) for chemotherapy-induced nausea and vomiting." | 5.07 | Randomized comparison of the antiemetic efficacy of a serotonin type 3 receptor antagonist (MDL 72,222) with a high-dose metoclopramide regimen. ( Barrett, RJ; Hahne, WF; Heck, K; Homesley, HD; Lentz, SS; Lovelace, JV; McLees, B; Woodlief, L, 1993) |
| " To address its use with a widely used but less emetogenic regimen, we performed a double-blind, randomized clinical trial comparing ondansetron with dexamethasone and metoclopramide in patients with breast cancer receiving chemotherapy with cyclophosphamide, methotrexate, and fluorouracil." | 5.07 | Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. ( Latreille, J; Levitt, M; Lofters, WS; Perrault, DJ; Potvin, M; Rayner, HL; Warner, E; Warr, D; Wilson, KS; Yelle, L, 1993) |
| "Tiapride (Tiapridal, Delagrange), a dopaminergic D2 receptor blocking agent having anxiolytic, sedative, antiemetic and analgesic properties was compared with metoclopramide and placebo in a randomized double-blind trial to determine its effects on post-operative nausea, vomiting, and sedation." | 5.07 | Tiapride versus metoclopramide: comparison after minor gynaecological surgery. ( Joshi, R; Sivaganesanathan, A, 1993) |
| "This report of a double-blind, randomized study performed to evaluate the comparative antiemetic efficacy of tropisetron (Navoban; Sandoz Pharma Ltd, Basel, Switzerland), a new 5-hydroxytryptamine receptor antagonist, focuses on treatment during stages of chemotherapy when nausea and vomiting are particularly severe." | 5.07 | A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis. ( Krzakowski, M; Lasota, W; Madej, G; Pawinski, A; Rogowski, W; Skoneczna, I, 1994) |
| "The efficacy and tolerability of tropisetron in preventing cisplatin-induced nausea and vomiting was studied in 2 open trials and compared with the efficacy and tolerability of metoclopramide plus lorazepam in a randomised crossover trial." | 5.07 | Three years' experience with tropisetron in the control of nausea and vomiting in cisplatin-treated patients. ( Antonacci, RA; Berruti, A; Dogliotti, L; Faggiuolo, R; Ortega, C; Pazè, E, 1992) |
| "Prevention and treatment of postoperative nausea and vomiting with ephedrine, droperidol and metoclopramide have been reported to be effective." | 5.07 | Comparison of antiemetic effect among ephedrine, droperidol and metoclopramide in pediatric inguinal hernioplasty. ( Kang, HM; Liou, CM; Liu, YC; Tso, HS, 1992) |
| "In order to decide the administration method of metoclopramide for prevention or control of chemotherapy-induced nausea and vomiting in multidrug chemotherapy, with cisplatin 5-day continuous intravenous infusion (25 mg/m2/day) for patients with advanced lung cancer, a randomised crossover study of intermittent bolus infusion (1 mg/kg, 30 min, every 8 h, day 1-5) and continuous infusion (3 mg/kg/24 h, 120 h) of metoclopramide was performed." | 5.07 | Comparison of continuous and intermittent bolus infusions of metoclopramide during 5-day continuous intravenous infusion with cisplatin. ( Miyazawa, N; Mori, K; Saitou, Y; Tominaga, K, 1991) |
| "Sixty patients were studied in a randomized, double-blind manner to determine whether metoclopramide added to droperidol decreased further the incidence of emetic symptoms (nausea, retching, vomiting) in outpatients receiving alfentanil anaesthesia for nasal surgery." | 5.07 | Metoclopramide does not decrease the incidence of nausea and vomiting after alfentanil for outpatient anaesthesia. ( AlHaddad, S; Furgerson, C; Khalil, I; Maurer, W; Whalley, DG, 1991) |
| " In this randomized, single-blind, multicenter, parallel group study, we compared the efficacy and safety of intravenous (IV) ondansetron with IV metoclopramide in the prevention of nausea and vomiting associated with high-dose (greater than or equal to 100 mg/m2) cisplatin chemotherapy." | 5.07 | A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. ( Gandara, D; Hainsworth, J; Harker, G; Harvey, W; Hesketh, P; Kasimis, B; Khojasteh, A; Monaghan, G; Oblon, D; Pendergrass, K, 1991) |
| "Ondansetron was compared with metoclopramide for antiemetic efficacy in a randomised double-blind trial in 122 patients with advanced breast cancer." | 5.07 | Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. ( Adler, M; Christmann, D; Fenzl, E; Marschner, NW; Nagel, GA; Upadhyaya, B, 1991) |
| "To prevent delayed emesis induced by cisplatin (mean dose 90 mg/m2), 120 consecutive patients were randomized to receive, in a 7-day crossover design, oral metoclopramide (20 mg q." | 5.07 | Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. ( Ballatori, E; Basurto, C; Boschetti, E; Bracarda, S; Patoia, L; Penza, O; Picciafuoco, M; Roila, F; Santi, E; Tonato, M, 1991) |
| "Ondansetron is a 5-hydroxytryptamine 3-receptor antagonist which has shown activity in the prevention of cytotoxic-induced emesis." | 5.06 | Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation. ( Adams, M; Collis, CH; Lucraft, H; Priestman, S; Priestman, TJ; Roberts, JT; Upadhyaya, BK, 1990) |
| "To compare ondansetron (GR 38032F), a 5-hydroxytryptamine3-receptor antagonist, with metoclopramide in the prophylaxis of acute cisplatin-induced emesis, we conducted a double-blind crossover study in 97 patients scheduled to receive cisplatin (80 to 100 mg per square meter of body-surface area) for treatment of cancer." | 5.06 | Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. ( Azab, M; Bons, J; Brion, N; Droz, JP; Marty, M; Paes, D; Paule, B; Pouillart, P; Pujade-Lauraine, E; Scholl, S, 1990) |
| "Seventy-five breast cancer patients scheduled to receive a first course (in a new cycle) of cyclophosphamide, fluorouracil, and doxorubicin (FAC) or epirubicin (FEC) participated in a double-blind crossover study to compare the antiemetic efficacy and safety of ondansetron (GR38032), a 5-hydroxytryptamine3 (5-HT3) receptor antagonist, and metoclopramide." | 5.06 | A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. ( Bonneterre, J; Bons, J; Chevallier, B; Fargeot, P; Metz, R; Paes, D; Pujade-Lauraine, E; Spielmann, M; Tubiana-Hulin, M, 1990) |
| "To compare the efficacy and side effects of ondansetron with those of high-dose metoclopramide in treating acute and delayed cisplatin-induced nausea and vomiting." | 5.06 | Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. ( Allman, EL; Beranek, P; De Mulder, PH; Mols-Jevdevic, S; Seynaeve, C; van Liessum, PA; Vermorken, JB; Verweij, J, 1990) |
| " All patients received intravenous (IV) metoclopramide, dexamethasone, and lorazepam for the control of acute emesis during the period from 0 to 24 hours after cisplatin." | 5.06 | Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. ( Cirrincione, C; Clark, RA; Gralla, RJ; Groshen, S; Kris, MG; Tyson, LB, 1989) |
| "In a randomized, double-blind study, we compared the efficacy of metoclopramide hydrochloride with that of low-dose droperidol for prevention of nausea and vomiting during and after elective cesarean section with epidural anesthesia." | 5.06 | Metoclopramide versus droperidol for prevention of nausea and vomiting during epidural anesthesia for cesarean section. ( Bates, JN; Chestnut, DH; Choi, WW; Geiger, M; Ostman, PL; Owen, CL, 1989) |
| "A double-blind, randomized, crossover study was conducted to compare the efficacy and safety of high-dose dexamethasone (Protocol D) with a combination of dexamethasone, metoclopramide and diphenhydramine (Protocol DMD) in the management of chemotherapy-induced nausea and vomiting in cancer patients." | 5.06 | Antiemetic efficacy of high-dose dexamethasone: randomized, double-blind, crossover study with a combination of dexamethasone, metoclopramide and diphenhydramine. ( Ababtain, WA; Abdullah, KA; al-Idrissi, HY; Boukhary, HA; Ibrahim, EM; Macaulay, HM, 1988) |
| " CMF were included in a double-blind comparative study aimed at evaluating the efficacy of 3 different drugs (methylprednisolone (MP), metoclopramide (MTC), and domperidone (DMP) in preventing chemotherapy-induced nausea and vomiting." | 5.06 | Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF. ( Ballatori, E; Basurto, C; del Favero, A; Minotti, V; Roila, F; Tonato, M, 1987) |
| "Forty patients with advanced lung cancer who had received chemotherapy containing cisplatin (80 mg/m2) were accrued for a randomized controlled trial to evaluate the additional effect of prochlorperazine on the combination of high-dose metoclopramide and dexamethasone for the treatment of acute cisplatin-induced emesis." | 5.06 | [A randomized controlled trial of acute and delayed cisplatin-induced emesis with metoclopramide, dexamethasone and prochlorperazine]. ( Eguchi, K; Inoue, I; Nino, S; Saijo, N; Sakurai, M; Sasaki, Y; Shinkai, T; Suemasu, K; Tamura, T; Umehara, H, 1987) |
| "The antiemetic efficacy and toxicity of methylprednisolone (MP) and metoclopramide (MTC) in prevention of nausea and vomiting in breast cancer patients receiving intravenous cyclophosphamide methotrexate 5-fluorouracil (CMF) chemotherapy has been evaluated in a double-blind trial." | 5.06 | Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized study. ( Ballatori, E; Basurto, C; Del Favero, A; Minotti, V; Roila, F; Tonato, M, 1988) |
| "A double-blind, randomized, crossover study was conducted to compare the efficacy and safety of high-dose dexamethasone and high-dose metoclopramide in the treatment of chemotherapy-induced nausea and vomiting." | 5.06 | Antiemetic efficacy of high-dose dexamethasone: randomized, double-blind, crossover study with high-dose metoclopramide in patients receiving cancer chemotherapy. ( Absood, G; Al-Dossary, E; Al-Ethan, S; Al-Idrissi, HY; Al-Jammaa, A; Eliopoulos, A; Ibrahim, A; Ibrahim, EM, 1986) |
| "Methylprednisolone sodium succinate and metoclopramide were compared for their efficacy, tolerance, and safety in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy in patients with cancer." | 5.06 | Superiority of methylprednisolone sodium succinate over low dose metoclopramide hydrochloride in the prevention of nausea and vomiting produced by cancer chemotherapy. ( Erlichman, C; Levitt, M; Osoba, D; Pater, JL; Willan, AR, 1986) |
| "A randomized cross-over study on the effects of methylprednisolone (MP), metoclopramide (MT) and droperidol (DP) on the control of nausea and vomiting associated with cis-platinum chemotherapy was performed." | 5.06 | [Randomized cross-over study on the effects of methylprednisolone, metoclopramide and droperidol on the control of nausea and vomiting associated with cis-platinum chemotherapy]. ( Akaza, H; Aso, Y; Fujita, K; Isurugi, K; Kawabe, K; Kinoshita, K; Koiso, K; Kondo, Y; Niijima, T; Yokoyama, M, 1986) |
| "25 mg droperidol, 20 mg metoclopramide or a saline placebo intravenously 5-10 min before the end of anaesthesia in a double-blind random fashion to prevent post-operative nausea and vomiting." | 5.06 | Droperidol, alizapride and metoclopramide in the prevention and treatment of post-operative emetic sequelae. ( Gordin, A; Heikkinen, H; Kauste, A; Korttila, K; Tuominen, M, 1986) |
| "Thirty three untreated patients being given cisplatin received metoclopramide (7 mg/kg) for antiemesis by either continuous or intermittent infusion in a random order." | 5.06 | Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin. ( Allan, SG; Cornbleet, MA; Leonard, RC; MacPherson, JS; Smyth, JF; Warrington, PS, 1986) |
| "The present trial was designed to compare the effect of metoclopramide(MCP) + dexamethasone(DM) (Method A) with that of MCP + DM + lorazepam(Lor) (Method B) in the treatment of CDDP (cis-diamminedichloroplatinum)-induced nausea and vomiting in a randomized fashion." | 5.06 | [Anti-emetic treatment with metoclopramide and other drugs during CDDP therapy]. ( Arai, R; Furuse, K; Hayashi, S; Kawahara, M; Kiyota, T; Kodama, N; Tsuruta, S, 1987) |
| " A combination of Nabilone and metoclopramide was used in an unrandomized pilot study (prior to the withdrawal of Nabilone from clinical use); these patients recorded better scores for nausea and vomiting and patient acceptability than those in the randomized study." | 5.05 | Antiemetics for patients treated with antitumor chemotherapy. ( Bolton, A; de Pemberton, R; Whitehouse, JM; Williams, CJ, 1980) |
| "One hundred and two patients with advanced solid tumors receiving chemotherapy were treated with metoclopramide (MCP; 100 mg) to prevent emesis." | 5.05 | Improved control of chemotherapy-induced emesis by the addition of dexamethasone to metoclopramide in patients resistant to metoclopramide. ( Bruera, ED; Cedaro, L; Chacón, R; Estévez, R; Roca, E, 1983) |
| " Compared to metoclopramide, alizapride caused a faster regression of inappetence and of the frequency of daily vomiting." | 5.05 | [Alizapride in a double-blind trial with metoclopramide in nausea and vomiting caused by radiotherapy]. ( Budach, V; Krüger, K, 1983) |
| "An open-label clinical trial was conducted to test the safety and efficacy of intravenous metoclopramide monohydrochloride in preventing chemotherapy-induced nausea and vomiting." | 5.05 | Intravenous metoclopramide. An effective antiemetic in cancer chemotherapy. ( McDermed, JE; Opfell, RW; Riech, LP; Strum, SB, 1982) |
| "Fifty-five patients with delayed gastric emptying and the symptoms of nausea, vomiting, postprandial bloating and early satiety were treated with metoclopramide." | 5.05 | Metoclopramide therapy in fifty-five patients with delayed gastric emptying. ( Davidson, ED; Hersh, T; Moore, C; Perkel, MS, 1980) |
| "A double-blind comparison of metoclopramide versus placebo was performed on 8 cirrhotic patients with nausea (8 cases) and heartburn (3 of the 8 cases) plus mild portal-systemic encephalopathy." | 5.05 | Successful administration of metoclopramide for the treatment of nausea in patients with advanced liver disease. A double-blind controlled trial. ( Ballesteros, A; Briones, A; Garcia Ramos, G; Garza, J; Rosales, J; Strauss, R; Uribe, M; Villalobos, A, 1985) |
| "The effect of high-dose metoclopramide (2 mg/kg, 4 times every 2 hours) on the emesis of patients treated with CDDP (80 mg/m2) was examined by randomized control trial." | 5.05 | [Randomized control study of high-dose metoclopramide in the prevention of CDDP-induced emesis]. ( Eguchi, K; Fujita, J; Funaki, Y; Futami, H; Sakurai, M; Sasaki, Y; Sawamura, N; Takahashi, S; Yokoyama, S; Yoshioka, S, 1985) |
| "Using a sensitive and specific high-pressure liquid chromatographic (HPLC) assay, we measured serum levels of metoclopramide in 18 cancer patients receiving high-dose intravenous (IV) therapy to prevent cisplatin-induced emesis." | 5.05 | Clinical pharmacokinetics of high-dose metoclopramide in cancer patients receiving cisplatin therapy. ( Cohen, JL; Joseph, C; McDermed, JE; Strum, SB, 1985) |
| "We tested the safety and antiemetic effectiveness of intravenous (IV) dexamethasone (DXM) as an adjunct to high-dose IV metoclopramide (MCP) to prevent nausea and vomiting induced by high-dose cisplatin chemotherapy." | 5.05 | High-dose intravenous metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind crossover comparison of antiemetic efficacy. ( Liponi, DF; McDermed, JE; Strum, SB, 1985) |
| "The antinausea and antivomiting effects of delta-9-tetrahydrocannabinol (THC) in children receiving cancer chemotherapy were compared with those of metoclopramide syrup and prochlorperazine tablets in two double-blind studies." | 5.04 | Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol. ( Ekert, H; Jurk, IH; Loughnan, P; Mobilia, J; Waters, KD, 1979) |
| "In a double-blind trial in 60 children suffering from gastroenteritis complicated by vomiting, it was found that suppositories of domperidone (30 mg) were more effective than either metoclopramide (10 mg) or placebo in reducing the severity of vomiting, nausea and other symptomatic parameters." | 5.04 | A double-blind comparison of domperidone and metoclopramide suppositories in the treatment of nausea and vomiting in children. ( Ameryckx, L; Dhondt, F; Heck, E; Van Eygen, M; Van Ravensteyn, H, 1979) |
| "Forty-seven infants and children suffering from chronic vomiting or regurgitation, participated in a two-week double-blind trial comparing 1% drops of domperidone, 1% metoclopramide drops or placebo." | 5.04 | Domperidone drops in the symptomatic treatment of chronic paediatric vomiting and regurgitation. A comparison with metoclopramide. ( Ameryckx, L; De Loore, I; Van Ravensteyn, H, 1979) |
| "One hundred and ninety-five female patients of child-bearing age were assessed for postoperative vomiting in a double-blind trial using domperidone, metoclopramide and placebo." | 5.04 | Prevention of postoperative nausea and vomiting by domperidone: A double-blind randomized study using domperidone, metoclopramide and a placebo. ( Ball, RW; Comyn, DJ; Cooke, RD, 1979) |
| " Although known to interfere with central dopamine mechanisms, it is frequently used in Parkinson's disease to prevent levodopa-induced nausea and vomiting." | 5.04 | Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias. ( Marsden, CD; Parkes, JD; Tarsy, D, 1975) |
| "To assess the efficacy and safety of olanzapine when used as an antiemetic in the prevention and treatment of nausea and vomiting related to cancer in adults." | 4.98 | Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. ( Burton, MJ; Head, K; Naessens, K; Plugge, E; Sutherland, A; Ware, L; Wee, B, 2018) |
| " Addition of metoclopramide 10 mg improves relief of nausea and vomiting." | 4.89 | Aspirin with or without an antiemetic for acute migraine headaches in adults. ( Derry, S; Kirthi, V; Moore, RA, 2013) |
| "To examine the medical evidence regarding the clinical efficacy and cost-effectiveness of the application of continuous subcutaneous metoclopramide and ondansetron to treat nausea and vomiting during pregnancy." | 4.88 | Reviewing the evidence for using continuous subcutaneous metoclopramide and ondansetron to treat nausea & vomiting during pregnancy. ( Kirkbride, MS; Reichmann, JP, 2012) |
| "In patients with advanced cancer not being treated with chemotherapy or radiation therapy, metoclopramide can be used to reduce nausea and vomiting." | 4.88 | [Treatment of nausea and vomiting with prokinetics and neuroleptics in palliative care patients : a review]. ( Alt-Epping, B; Benze, G; Geyer, A; Nauck, F, 2012) |
| "The objective of the present study was to conduct a systematic review and meta-analysis of randomized controlled trials, comparing metoclopramide with placebo, for preventing vomiting in patients who have received i." | 4.87 | Review article: Prophylactic metoclopramide for patients receiving intravenous morphine in the emergency setting: a systematic review and meta-analysis of randomized controlled trials. ( Bendall, JC; Middleton, PM; Simpson, PM, 2011) |
| "Based on the safety and efficacy of ondansetron, it may be used as a first-line agent for relief of nausea or vomiting for most patient populations in the ED." | 4.86 | Antiemetic therapy for nausea and vomiting in the emergency department. ( Amini, R; Hays, DP; Patanwala, AE; Rosen, P, 2010) |
| " Addition of metoclopramide 10 mg improves relief of nausea and vomiting." | 4.86 | Aspirin with or without an antiemetic for acute migraine headaches in adults. ( Derry, S; Kirthi, V; McQuay, HJ; Moore, RA, 2010) |
| "A short cut review was carried out to establish whether metoclopramide reduced nausea and vomiting after the administration of morphine." | 4.82 | Best evidence topic reports. Metoclopramide versus placebo with opioid. ( Alsalim, W; Butler, J; Leung, WC, 2004) |
| " In the last decade the use of high-dose metoclopramide and, especially, the introduction of the 5-HT3 receptor antagonists, have been major leaps forward in the control of chemotherapy-induced emesis." | 4.79 | Optimal control of acute cisplatin-induced emesis. ( de Mulder, PH; de Wit, R; Verweij, J, 1996) |
| "In the past few years important progress in the prevention of chemotherapy-induced nausea and vomiting has been made mainly thanks to the introduction of the 5-HT3 receptor antagonists in clinical practice (ondansetron, granisetron, tropisetron)." | 4.79 | [Recent improvements in antiemetic therapy]. ( Basurto, C; Ciccarese, G; Palladino, MA; Roila, F, 1997) |
| "8 mg/kg was superior to metoclopramide in preventing emesis induced by high dose cisplatin or by moderately emetogenic chemotherapy in high risk subgroups." | 4.79 | Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. ( Balfour, JA; Goa, KL, 1997) |
| "This paper described an outline of clinically applications of 5-HT3 receptor antagonists, mainly on ondansetron, which control nausea and vomiting associated with cancer chemotherapy." | 4.78 | [An outline of 5-HT3 receptor antagonists (2)--In clinical applications]. ( Ohta, J; Taguchi, T; Tsukagoshi, S, 1993) |
| "Ondansetron is more effective than high-dose metoclopramide in the prevention of acute nausea and vomiting due to highly emetogenic chemotherapy, and, unlike metoclopramide, is rarely associated with extrapyramidal effects." | 4.78 | Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy. ( Milne, RJ; Plosker, GL, 1992) |
| "Monosodium glutamate induces behaviors thought to reflect headache and nausea in rats." | 4.12 | Peripheral N-methyl-D-aspartate receptor activation contributes to monosodium glutamate-induced headache but not nausea behaviours in rats. ( Benbow, T; Cairns, BE; Exposto, FG; Sheikhi, A; Svensson, P; Teja, F, 2022) |
| "The objective of the study was to evaluate the rate of major congenital anomalies after first trimester exposure to ondansetron for nausea and vomiting of pregnancy (NVP)." | 4.02 | Pregnancy outcome following in-utero exposure to ondansetron: A prospective comparative observational study. ( Arnon, J; Diav-Citrin, O; Sakran, R; Shechtman, S, 2021) |
| "This study aimed to compare the therapeutic efficacy of dimenhydrinate and metoclopramide in patients with nausea and vertigo." | 4.02 | Comparison of efficacy dimenhydrinate and metoclopramide in the treatment of nausea due to vertigo; a randomized study. ( Ercin, D; Erdur, B; Ozen, M; Seyit, M; Turkcuer, I; Yilmaz, A; Zincir Ercin, DO, 2021) |
| " Common etiologies included constipation, opioid use, and "other," and treatments associated with a statistically significant decrease in nausea/vomiting were olanzapine, laxatives, corticosteroids, domperidone, and metoclopramide." | 3.91 | The nature of nausea: prevalence, etiology, and treatment in patients with advanced cancer not receiving antineoplastic treatment. ( Frandsen, K; Groenvold, M; Harder, S; Herrstedt, J; Isaksen, J; Jespersen, BA; Mondrup, L; Neergaard, MA; Sigaard, J, 2019) |
| "Using the Quebec Pregnancy Cohort (1998-2015), first-trimester doxylamine-pyridoxine, metoclopramide, and ondansetron exposures were assessed for their association with MCM." | 3.91 | New evidence for concern over the risk of birth defects from medications for nausea and vomitting of pregnancy. ( Bérard, A; Bernatsky, S; Gorgui, J; Sheehy, O; Soares de Moura, C; Zhao, JP, 2019) |
| " Delayed emesis following Cycle 1 of carboplatin was observed in 30% of patients." | 3.83 | Delayed nausea and vomiting from carboplatin doublet chemotherapy. ( Baggstrom, MQ; Chitneni, P; Gao, F; Govindan, R; Mann, J; Morgensztern, D; Waqar, MA; Waqar, SN; Williams, K, 2016) |
| "For nausea, a commonly encountered symptom in palliative care, clinicians' favored metoclopramide and haloperidol; however, after these choices, there was large variation in antiemetic selection." | 3.80 | Prescribing for nausea in palliative care: a cross-sectional national survey of Australian palliative medicine doctors. ( Agar, M; Currow, DC; To, TH; Yates, P, 2014) |
| "Patients with cancer frequently report gastrointestinal symptoms such as anorexia, early satiety, nausea, vomiting, and bloating." | 3.80 | Long-term safety and clinical effectiveness of controlled-release metoclopramide in cancer-associated dyspepsia syndrome: a multicentre evaluation. ( Chow, W; Darke, A; Harsanyi, Z; Marshall, D; Pearen, S; Plourde, JY; Wilson, J; Yoshida, S, 2002) |
| "The purpose of this study was to formulate and characterize metoclopramide solid lipid nanoparticles (MCP-SLNs) and incorporating it into suppository bases for treatment of nausea and vomiting, produced with chemotherapeutic agents, using one dose per day." | 3.79 | Formulation and evaluation of metoclopramide solid lipid nanoparticles for rectal suppository. ( Abass, HA; Attia, MA; Heikal, OA; Mohamed, RA, 2013) |
| "While providing a better efficacy in acute emesis control, the low incidence of acute emesis and high ICER makes use of granisetron as primary prophylaxis in LEC controversial." | 3.79 | Cost-effectiveness analysis of granisetron-based versus standard antiemetic regimens in low-emetogenic chemotherapy: a hospital-based perspective from Malaysia. ( Ghani, NA; Keat, CH, 2013) |
| "We examined treatment outcomes in women with severe nausea and vomiting of pregnancy (NVP) receiving outpatient nursing support and either subcutaneous metoclopramide or subcutaneous ondansetron via a microinfusion pump." | 3.77 | Treatment of severe nausea and vomiting of pregnancy with subcutaneous medications. ( Desch, C; Fox, NS; Istwan, N; Klauser, CK; Palmer, B; Rebarber, A; Rhea, D; Saltzman, D, 2011) |
| " Ondansetron 8 mg and dexamethasone 8 mg intravenously were the standard antiemetic therapy for prevention of acute chemotherapy-induced nausea and vomiting." | 3.77 | Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy. ( Baak-Pablo, RF; Gelderblom, H; Guchelaar, HJ; Hakimi, M; Mustofa, M; Nortier, JW; Perwitasari, DA; van der Straaten, RJ; Wessels, JA, 2011) |
| "Ondansetron was superior to placebo in Study 1; complete control of emesis (0 emetic episodes) over 15 days was achieved in 62% of ondansetron-treated patients compared to 34% of placebo-treated patients (P = 0." | 3.77 | Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review. ( Marschner, N, 1991) |
| "The aim of the study was to evaluate the role of ramosetron for the prevention of chemoradiotherapy-induced nausea and vomiting (CRINV) in patients receiving upper abdominal irradiation with concurrent 5-fluorouracil chemotherapy." | 3.75 | Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer. ( Bang, YJ; Chie, EK; Ha, SW; Im, SA; Jang, JY; Kim, K; Kim, SW; Kim, TY; Oh, DY, 2009) |
| "In various countries, metoclopramide is the antiemetic drug of choice in pregnant women, but insufficient information exists regarding its safety in pregnancy." | 3.75 | The safety of metoclopramide use in the first trimester of pregnancy. ( Gorodischer, R; Koren, G; Levy, A; Matok, I; Sheiner, E; Wiznitzer, A, 2009) |
| "A patient who was given metoclopramide for vomiting and diarrhoea developed circulatory collapse with his blood pressure dropping to 50/20 mm Hg." | 3.75 | Circulatory collapse in a patient with gastrinoma after metoclopramide administration. ( Chan, AY; Chan, KW; Ching, CK; Lam, AW; Lau, KK; Lee, HH; Li, SM; Lo, J; Lok, CM; Luk, WF; Mak, CM, 2009) |
| "Two double-blind, placebo-controlled, prospective randomized trials in the emergency department (ED) setting have examined the use of metoclopramide for the prevention of opiate-induced nausea and vomiting." | 3.71 | Low incidence of nausea and vomiting with intravenous opiate analgesia in the ED. ( Paoloni, R; Talbot-Stern, J, 2002) |
| "To assess the effectiveness of ondansetron in relieving symptoms of nausea and vomiting which were refractory to metoclopramide and cyclizine, in a patient receiving iloprost infusions." | 3.71 | Pre-emptive metoclopramide and ondansetron for nausea and vomiting associated with iloprost infusions. ( Roome, C; Thompson, J, 2001) |
| " Two doses of oral metoclopramide 10 mg in solution were administered for nausea and vomiting." | 3.70 | Respiratory failure following oral administration of metoclopramide. ( MacLaren, R; Shields, CA, 1998) |
| "A prospective trial was performed to better assess the risk of nausea and vomiting and the rescue value of tropisetron (TRO), a 5-HT3 receptor antagonist, in 88 patients undergoing fractionated radiotherapy to the abdomen or to large supradiaphragmatic fields and failing a first anti-emetic trial with metoclopramide (MET)." | 3.69 | Nausea and vomiting in fractionated radiotherapy: a prospective on-demand trial of tropisetron rescue for non-responders to metoclopramide. ( Behrouz, F; Blazek, N; Coucke, P; Gebhard, S; Melliger, M; Miralbell, R; Philipp, S; Rosset, A; Schwabb, T; Wickenhauser, R, 1995) |
| " In the present study, the role of nausea in TCDD-induced hypophagia was assessed by a battery of behavioral (conditioned taste aversion [CTA], kaolin consumption, protein selection), biochemical (plasma oxytocin), and antiemetic drug intervention (trimethobenzamine, metoclopramide) approaches." | 3.69 | TCDD-induced hypophagia is not explained by nausea. ( Pohjanvirta, R; Tuomisto, J; Unkila, M, 1994) |
| "Although buprenorphine sometimes causes severe emesis, its relation to the menstrual cycle has not been reported." | 3.69 | Menstrual stage influences postoperative nausea and vomiting following epidural buprenorphine. ( Kamiyama, M; Kitamura, A; Kon, T; Ogawa, R, 1996) |
| "Fifty-one patients who received their first course of chemotherapy were studied to compare the respective efficacy and safety of granisetron and metoclopramide plus dexamethasone in the prevention of nausea and vomiting induced by emetogenic cytotoxic drugs." | 3.69 | Comparison of intravenous granisetron with metoclopramide plus dexamethasone in the prevention of nausea and vomiting associated with emetogenic cytotoxic chemotherapy. ( Chang, CS; Chen, LT; Chen, TP; Huang, SM; Lin, SF; Liu, TC; Wei, TC, 1997) |
| "The purpose of this study was to investigate a possible effect of metoclopramide on the bioavailability of 8-MOP since these drugs are frequently combined to prevent nausea, a common side effect of systemic 8-MOP." | 3.69 | Influence of metoclopramide on the pharmacokinetics of 8-methoxypsoralen. ( Fathi, M; Piletta, PA; Salomon, D; Saurat, JH; Studer-Sachsenberg, EM, 1997) |
| " The syndrome was associated with metoclopramide antiemetic therapy given for post-operative nausea and vomiting." | 3.68 | Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy. ( Bakri, YN; Kawi, Z; Khan, R; Subhi, J, 1992) |
| "Lorazepam, dexamethasone and high-dose metoclopramide were given to 54 patients to prevent emesis induced by cisplatin (50-120 mg/m2) on day 1, while prochlorperazine and dexamethasone were administered on days 2 and 3 for control of delayed emesis." | 3.68 | Acute and delayed emesis after cisplatin-based regimen: description and prevention. ( Beaulieu, R; Courchesne, Y; Latreille, J; Letendre, F; Lorange, A; Louvet, C; Monte, M; Neemeh, JA; Pretty, HM, 1991) |
| "To evaluate the efficacy of a combined therapy of prednisolone and alprazolam for controlling cisplatin-induced delayed emesis, a study involving 14 non-small cell lung cancer patients receiving cisplatin (80 mg/m2) was conducted." | 3.68 | [A combined anti-emesis therapy of oral prednisolone and alprazolam for cisplatin-induced delayed emesis]. ( Horio, Y; Iwahara, T; Minami, H; Sakai, S; Shibagaki, T; Shimokata, K; Watanabe, A, 1990) |
| "Nabilone is a cannabinoid anti-emetic which has been extensively evaluated in control of chemotherapy-induced vomiting." | 3.67 | An initial evaluation of Nabilone in the control of radiotherapy-induced nausea and vomiting. ( Priestman, SG; Priestman, TJ, 1984) |
| "Repeated oral doses of metoclopramide (50 mg) and prednisone (25 mg) completely prevented nausea and vomiting (N + V) in approximately 50% and substantially reduced N + V in an additional 27%-36% of 56 chemotherapy courses in 30 consecutive cancer patients who were receiving primarily cisplatin." | 3.67 | Effective control of chemotherapy-induced nausea and vomiting with oral prednisone and metoclopramide. ( Bachmann-Mettler, I; Glaus, A; Senn, HJ, 1984) |
| "The authors tested the safety and efficacy of intravenous metoclopramide in the prevention of chemotherapy-induced nausea and vomiting." | 3.67 | Intravenous metoclopramide: prevention of chemotherapy-induced nausea and vomiting. A preliminary evaluation. ( McDermed, JE; Pileggi, J; Riech, LP; Strum, SB; Whitaker, H, 1984) |
| "We evaluated whether chronic nausea and vomiting in diabetic patients correlate with abnormal gastric emptying of liquid or solid, or both liquid and solid, radiolabeled meals and recorded the acute effects of metoclopramide." | 3.67 | Gastric emptying in patients with diabetes mellitus. ( Kalbfleisch, JH; Loo, FD; Palmer, DW; Soergel, KH; Wood, CM, 1984) |
| " The nausea and vomiting were reasonably well controlled with methylprednisolone and metoclopramide." | 3.67 | [Clinical study of chemotherapy (PPM therapy) with cisplatin, peplomycin and mitomycin C in squamous cell lung cancer]. ( Arai, S; Honda, Y; Ito, T; Kato, M; Kawata, Y; Kori, Y; Koyama, M, 1986) |
| "Metoclopramide infusions are used to prevent nausea and vomiting in cancer patients during chemotherapy." | 3.67 | Population analysis of the pharmacokinetic variability of high-dose metoclopramide in cancer patients. ( Bateman, DN; Grevel, J; Kelman, AW; Taylor, WB; Whiting, B, 1988) |
| "The effect of metoclopramide premedication on the incidence of gastric regurgitation and postoperative nausea and vomiting was studied in 101 women during gynaecological procedures performed under mask anaesthesia." | 3.67 | Silent regurgitation in day case gynaecological patients. ( Anderson, WG; Miller, CD, 1988) |
| "Forty-six outpatients with breast cancer who had experienced severe emesis as a result of chemotherapy were evaluated for the antiemetic efficacy of high-dose metoclopramide (HD-MCP) and dexamethasone (DXM)." | 3.67 | High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second study. ( Ben-Baruch, N; Ben-Yosef, R; Biran, S; Brufman, G; Gez, E; Uziely, B; Warner-Efraty, E; Yitzhaki, N, 1987) |
| "In two previous consecutive studies on antiemetic combination of metoclopramide and dexamethasone was found to be very active against nausea and vomiting induced by cisplatin (DDP; 50 mg/m2) alone or in combination with other cytotoxic emetogenic drugs." | 3.67 | Maintenance of antiemetic effect of a metoclopramide-dexamethasone combination during subsequent cisplatin courses. ( Caporali, C; Carlini, P; Cognetti, F; Pinnarò, P; Ruggeri, EM, 1986) |
| "Orally administered metoclopramide (REGLAN) at doses of 10 or 20 mg, 75 min prior to either stressful linear acceleration (parabolic flight) or cross-coupled accelerative semicircular canal stimulation in a rotating chair was evaluated for its ability to prevent emesis or nausea II, respectively." | 3.67 | Failure of metoclopramide to control emesis or nausea due to stressful angular or linear acceleration. ( Kohl, RL, 1987) |
| "The ergoline derivative, Metergoline, in a dosage of 4 to 24 mg/day, was administered for one to eight months to 42 patients with hyperprolactinemic amenorrhea." | 3.67 | Treatment of hyperprolactinemic amenorrhea with Metergoline. ( Bohnet, HG; Kato, K; Wolf, AS, 1986) |
| " She was given 1,700 mg metoclopramide IV for 2 months to prevent nausea and vomiting." | 3.67 | Metoclopramide-induced phantom dyskinesia. ( Glass, JP; Jankovic, J, 1985) |
| "Sixteen of 26 patients given 51 courses of treatment of the doxorubicin and cisplatin combination with no antiemetic therapy suffered the same number of vomiting episodes and had the same duration of vomiting as did the remaining ten patients given 20 cycles of this chemotherapy plus the standard high-dose metoclopramide regimen." | 3.67 | Lack of antiemetic effect of high-dose metoclopramide. ( Christiansen, NP; Hrushesky, WJ; Roemeling, RV, 1985) |
| "Early clinical trials of metoclopramide at traditional doses failed to demonstrate protection against antineoplastic drug-induced vomiting, and its antiemetic potential for oncology patients was not re-examined until the unacceptable nausea and vomiting of the newly introduced cisplatin emphasised the need for improved supportive care." | 3.66 | Metoclopramide. A review of antiemetic trials. ( Gralla, RJ, 1983) |
| "When given with pethidine 100 mg or morphine 10 mg as preanaesthetic medication, 10 and 20 mg of metoclopramide cause a reduction in postoperative nausea and vomiting in women undergoing a standard operation with a standard anaesthetic technique." | 3.65 | Studies of drugs given before anaesthesia. XXIV: Metocloramide with morphine and pethidine. ( Assaf, RA; Clarke, RS; Dundee, JW; Samuel, IO, 1974) |
| "Metoclopramide was administered as a 2-minute bolus infusion." | 2.77 | A trial of midazolam vs diphenhydramine in prophylaxis of metoclopramide-induced akathisia. ( Aydin, B; Erdur, B; Ergin, A; Kabay, B; Ozen, M; Parlak, I; Tura, P, 2012) |
| "Metoclopramide is a dopamine antagonist, which may enhance efficacy of ondansetron and dexamethasone." | 2.77 | Randomized, double-blinded, placebo-controlled trial of ondansetron plus dexamethasone with or without metoclopramide as antiemetic prophylaxis in patients receiving high-dose cisplatin in medical practice. ( Akewanlop, C; Ithimakin, S; Keerativitayanan, N; Laocharoenkeat, A; Nimmannit, A; Runglodvatana, K; Soparattanapaisarn, N; Srimuninnimit, V, 2012) |
| "Pretreatment with ondansetron or metoclopramide does not reduce oral contrast solution ingestion time." | 2.74 | Pretreatment of patients requiring oral contrast abdominal computed tomography with antiemetics: a randomized controlled trial of efficacy. ( Bamber, D; Chohan, J; Garra, G; Singer, AJ; Thode, HC; Troxell, R, 2009) |
| "Droperidol (-54." | 2.72 | Antiemetics in the ED: a randomized controlled trial comparing 3 common agents. ( Andrews, J; Braude, D; Crandall, C; Hendey, G; Soliz, T; Weichenthal, L, 2006) |
| "Nausea and emesis are common side effects of opioid drugs administered for pain relief in cancer patients." | 2.70 | A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. ( Albertsson, M; Chimontsi-Kypriou, V; Curtis, P; Daly, S; Hardy, J; McQuade, B; Stathopoulos, P, 2002) |
| " The global incidence of adverse events was 45% higher with EC, though not significant (32 vs." | 2.69 | Comparative efficacy and safety of calcium carbasalate plus metoclopramide versus ergotamine tartrate plus caffeine in the treatment of acute migraine attacks. ( Geraud, G; Gómez, JP; Henry, P; Joffroy, A; Lainez, JM; Le Jeunne, C; Liaño, H; Pradalier, A; Titus i Albareda, F, 1999) |
| "198 chemonaive patients with breast cancer, treated with a moderately emetogenic chemotherapy, were randomly assigned to receive either oral granisetron 1 mg twice a day on day 1, followed by metoclopramide, 60 mg on day 2 and 3, or ondansetron, 8 mg IV on day 1, followed by ondansetron 8 mg tablet twice a day on day 2 and 3." | 2.69 | [Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron]. ( Granisétron, PK; Mabro, M, 1999) |
| "None of these differences reached statistical significance." | 2.69 | Prophylactic metoclopramide is unnecessary with intravenous analgesia in the ED. ( Paoloni, R; Talbot-Stern, J, 2000) |
| "Metoclopramide was ineffective." | 2.68 | The efficacy of prophylactic ondansetron, droperidol, perphenazine, and metoclopramide in the prevention of nausea and vomiting after major gynecologic surgery. ( Clark, K; Cronin, MK; Darvish, AH; Desilva, PH; McDonald, SM, 1995) |
| "An intermittent intake of low-dose droperidol with morphine given via a PCA delivery system in two treatment groups gave evidence for a dose-response relation between the amount of droperidol added and the proportion of patients needing a rescue antiemetic." | 2.68 | Antiemetic efficacy of a droperidol-morphine combination in patient-controlled analgesia. ( Bach, T; Jackson, D; McKenzie, R; Riley, T; Tantisira, B, 1995) |
| "Metoclopramide was given i." | 2.68 | Ondansetron versus metoclopramide as antiemetic treatment during cisplatin-based chemotherapy. A prospective study with special regard to regard to electrolyte imbalance. ( Benou, N; Charalambidis, G; Ganas, N; Karabellis, A; Kosmidis, P; Mylonakis, N; Pagou, M; Tsavaris, N; Tsikalakis, D, 1995) |
| "Nausea and vomiting are extremely common and most distressing side effects of high-dose cisplatin therapy." | 2.68 | Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. ( Ata, E; Butt, A; Khan, MA; Khan, WA; Malik, IA; Qazilbash, M, 1995) |
| "Metoclopramide was ineffective." | 2.68 | Prophylactic antiemetic therapy with ondansetron, tropisetron, granisetron and metoclopramide in patients undergoing laparoscopic cholecystectomy: a randomized, double-blind comparison with placebo. ( Attia, M; Channa, AB; el Bakry, AK; el Gammal, K; el Gammal, M; Elhattab, YS; Jaroudi, R; Khoshim, MH; Naguib, M; Saddique, A, 1996) |
| " We compared ondansetron and metoclopramide, both combined with dexamethasone, in cisplatin-treated patients." | 2.68 | Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research. ( , 1997) |
| "Tropisetron+dexamethasone was significantly superior to tropisetron alone both for acute (P = 0." | 2.68 | Comparison of three tropisetron-containing antiemetic regimens in the prophylaxis of acute and delayed chemotherapy-induced emesis and nausea. ( Bangerter, M; Bruntsch, U; Drechsler, S; Eggert, J; Faerber, L; Gallmeier, WM; Gosse, H; Grote-Kiehn, J; Imhoff, W; Mezger, J; Oehm, C; Ukena, D; Untch, M, 1997) |
| "Delayed emesis has not been seen during the antiemetic therapies." | 2.67 | [Nausea and vomiting in cytostatic therapy of melanoma patients with the use of metoclopramide and corticosteroid or ondansetron]. ( Baki, M; Czeglédi, F, 1994) |
| "Female patients with ovarian cancer are at high risk for emesis." | 2.67 | Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer. Italian Group for Antiemetic Research. ( , 1994) |
| "Tropisetron is an effective and well-tolerated agent in the prevention of chemotherapy-induced vomiting." | 2.67 | Tropisetron compared with a metoclopramide-based regimen in the prevention of chemotherapy-induced nausea and vomiting. ( Anderson, H; de Bruijn, KM; Howell, A; Logan, K; Sage, T; Thatcher, N, 1994) |
| "ondansetron was superior to metoclopramide in preventing nausea and vomiting after general anaesthesia for day-case gynaecological laparoscopic surgery." | 2.67 | Antiemetic efficacy of prophylactic ondansetron in laparoscopic surgery: randomized, double-blind comparison with metoclopramide. ( Norton, AC; Raphael, JH, 1993) |
| " Tropisetron in combination with dexamethasone produced the best control of both acute and delayed emesis." | 2.67 | Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents. ( Bruntsch, U; Drechsler, S; Eggert, J; Faerber, L; Gosse, H; Imhoff, W; Ukena, D, 1994) |
| "Emesis is one of the most frequent and distressing adverse effects of cytotoxic chemotherapy." | 2.67 | Prevention of emesis by tropisetron (Navoban) in children receiving cytotoxic therapy for solid malignancies. ( Balduck, N; Hachimi-Idrissi, S; Maurus, R; Otten, J, 1994) |
| "Acute nausea was prevented completely in 40% of patients in the tropisetron group and in 61% of the metoclopramide cocktail group during course 1 (P < ." | 2.67 | Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience. ( Sorbe, BG, 1994) |
| "Ondansetron was well tolerated in the dose and schedule used." | 2.67 | The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. ( Bryson, JC; Finn, AL; Gandara, DR; Harvey, WH; Hesketh, PJ; Monaghan, GG; Perez, EA; Stokes, C, 1992) |
| "The metoclopramide regimen was five times as expensive as prochlorperazine." | 2.67 | A randomised double-blind study of high-dose intravenous prochlorperazine versus high-dose metoclopramide as antiemetics for cancer chemotherapy. ( Bishop, JF; Buchanan, L; Cooper, IA; Laidlaw, C; Matthews, J; Olver, IN; Smith, R; Wolf, M, 1992) |
| "Ondansetron hydrochloride is a selective serotonin subtype 3 (5HT3) receptor antagonist that has been shown to be an effective antiemetic in patients receiving cisplatin chemotherapy." | 2.67 | Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. ( Einhorn, L; House, K; Nagy, C; Sledge, GW, 1992) |
| "Vomiting was decreased in the DXM groups compared to groups A and C (p < 0." | 2.67 | Antiemetic efficacy of high-dose metoclopramide and dexamethasone in patients receiving cisplatin chemotherapy: a randomized trial. ( Bacoyannis, C; Droufakou, S; Kosmidis, P; Kozatsani-Halividi, D; Mylonakis, N; Tsaroucha-Noutsou, E; Tsavaris, N; Tsoutsos, H; Valilis, P, 1992) |
| " Regimen B, employing a lower dosage of metoclopramide and steroids and using a more simple schedule of administration should be the preferred treatment." | 2.67 | Antiemetic activity of two different high doses and schedules of metoclopramide in dacarbazine-treated cancer patients. ( Basurto, C; Boschetti, E; Bracarda, S; Del Favero, A; Lupattelli, M; Picciafuoco, M; Roila, F; Sassi, M; Tonato, M, 1992) |
| "Metoclopramide-treated patients did not demonstrate a lower incidence of nausea or emesis but did tolerate oral liquids earlier after surgery than the placebo group (P less than 0." | 2.67 | Outpatient cholecystectomy simulated in an inpatient population. ( Downes, TW; Hayes, DH; McKinnon, WM; Treen, DC, 1991) |
| "At the end of the treatment period, nausea, vomiting and reflux symptoms, adverse events and a global assessment of patients' symptom control were recorded by the investigator." | 2.67 | A comparison of controlled release metoclopramide and domperidone in the treatment of nausea and vomiting. ( Miller, AJ; Patel, NH; Roy, P, 1991) |
| "Severe nausea was significantly less frequent with cinnarizine and 59% of the chemotherapy days were without nausea, compared to 46% of the days without cinnarizine (p less than 0." | 2.67 | Cinnarizine for prevention of nausea and vomiting during platin chemotherapy. ( Osterwalder, B; Schimke, J; Senn, HJ; Wilder-Smith, CH, 1991) |
| "Vomiting was not satisfactorily prevented by either treatment." | 2.67 | Betamethasone-dixyrazine versus betamethasone-metoclopramide as antiemetic treatment of cisplatin-doxorubicin-induced nausea in ovarian carcinoma patients. ( Hallén, C; Sorbe, B, 1991) |
| "The metoclopramide dosage was escalated in six steps from 0." | 2.66 | Dose-ranging antiemetic trial of high-dose oral metoclopramide. ( Clark, RA; Gralla, RJ; Kris, MG; Tyson, LB; Young, CW, 1989) |
| " We have, therefore, carried out a multicenter, double-blind randomized trial comparing a combination of high-dose metoclopramide (MTC) (1 mg/kg x 4) and methylprednisolone (P) (treatment A) with a shorter but higher single-dose schedule of metoclopramide (3 mg/kg x 2) combined with dexamethasone (DEX) and diphenhydramine (DIP) to prevent extrapyramidal reactions (treatment B)." | 2.66 | Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research ( Basurto, C; Bracarda, S; Di Costanzo, F; Donati, D; Malacarne, P; Monici, L; Patoia, L; Picciafuoco, M; Roila, F; Tonato, M, 1989) |
| " However, in the group of patients who received a high dosage of cisplatin (70-100 mg/m2), or ethylenediamine platinum II malonate (800-900 mg/m2), there was a significant difference in nausea and vomiting between patients who had and those who had not received prior chemotherapy, most probably due to anticipation." | 2.66 | Comparison of two different high doses of metoclopramide in the prevention of chemotherapy-induced emesis. ( Gall, HE; Knobf, MK; Nauta, J; Pinedo, HM; Simons, KA; van Groeningen, CJ; van Loenen, AC; Vermorken, JB, 1989) |
| "Droperidol was significantly more effective than domperidone, metoclopramide or placebo in reducing emetic sequelae." | 2.66 | Comparison of the use of domperidone, droperidol and metoclopramide in the prevention of nausea and vomiting following major gynaecological surgery. ( Madej, TH; Simpson, KH, 1986) |
| "Nausea and vomiting are reported in approximately 60% of neoplastic patients treated with doxorubicin used alone at doses greater than or equal to 50 mg/m2 or in combination with other noncisplatin antiblastic agents." | 2.66 | A double-blind trial comparing antiemetic efficacy and toxicity of metoclopramide versus methylprednisolone versus domperidone in patients receiving doxorubicin chemotherapy alone or in combination with other antiblastic agents. ( Ballatori, E; Basurto, C; Bracarda, S; Del Favero, A; Roila, F; Tonato, M, 1988) |
| "Thirty-two patients with primary lung cancer receiving combination chemotherapy including cisplatin at a dosage of 80-120 mg/m2 were entered into an antiemetic randomized crossover trial." | 2.66 | [Antiemetic effects of combinations of metoclopramide, droperidol and dexamethasone for the prevention of cisplatin-induced gastro-intestinal toxicity: a randomized crossover trial]. ( Fujii, M; Kamei, H; Kiura, K; Okabe, K; Toki, H, 1987) |
| "Metoclopramide serum levels were measured by high-performance liquid chromatography." | 2.66 | Antiemetic effect of oral versus intravenous metoclopramide in patients receiving cisplatin: a randomized, double-blind trial. ( Anthony, LB; Brenner, DE; Burish, TG; Greco, FA; Hainsworth, JD; Hande, KR; Krozely, MG; Woodward, NJ, 1986) |
| "In a randomized trial of 58 cancer patients receiving strongly emetogenic cytostatic drugs (cisplatin or comparable cytostatic agents, alone or in combination), the anti-emetic action of oral metoclopramide was tested, alone or combined with prednisone." | 2.66 | [Prevention of nausea and emesis during cytostatic therapy. Antiemetic efficacy of high-dosage oral metoclopramide without and with prednisone]. ( Bachmann-Mettler, I; Glaus, A; Köhler, M; Senn, HJ; Weigand, W, 1986) |
| "Metoclopramide was more effective in decreasing the volume of emesis than was alizapride (median of 100 ml vs." | 2.66 | The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective, randomized, double-blind trial. ( Bischoff, AK; Brunner, KW; Galeazzi, RL; Joss, RA; Pirovino, M; Ryssel, HJ, 1986) |
| " A further trial is necessary to determine the optimal dosage and scheduling of the available agents." | 2.66 | [Randomized crossover trial of the antiemetic effects obtained with metoclopramide and droperidol versus those obtained with metoclopramide, droperidol and methylprednisolone in patients receiving cis-platinum chemotherapy]. ( Fujii, M; Kiura, K; Okabe, K; Tamai, M; Toki, H, 1986) |
| "The metoclopramide-treated group demonstrated a statistically significant decrease in the incidence of nausea and vomiting." | 2.66 | Metoclopramide as prophylaxis for nausea and vomiting induced by fluorescein. ( Brown, RE; Drew, SJ; Sabates, R, 1987) |
| "Four consecutive trials were undertaken to study lorazepam at each of three dosage levels and diphenhydramine when used in combination with iv metoclopramide and dexamethasone in patients receiving cisplatin at 120 mg/m2." | 2.66 | Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone. ( Clark, RA; Fiore, JJ; Gralla, RJ; Groshen, S; Kelsen, DP; Kris, MG; Tyson, LB, 1985) |
| "Metoclopramide was given at a dosage of 2 mg/kg (H) or 1 mg/kg (M), intravenously, 30 minutes before and 2." | 2.66 | [Randomized controlled study of high-dose metoclopramide (2 mg/kg x 4:H) vs moderate-dose metoclopramide (1 mg/kg x 4:M) in the prevention of CDDP-induced emesis]. ( Dozono, H; Ohmi, K, 1986) |
| " IV prochlorperazine at 20-mg dosage is surprisingly effective." | 2.66 | A comparison of the antiemetic efficacy of prochlorperazine and metoclopramide for the treatment of cisplatin-induced emesis: a prospective, randomized, double-blind study. ( Bertrand, M; Browning, S; Carr, BI; Doroshow, JH; Hill, LR; Presant, C; Pulone, B, 1985) |
| "Metoclopramide (MCP) was given i." | 2.65 | Randomized open cross-over trial between metoclopramide (MCP) and dexamethazone (DXM) for the prevention of cisplatin-induced nausea and vomiting. ( Carlini, P; Cognetti, F; Conti, EM; Cortese, M; Pinnarò, P; Pollera, CF, 1984) |
| "Metoclopramide was superior to placebo and to prochlorperazine in reducing the volume of emesis (P = 0." | 2.65 | Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. ( Bordin, LA; Braun, DW; Braun, TJ; Gralla, RJ; Itri, LM; Kelsen, DP; Pisko, SE; Squillante, AE; Young, CW, 1981) |
| " The importance of adequate dosage of metoclopramide and the role of IV metoclopramide are emphasized." | 2.65 | Metoclopramide in the reduction of nausea and vomiting associated with combined chemotherapy. ( Cox, R; Leyland, MJ; Newman, CE, 1982) |
| "5." | 2.64 | Plasma bromocriptine levels, clinical and growth hormone responses in Parkinsonism. ( Debono, A; Marsden, CD; Parkes, JD; Price, P; Rosenthaler, J, 1978) |
| "Nausea is a common symptom in advanced cancer, with a prevalence of up to 70%." | 2.55 | Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy, or surgery). ( Good, P; Hardy, JR; Haywood, A; Khan, S; Rickett, K; Vayne-Bossert, P, 2017) |
| "Nausea and vomiting is a common and distressing presenting complaint in emergency departments (ED)." | 2.52 | Drugs for the treatment of nausea and vomiting in adults in the emergency department setting. ( Egerton-Warburton, D; Furyk, JS; Meek, RA, 2015) |
| "Metoclopramide is a prokinetic agent reported to be safe in parturients." | 2.48 | Metoclopramide for nausea and vomiting prophylaxis during and after Caesarean delivery: a systematic review and meta-analysis. ( Habib, AS; Mishriky, BM, 2012) |
| "Nausea and vomiting are common symptoms of migraine, which can be controlled with a variety of anti-emetics including phenothiazines and antihistamines." | 2.41 | Anti-emetics. ( MacGregor, EA, 2001) |
| "Nausea and vomiting are debilitating side effects that often accompany the administration of chemotherapy and may lead to adverse physiological and psychological effects." | 2.39 | Antiemetics in children receiving cancer chemotherapy. ( Billett, AL; Sallan, SE, 1994) |
| "Ondansetron (GR 38032F) is a highly selective 5-HT3 receptor antagonist, one of a new class of compounds which may have several therapeutic applications." | 2.38 | Ondansetron. Therapeutic use as an antiemetic. ( Heel, RC; Milne, RJ, 1991) |
| "Nausea and vomiting are a serious side effect of chemotherapy, frequently leading to failure of treatment compliance." | 2.38 | [Nausea and vomiting induced by chemotherapy: bases to a rational treatment]. ( Fodor, M; Gallardo, J, 1989) |
| "Nausea and vomiting are the most feared toxicities of chemotherapy." | 2.38 | Advances in the management of nausea and vomiting induced by non-cisplatin containing chemotherapeutic regimens. ( Grunberg, SM, 1989) |
| " Pyridoxine is considered safe for use during pregnancy, but its efficacy in treating nausea and vomiting has not been determined." | 2.37 | Safety and efficacy of antiemetics used to treat nausea and vomiting in pregnancy. ( Leathem, AM, 1986) |
| "Metoclopramide also has an important place in the investigation of the role of dopamine in physiological and pathological processes." | 2.37 | Metoclopramide--a review. ( Desmond, PV; Watson, KJ, 1986) |
| "Metoclopramide (MCP) is a commonly used anti-emetic in the emergency department (ED)." | 1.48 | Metoclopramide induced pheochromocytoma crisis. ( Kim, HK; Leonard, JB; Munir, KM, 2018) |
| "Nausea is a common symptom in patients taken care of by the ambulance service." | 1.43 | Preventing and alleviating patients' symptoms of nausea and vomiting while in the care of the ambulance service - a qualitative study. ( Hjelte Judell, O; Lindström, V; Vicente, V; Westerlund, A, 2016) |
| "Nausea and vomiting are common, but prevalence of antiemetic use in ED patients is unknown." | 1.43 | Oligoantiemesis or Inadequate Prescription of Antiemetics in the Emergency Department: A Local and National Perspective. ( Garra, G; Singer, AJ; Thode, HC, 2016) |
| "All patients scheduled for breast cancer surgery at Danderyd Hospital, Stockholm, Sweden during 1 year (March 2003-March 2004) were asked to participate in this prospective, observational study." | 1.39 | Is there an association between PONV and chemotherapy-induced nausea and vomiting? ( Eksborg, S; Lönnqvist, PA; Öbrink, E; Oddby-Muhrbeck, E; Rotstein, S, 2013) |
| " Using a Delphi study method, physicians were asked to rank preferences of drug and dosing schedule for first-line opioid, antiemetic, and laxative for the treatment of adults with chronic pain due to cancer and other life-threatening conditions." | 1.38 | Strategic pain management: the identification and development of the IAHPC opioid essential prescription package. ( Bennett, MI; Bruera, E; De Lima, L; Nekolaichuk, C; Ripamonti, CI; Vignaroli, E; Wenk, R, 2012) |
| "Metoclopramide has the greatest evidence for efficacy followed by phenothiazines and tropisetron." | 1.36 | Nausea and vomiting in advanced cancer. ( Ang, SK; Davis, MP; Shoemaker, LK, 2010) |
| "The side effect of anticancer agents such as nausea and vomiting frequently interrupt chemotherapy." | 1.33 | [Effect of steroid on antiemetic for side effect of anticancer chemotherapy]. ( Matsumoto, T; Mikami, T; Momokawa, K; Nakamura, Y; Sakayauchi, T; Sasaki, T; Watanabe, T, 2005) |
| "Metoclopramide is a dopamine receptor blocking drug that is commonly used to treat nausea and vomiting." | 1.31 | Metoclopramide for nausea and vomiting of pregnancy: a prospective multicenter international study. ( Addis, A; Arnon, J; Berkovitch, M; Elbirt, D; Greenberg, R; Magee, L; Mazzota, P; Merlob, P; Moretti, M; Ornoy, A; Schuler-Faccini, L; Stahl, B, 2002) |
| "The nausea was treated with metoclopramide." | 1.31 | [Severe parkinsonism due to metoclopramide in a patient with polypharmacy]. ( Frijns, CJ; Heeringa, M; Hofmeijer, J; Hoogendam, A; Jansen, PA; Schouten-Tjin a Tsoi, SL, 2002) |
| " Thus, controlling the adverse side effects associated with radiation therapy is critical to optimal patient care." | 1.29 | Controlling the toxicity of palliative radiotherapy: the role of 5-HT3 antagonists. ( Priestman, TJ, 1996) |
| "and metoclopramide 0." | 1.29 | Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study. ( Cannata, G; Gebbia, N; Gebbia, V; Testa, A, 1996) |
| "Twenty-two advanced consecutive thyroid cancer patients with varying histologies were treated with the so called BAP regime which consisted of bleomycin (B) 30 mg a day for three days, adriamycin (A) 60 mg/m2 iv in day 5, and cisplatinum (P) 60 to mg/m2 iv in day 5." | 1.28 | Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. ( Busnardo, B; Casara, D; De Besi, P; Fiorentino, MV; Girelli, ME; Nacamulli, D; Simioni, N; Toso, S; Zorat, P, 1991) |
| "Despite this preventative treatment, nausea and/or vomiting occurred in over one-third of all the courses." | 1.28 | [Treatment of nausea and vomiting induced by a 24-hour i.v. infusion of cisplatin]. ( Aoki, Y; Horiuchi, Y; Kamikawa, R; Kyokane, K; Miwa, Y; Nagai, H; Ninomiya, E; Noro, T; Suga, S; Yasue, K, 1990) |
| "Nausea and emesis during cancer chemotherapy are very common, but can often be controlled with repetitive boli of antiemetic drugs." | 1.28 | Patient-controlled antiemesis for cancer chemotherapy-induced nausea and vomiting. ( Naji, P; Osterwalder, B; Schuler, L; Senn, HJ; Wilder-Smith, CH, 1990) |
| "Metoclopramide is a very effective drug in preventing the acute emetic and nauseating effects of cisplatin." | 1.28 | Suitability of long-acting metoclopramide for prophylaxis of chemotherapy-induced delayed nausea and vomiting. ( Schimke, J; Senn, HJ; Vergin, H; Wilder-Smith, C, 1989) |
| " The study indicated that the dosage level of 4 mg/kg is suitable for clinical use." | 1.27 | [Phase I study of alizapride in cancer patients treated with cisplatin]. ( Bleiberg, H; Frisque, C; Nicaise, C; Ortmans, M; Rozencweig, M, 1983) |
| "In a randomized crossover study 57 cancer patients receiving chemotherapy with high emetic potential were treated with low-dose levonantradol or standard-dose metoclopramide and crossed over to the other antiemetic drug in the next identical chemotherapy cycle." | 1.27 | Randomized crossover study of the antiemetic activity of levonantradol and metoclopramide in cancer patients receiving chemotherapy. ( Altenburg, HP; Heim, ME; Queisser, W, 1984) |
| "With increasingly effective cancer chemotherapy, the control of chemotherapy-induced nausea and vomiting has become more important." | 1.27 | Control of cancer chemotherapy-induced nausea and vomiting. ( Eyre, HJ; Ward, JH, 1984) |
| "Metoclopramide is an effective non-phenothiazine antiemetic that acts, in part, by blockade of the dopamine receptors." | 1.27 | Prolonged metoclopramide-induced dyskinetic reaction. ( Leopold, NA, 1984) |
| " Metoclopramide and methylprednisolone, at the dosage and schedule used, were well tolerated and moderately active in preventing nausea and vomiting induced by cis-platin; their use in combination could further improve these results." | 1.27 | Comparison of methylprednisolone and metoclopramide in the prophylactic treatment of cis-platin-induced nausea and vomiting. ( Bertetto, O; Calciati, A; Ciuffreda, L; Clerico, M; Donadio, M; Ferrati, P; Giaccone, G; Musella, R, 1984) |
| "Metoclopramide was orally administered (10 or 20 mg) to 22 subjects, 75 min before parabolic flight." | 1.27 | Hormonal responses of metoclopramide-treated subjects experiencing nausea or emesis during parabolic flight. ( Kohl, RL, 1987) |
| "Diphenhydramine was administered intramuscularly 30 minutes before and 5 hours after chemotherapy." | 1.27 | [The prevention of CDDP-induced emesis with a combination regimen including metoclopramide, dexamethasone, droperidol and diphenhydramine]. ( Arihiro, T; Dozono, H; Morimoto, O; Ochiai, K; Sasaki, H; Takahashi, S; Terashima, Y; Tsuruoka, M; Yasuda, M; Yokoyama, S, 1987) |
| "Nausea and vomiting are common complications of cisplatin chemotherapy." | 1.27 | Evaluation of ethanol as an antiemetic in patients receiving cisplatin. ( Adelstein, DJ; Hines, JD; Spiess, JL, 1987) |
| "Emesis was observed from 0." | 1.27 | [Experimental study on the control of cisplatin-induced emesis in dogs]. ( Abo, T; Ito, J; Okada, M; Okamoto, Y; Takahashi, K; Yamashita, T, 1987) |
| " Before studying the efficacy of MCP as an antiemetic in children, we first had to establish the safe dose range." | 1.27 | Metoclopramide: dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy. ( Allen, JC; Gralla, R; Kellick, M; Reilly, L; Young, C, 1985) |
| "Metoclopramide was given intravenously 4 times during a 6-hour period (1/2 h before and 1 1/2, 3 1/2 and 5 1/2 h after cytostatic treatment) in a total dose of 1, 2, 4, 6, or 8 mg/kg." | 1.27 | High-dose metoclopramide in the treatment of cis-platinum induced emesis. A dose-finding study. ( Danneskiold-Samsøe, P; Hauksson, A; Tropé, C, 1985) |
| "Magnesium deficiency was present in seven patients and its correction resulted in amelioration of the symptom complex." | 1.26 | Chronic intestinal pseudo-obstruction. ( Brandenburg, D; Brooks, WS; Hersh, T; Hirsh, EH, 1981) |
| " The toxicity of high dose metoclopramide was of concern mainly in patients younger than 30, and/or when dosage escalation have been attempted." | 1.26 | [High dose metoclopramide during cancer chemotherapy. Phase II study in 80 consecutive patients]. ( Albin, H; Bui, NB; Durand, M; Hoerni, B; Marit, G; Mauriac, L, 1982) |
| "The nausea was relieved in 71% of the patients by placebo and bed rest, but metoclopramide was significantly (p = 0." | 1.26 | A double blind study of metoclopramide in the treatment of migraine attacks. ( Aebelholt-Krabbe, A; Melgaard, B; Olesen, J; Tfelt-Hansen, P; Veilis, B, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 193 (36.14) | 18.7374 |
| 1990's | 205 (38.39) | 18.2507 |
| 2000's | 60 (11.24) | 29.6817 |
| 2010's | 61 (11.42) | 24.3611 |
| 2020's | 15 (2.81) | 2.80 |
| Authors | Studies |
|---|---|
| Monković, I | 1 |
| Willner, D | 1 |
| Adam, MA | 1 |
| Brown, M | 1 |
| Crenshaw, RR | 1 |
| Fuller, CE | 1 |
| Juby, PF | 1 |
| Luke, GM | 1 |
| Matiskella, JA | 1 |
| Montzka, TA | 1 |
| Sun, L | 1 |
| Xi, Y | 1 |
| Wen, X | 1 |
| Zou, W | 1 |
| Robson, S | 1 |
| McParlin, C | 1 |
| Mossop, H | 1 |
| Lie, M | 1 |
| Fernandez-Garcia, C | 1 |
| Howel, D | 1 |
| Graham, R | 1 |
| Ternent, L | 1 |
| Steel, A | 1 |
| Goudie, N | 1 |
| Nadeem, A | 1 |
| Phillipson, J | 1 |
| Shehmar, M | 1 |
| Simpson, N | 1 |
| Tuffnell, D | 1 |
| Campbell, I | 1 |
| Williams, R | 1 |
| O'Hara, ME | 1 |
| McColl, E | 1 |
| Nelson-Piercy, C | 1 |
| Gottlieb, M | 1 |
| Carlson, JN | 1 |
| Peksa, GD | 1 |
| Henze, L | 1 |
| Foth, S | 1 |
| Meller, S | 1 |
| Twele, F | 1 |
| Charalambous, M | 1 |
| Kenward, H | 1 |
| Elliott, J | 1 |
| Pelligand, L | 1 |
| Volk, HA | 1 |
| Na, S | 1 |
| Jung, DE | 1 |
| Hwang, E | 1 |
| Kim, T | 1 |
| Benbow, T | 1 |
| Teja, F | 1 |
| Sheikhi, A | 1 |
| Exposto, FG | 1 |
| Svensson, P | 1 |
| Cairns, BE | 1 |
| Abdelmonem, H | 1 |
| Abdelhay, HM | 1 |
| Abdelwadoud, GT | 1 |
| Alhosini, ANM | 1 |
| Ahmed, AE | 1 |
| Mohamed, SW | 1 |
| Al-Dardery, NM | 1 |
| Abd-ElGawad, M | 1 |
| Kamel, MA | 1 |
| Sriwiset, H | 1 |
| Lokeskrawee, T | 1 |
| Patumanond, J | 1 |
| Wongyikul, P | 1 |
| Phinyo, P | 1 |
| Harder, S | 2 |
| Groenvold, M | 2 |
| Herrstedt, J | 3 |
| Kaneishi, K | 1 |
| Imai, K | 1 |
| Nishimura, K | 1 |
| Sakurai, N | 1 |
| Kohara, H | 1 |
| Ishiki, H | 1 |
| Kanai, Y | 1 |
| Oyamada, S | 1 |
| Yamaguchi, T | 1 |
| Morita, T | 1 |
| Iwase, S | 1 |
| van der Vorst, MJDL | 1 |
| Toffoli, EC | 1 |
| Beusink, M | 1 |
| van Linde, ME | 1 |
| van Voorthuizen, T | 1 |
| Brouwer, S | 1 |
| van Zweeden, AA | 1 |
| Vrijaldenhoven, S | 1 |
| Berends, JC | 1 |
| Berkhof, J | 1 |
| Verheul, HMW | 1 |
| Sakran, R | 1 |
| Shechtman, S | 1 |
| Arnon, J | 2 |
| Diav-Citrin, O | 1 |
| Ercin, D | 1 |
| Erdur, B | 3 |
| Turkcuer, I | 2 |
| Seyit, M | 1 |
| Ozen, M | 2 |
| Yilmaz, A | 1 |
| Zincir Ercin, DO | 1 |
| Lacy, BE | 1 |
| Cangemi, DJ | 1 |
| Davis, M | 1 |
| Hui, D | 1 |
| Davies, A | 1 |
| Ripamonti, C | 1 |
| Capela, A | 1 |
| DeFeo, G | 1 |
| Del Fabbro, E | 1 |
| Bruera, E | 7 |
| Vayne-Bossert, P | 1 |
| Haywood, A | 1 |
| Good, P | 1 |
| Khan, S | 1 |
| Rickett, K | 1 |
| Hardy, JR | 1 |
| Brioschi, FA | 1 |
| Gioeni, D | 1 |
| Jacchetti, A | 1 |
| Carotenuto, AM | 1 |
| Leonard, JB | 1 |
| Munir, KM | 1 |
| Kim, HK | 1 |
| Moorthy, GS | 1 |
| Letizia, M | 1 |
| Sutherland, A | 1 |
| Naessens, K | 1 |
| Plugge, E | 1 |
| Ware, L | 1 |
| Head, K | 1 |
| Burton, MJ | 1 |
| Wee, B | 1 |
| Isaksen, J | 1 |
| Neergaard, MA | 1 |
| Frandsen, K | 1 |
| Sigaard, J | 1 |
| Mondrup, L | 1 |
| Jespersen, BA | 1 |
| Giusti, R | 1 |
| Mazzotta, M | 1 |
| Filetti, M | 1 |
| Daniele, G | 1 |
| Tsukuura, H | 2 |
| Ficorella, C | 1 |
| Porzio, G | 1 |
| Marchetti, P | 1 |
| Verna, L | 1 |
| Havnen, GC | 1 |
| Truong, MB | 1 |
| Do, MH | 1 |
| Heitmann, K | 1 |
| Holst, L | 1 |
| Nordeng, H | 1 |
| Bérard, A | 1 |
| Sheehy, O | 1 |
| Gorgui, J | 1 |
| Zhao, JP | 1 |
| Soares de Moura, C | 1 |
| Bernatsky, S | 1 |
| Keat, CH | 2 |
| Phua, G | 1 |
| Abdul Kassim, MS | 1 |
| Poh, WK | 1 |
| Sriraman, M | 1 |
| Kirthi, V | 2 |
| Derry, S | 2 |
| Moore, RA | 2 |
| Habib, AS | 3 |
| George, RB | 1 |
| McKeen, DM | 1 |
| White, WD | 1 |
| Ituk, US | 1 |
| Megalla, SA | 1 |
| Allen, TK | 1 |
| Silvestris, N | 1 |
| Brunetti, AE | 1 |
| Russano, M | 1 |
| Nardulli, P | 1 |
| Rock, EM | 1 |
| Parker, LA | 1 |
| Mohamed, RA | 1 |
| Abass, HA | 1 |
| Attia, MA | 1 |
| Heikal, OA | 1 |
| Ghani, NA | 1 |
| Egerton-Warburton, D | 3 |
| Meek, R | 3 |
| Mee, MJ | 2 |
| Braitberg, G | 1 |
| Furyk, JS | 2 |
| McKenzie, S | 1 |
| To, TH | 1 |
| Agar, M | 1 |
| Yates, P | 1 |
| Currow, DC | 1 |
| Pitts, SR | 1 |
| Roila, F | 14 |
| Ruggeri, B | 1 |
| Ballatori, E | 9 |
| Fatigoni, S | 1 |
| Caserta, C | 1 |
| Licitra, L | 1 |
| Mirabile, A | 1 |
| Ionta, MT | 1 |
| Massidda, B | 1 |
| Cavanna, L | 1 |
| Palladino, MA | 2 |
| Tocci, A | 1 |
| Fava, S | 1 |
| Colantonio, I | 1 |
| Angelelli, L | 1 |
| Ciuffreda, L | 2 |
| Fasola, G | 1 |
| Zerilli, F | 1 |
| Immovilli, P | 1 |
| Rota, E | 1 |
| Morelli, N | 1 |
| Iafelice, I | 1 |
| Magnacavallo, A | 1 |
| Guidetti, D | 1 |
| Meek, RA | 1 |
| Kim, JC | 1 |
| Cha, WW | 1 |
| Chang, DS | 1 |
| Lee, HY | 1 |
| Ando, Y | 1 |
| Gyawali, B | 1 |
| Matsumoto, M | 1 |
| Sugishita, M | 1 |
| Honda, K | 1 |
| Urakawa, H | 1 |
| Maeda, O | 1 |
| Hasegawa, Y | 1 |
| Smith, LA | 1 |
| Azariah, F | 1 |
| Lavender, VT | 1 |
| Stoner, NS | 1 |
| Bettiol, S | 1 |
| Bajgoric, S | 1 |
| Samra, K | 1 |
| Chandrapalan, S | 1 |
| Gautam, N | 1 |
| Beer, AM | 1 |
| Westerlund, A | 1 |
| Vicente, V | 1 |
| Hjelte Judell, O | 1 |
| Lindström, V | 1 |
| Waqar, SN | 1 |
| Mann, J | 1 |
| Baggstrom, MQ | 1 |
| Waqar, MA | 1 |
| Chitneni, P | 1 |
| Williams, K | 1 |
| Gao, F | 1 |
| Morgensztern, D | 1 |
| Govindan, R | 1 |
| Singer, AJ | 2 |
| Garra, G | 2 |
| Thode, HC | 2 |
| Ocak, T | 1 |
| Tekin, E | 1 |
| Basturk, M | 1 |
| Duran, A | 1 |
| Serinken, M | 1 |
| Emet, M | 1 |
| Lorenzutti, AM | 1 |
| Martín-Flores, M | 1 |
| Litterio, NJ | 1 |
| Himelfarb, MA | 1 |
| Invaldi, SH | 1 |
| Zarazaga, MP | 1 |
| Malekolkottab, M | 1 |
| Khalili, H | 1 |
| Mohammadi, M | 1 |
| Ramezani, M | 1 |
| Nourian, A | 1 |
| Bamber, D | 1 |
| Chohan, J | 1 |
| Troxell, R | 1 |
| Krobbuaban, B | 1 |
| Pitakpol, S | 1 |
| Diregpoke, S | 1 |
| Friedman, BW | 1 |
| Bender, B | 1 |
| Davitt, M | 1 |
| Solorzano, C | 1 |
| Paternoster, J | 1 |
| Esses, D | 1 |
| Bijur, P | 1 |
| Gallagher, EJ | 1 |
| Kim, K | 1 |
| Chie, EK | 1 |
| Jang, JY | 1 |
| Kim, SW | 2 |
| Oh, DY | 1 |
| Im, SA | 1 |
| Kim, TY | 1 |
| Bang, YJ | 1 |
| Ha, SW | 1 |
| Hawkins, R | 1 |
| Grunberg, S | 1 |
| Pikó, B | 1 |
| Bassam, A | 1 |
| Du Bois, A | 1 |
| Matok, I | 1 |
| Gorodischer, R | 1 |
| Koren, G | 1 |
| Sheiner, E | 1 |
| Wiznitzer, A | 1 |
| Levy, A | 1 |
| Lau, KK | 1 |
| Chan, KW | 1 |
| Lok, CM | 1 |
| Lam, AW | 1 |
| Lee, HH | 1 |
| Luk, WF | 1 |
| Mak, CM | 1 |
| Ching, CK | 1 |
| Lo, J | 1 |
| Li, SM | 1 |
| Chan, AY | 1 |
| Patanwala, AE | 1 |
| Amini, R | 1 |
| Hays, DP | 1 |
| Rosen, P | 1 |
| Trepanier, L | 1 |
| Ang, SK | 1 |
| Shoemaker, LK | 1 |
| Davis, MP | 1 |
| McQuay, HJ | 1 |
| Zang, J | 1 |
| Hou, M | 1 |
| Gou, HF | 1 |
| Qiu, M | 1 |
| Wang, J | 1 |
| Zhou, XJ | 1 |
| Luo, de Y | 1 |
| Yang, Y | 1 |
| Jiang, M | 1 |
| Cao, D | 1 |
| Bi, F | 1 |
| Xu, F | 1 |
| Shen, Y | 1 |
| Yi, C | 1 |
| Molassiotis, A | 3 |
| Brearley, SG | 1 |
| Stamataki, Z | 1 |
| Barrett, TW | 1 |
| DiPersio, DM | 1 |
| Jenkins, CA | 1 |
| Jack, M | 1 |
| McCoin, NS | 1 |
| Storrow, AB | 1 |
| Singleton, LM | 1 |
| Lee, P | 1 |
| Zhou, C | 1 |
| Slovis, CM | 1 |
| Salvo, N | 1 |
| Doble, B | 1 |
| Khan, L | 1 |
| Amirthevasar, G | 1 |
| Dennis, K | 1 |
| Pasetka, M | 1 |
| Deangelis, C | 1 |
| Tsao, M | 1 |
| Chow, E | 1 |
| Tura, P | 2 |
| Aydin, B | 2 |
| Ergin, A | 1 |
| Parlak, I | 2 |
| Kabay, B | 1 |
| Ithimakin, S | 1 |
| Runglodvatana, K | 1 |
| Nimmannit, A | 1 |
| Akewanlop, C | 1 |
| Srimuninnimit, V | 1 |
| Keerativitayanan, N | 1 |
| Soparattanapaisarn, N | 1 |
| Laocharoenkeat, A | 1 |
| Klauser, CK | 1 |
| Fox, NS | 1 |
| Istwan, N | 1 |
| Rhea, D | 1 |
| Rebarber, A | 1 |
| Desch, C | 1 |
| Palmer, B | 1 |
| Saltzman, D | 1 |
| Ebrahim Soltani, AR | 1 |
| Mohammadinasab, H | 1 |
| Goudarzi, M | 1 |
| Arbabi, S | 1 |
| Mohammadinasab, A | 1 |
| Mohammadinasab, F | 1 |
| Samimi, M | 1 |
| Festin, M | 1 |
| Simpson, PM | 1 |
| Bendall, JC | 1 |
| Middleton, PM | 1 |
| Perwitasari, DA | 1 |
| Wessels, JA | 1 |
| van der Straaten, RJ | 1 |
| Baak-Pablo, RF | 1 |
| Mustofa, M | 1 |
| Hakimi, M | 1 |
| Nortier, JW | 1 |
| Gelderblom, H | 1 |
| Guchelaar, HJ | 1 |
| Chae, J | 1 |
| Taylor, DM | 1 |
| Frauman, AG | 1 |
| Vignaroli, E | 1 |
| Bennett, MI | 1 |
| Nekolaichuk, C | 1 |
| De Lima, L | 1 |
| Wenk, R | 1 |
| Ripamonti, CI | 1 |
| Mishriky, BM | 2 |
| Wickham, R | 1 |
| Mohammadbeigi, R | 1 |
| Shahgeibi, S | 1 |
| Soufizadeh, N | 1 |
| Rezaiie, M | 1 |
| Farhadifar, F | 1 |
| Grossmann, J | 1 |
| Neuwald, S | 1 |
| Wiese, B | 1 |
| Reichmann, JP | 1 |
| Kirkbride, MS | 1 |
| Benze, G | 1 |
| Alt-Epping, B | 1 |
| Geyer, A | 1 |
| Nauck, F | 1 |
| Oddby-Muhrbeck, E | 1 |
| Öbrink, E | 1 |
| Eksborg, S | 1 |
| Rotstein, S | 1 |
| Lönnqvist, PA | 1 |
| Navari, RM | 3 |
| Nagy, CK | 1 |
| Gray, SE | 1 |
| Woodall, HE | 1 |
| Wilson, J | 1 |
| Plourde, JY | 1 |
| Marshall, D | 1 |
| Yoshida, S | 1 |
| Chow, W | 1 |
| Harsanyi, Z | 4 |
| Pearen, S | 1 |
| Darke, A | 3 |
| Gupta, R | 1 |
| Gupta, S | 1 |
| Berkovitch, M | 1 |
| Mazzota, P | 1 |
| Greenberg, R | 1 |
| Elbirt, D | 1 |
| Addis, A | 1 |
| Schuler-Faccini, L | 1 |
| Merlob, P | 1 |
| Stahl, B | 1 |
| Magee, L | 1 |
| Moretti, M | 1 |
| Ornoy, A | 1 |
| Paoloni, R | 2 |
| Talbot-Stern, J | 2 |
| MacGregor, EA | 1 |
| Numbenjapon, T | 1 |
| Sriswasdi, C | 1 |
| Mongkonsritragoon, W | 1 |
| Leelasiri, A | 1 |
| Prayoonwiwat, W | 1 |
| Ragan, RE | 1 |
| Rock, RW | 1 |
| Buck, HW | 1 |
| Fujii, Y | 9 |
| Tanaka, H | 9 |
| Kawasaki, T | 1 |
| Bsat, FA | 1 |
| Hoffman, DE | 1 |
| Seubert, DE | 1 |
| Kubota, Y | 1 |
| Mihara, K | 1 |
| Ishii, F | 1 |
| Ohno, K | 1 |
| Ogata, H | 1 |
| Makimura, M | 1 |
| Kikuchi, N | 1 |
| Kitano, T | 1 |
| Alsalim, W | 1 |
| Leung, WC | 1 |
| Butler, J | 1 |
| Cham, S | 1 |
| Basire, M | 1 |
| Kelly, AM | 1 |
| Buss, MK | 1 |
| Arnold, RM | 1 |
| Moyano, JR | 1 |
| Sala, R | 1 |
| Rico, MA | 1 |
| Bosnjak, S | 1 |
| Bertolino, M | 1 |
| Willey, J | 1 |
| Strasser, F | 1 |
| Palmer, JL | 1 |
| Swidan, SZ | 1 |
| Lake, AE | 1 |
| Saper, JR | 1 |
| Nakamura, Y | 1 |
| Momokawa, K | 1 |
| Sasaki, T | 1 |
| Sakayauchi, T | 1 |
| Watanabe, T | 1 |
| Mikami, T | 1 |
| Matsumoto, T | 1 |
| Buscaglia, J | 1 |
| Faris, J | 1 |
| Basurto, C | 12 |
| Bracarda, S | 7 |
| Del Favero, A | 10 |
| Tonato, M | 12 |
| Weschules, DJ | 1 |
| Ozucelik, DN | 1 |
| Karaca, MA | 1 |
| Sivri, B | 1 |
| Braude, D | 1 |
| Soliz, T | 1 |
| Crandall, C | 1 |
| Hendey, G | 1 |
| Andrews, J | 1 |
| Weichenthal, L | 1 |
| Bradshaw, M | 1 |
| Sen, A | 1 |
| Axelsson, P | 1 |
| Thörn, SE | 1 |
| Lövqvist, A | 1 |
| Wattwil, L | 1 |
| Wattwil, M | 1 |
| Leksowski, K | 1 |
| Peryga, P | 1 |
| Szyca, R | 1 |
| Inoue, S | 1 |
| Endo, K | 2 |
| Nakamura, R | 1 |
| Itou, H | 1 |
| Luisi, FA | 1 |
| Petrilli, AS | 1 |
| Tanaka, C | 1 |
| Caran, EM | 1 |
| Celik, Y | 1 |
| Kerstan, A | 1 |
| Seitz, CS | 1 |
| Bröcker, EB | 1 |
| Trautmann, A | 1 |
| Lajolo, PP | 1 |
| del Giglio, A | 1 |
| Lou, E | 1 |
| Abou-Zeid, N | 1 |
| Kluge, M | 1 |
| Schüssler, P | 1 |
| Steiger, A | 1 |
| Dingli, K | 1 |
| Morgan, R | 1 |
| Leen, C | 1 |
| Koh, YH | 1 |
| Wu, HY | 1 |
| Lim, WP | 1 |
| Fiore, JJ | 2 |
| Gralla, RJ | 7 |
| Bakowski, MT | 1 |
| Maule, WF | 1 |
| Perry, MC | 1 |
| Colls, BM | 1 |
| Ferry, DG | 1 |
| Gray, AJ | 1 |
| Harvey, VJ | 1 |
| McQueen, EG | 1 |
| Williams, CJ | 1 |
| Bolton, A | 1 |
| de Pemberton, R | 1 |
| Whitehouse, JM | 1 |
| Laszlo, J | 2 |
| Nicaise, C | 1 |
| Rozencweig, M | 1 |
| Ortmans, M | 1 |
| Frisque, C | 1 |
| Bleiberg, H | 2 |
| Priestman, TJ | 4 |
| Priestman, SG | 2 |
| Jensen, NH | 1 |
| Termansen, K | 1 |
| Bruera, ED | 2 |
| Roca, E | 1 |
| Cedaro, L | 1 |
| Chacón, R | 1 |
| Estévez, R | 1 |
| Guldager, H | 1 |
| Jensen, FM | 1 |
| Andersen, KH | 1 |
| Arnfred, I | 1 |
| Clarke, RS | 3 |
| Spelina, KR | 1 |
| Gerber, HR | 1 |
| Pagels, IL | 1 |
| Cognetti, F | 2 |
| Pinnarò, P | 2 |
| Carlini, P | 2 |
| Conti, EM | 1 |
| Cortese, M | 1 |
| Pollera, CF | 1 |
| Stoudemire, A | 1 |
| Cotanch, P | 1 |
| Meyer, BR | 1 |
| Lewin, M | 1 |
| Pasmantier, M | 1 |
| Drayer, DE | 1 |
| Reidenberg, MM | 1 |
| Valenzuela, JE | 1 |
| Dooley, CP | 1 |
| Chiara, S | 1 |
| Scarsi, P | 1 |
| Campora, E | 1 |
| Bruzzi, P | 1 |
| Tatarek, R | 1 |
| Rosso, R | 1 |
| Feldman, M | 1 |
| Schiller, LR | 1 |
| Allan, SG | 3 |
| Cornbleet, MA | 2 |
| Warrington, PS | 3 |
| Golland, IM | 1 |
| Leonard, RC | 3 |
| Smyth, JN | 1 |
| Heim, ME | 1 |
| Queisser, W | 1 |
| Altenburg, HP | 1 |
| Perego, P | 1 |
| Brivio, F | 1 |
| Pulinetti, B | 1 |
| Bugatti, A | 1 |
| Baldoni, A | 1 |
| Eyre, HJ | 1 |
| Ward, JH | 1 |
| Leopold, NA | 1 |
| Roberts, WS | 1 |
| Berman, M | 1 |
| Di Saia, PJ | 1 |
| Leyva, M | 1 |
| Senn, HJ | 5 |
| Glaus, A | 2 |
| Bachmann-Mettler, I | 2 |
| Aapro, MS | 1 |
| Plezia, PM | 1 |
| Alberts, DS | 1 |
| Graham, V | 1 |
| Jones, SE | 1 |
| Surwit, EA | 1 |
| Moon, TE | 1 |
| Giaccone, G | 1 |
| Donadio, M | 1 |
| Musella, R | 1 |
| Bertetto, O | 1 |
| Ferrati, P | 1 |
| Clerico, M | 1 |
| Calciati, A | 1 |
| Murakami, M | 2 |
| David, M | 1 |
| Durand, M | 2 |
| Chauvergne, J | 1 |
| Mauriac, L | 2 |
| Bui, BN | 1 |
| Hoerni, B | 3 |
| Reich, SD | 1 |
| Paice, JA | 1 |
| Joss, RA | 2 |
| Galeazzi, RL | 2 |
| Brunner, KW | 2 |
| Taylor, WD | 1 |
| Bateman, DN | 3 |
| Budach, V | 1 |
| Krüger, K | 1 |
| Burrows, CF | 1 |
| Garnick, MB | 1 |
| Terrin, BN | 1 |
| McWilliams, NB | 1 |
| Maurer, HM | 1 |
| Strum, SB | 5 |
| McDermed, JE | 6 |
| Pileggi, J | 1 |
| Riech, LP | 2 |
| Whitaker, H | 1 |
| Loo, FD | 1 |
| Palmer, DW | 1 |
| Soergel, KH | 1 |
| Kalbfleisch, JH | 1 |
| Wood, CM | 1 |
| Hirsh, EH | 1 |
| Brandenburg, D | 1 |
| Hersh, T | 2 |
| Brooks, WS | 1 |
| Daniels, M | 1 |
| Belt, RJ | 1 |
| Schulze-Delrieu, K | 2 |
| Caruso, U | 1 |
| D'Iddio, S | 1 |
| Cravotto, E | 1 |
| Pesce, S | 1 |
| Betti, I | 1 |
| Ruscitto, G | 1 |
| Ecari, U | 1 |
| Sabrie, AM | 1 |
| Itri, LM | 1 |
| Pisko, SE | 1 |
| Squillante, AE | 1 |
| Kelsen, DP | 2 |
| Braun, DW | 1 |
| Bordin, LA | 1 |
| Braun, TJ | 1 |
| Young, CW | 2 |
| Mosca, S | 1 |
| D'Amato, L | 1 |
| Gargiulo, PL | 1 |
| Cautela, G | 1 |
| Cristau, P | 1 |
| Laverdant, C | 1 |
| Coquelin, JP | 1 |
| Narbonne, G | 1 |
| Opfell, RW | 1 |
| Cox, R | 1 |
| Newman, CE | 1 |
| Leyland, MJ | 1 |
| Bui, NB | 2 |
| Marit, G | 2 |
| Albin, H | 1 |
| Bolis, PF | 1 |
| Guaschino, S | 1 |
| Paganelli, AM | 1 |
| Sampaolo, P | 1 |
| Green, L | 1 |
| Brown, MD | 1 |
| Diamond, MJ | 1 |
| Keeri-Szanto, M | 1 |
| Tfelt-Hansen, P | 1 |
| Olesen, J | 1 |
| Aebelholt-Krabbe, A | 1 |
| Melgaard, B | 1 |
| Veilis, B | 1 |
| Perkel, MS | 1 |
| Moore, C | 1 |
| Davidson, ED | 1 |
| Dick, GS | 1 |
| Meller, ST | 1 |
| Pinkerton, CR | 1 |
| Cook, RJ | 2 |
| Parasuraman, TV | 1 |
| Osterhaus, JT | 1 |
| Miralbell, R | 1 |
| Coucke, P | 1 |
| Behrouz, F | 1 |
| Blazek, N | 1 |
| Melliger, M | 1 |
| Philipp, S | 1 |
| Wickenhauser, R | 1 |
| Gebhard, S | 1 |
| Schwabb, T | 1 |
| Rosset, A | 1 |
| Desilva, PH | 1 |
| Darvish, AH | 1 |
| McDonald, SM | 1 |
| Cronin, MK | 1 |
| Clark, K | 1 |
| McKenzie, R | 1 |
| Tantisira, B | 1 |
| Jackson, D | 1 |
| Bach, T | 1 |
| Riley, T | 1 |
| Thune, A | 1 |
| Appelgren, L | 1 |
| Haglind, E | 1 |
| Framarino dei Malatesta, M | 1 |
| Veneziano, M | 1 |
| Fiorelli, C | 1 |
| Bandiera, AF | 1 |
| Yacoub, M | 1 |
| Toccaceli Blasi, MR | 1 |
| Marzetti, L | 1 |
| Lee, CW | 1 |
| Suh, CW | 1 |
| Lee, JS | 1 |
| Lee, KH | 1 |
| Cho, GY | 1 |
| Kim, SH | 1 |
| Tsavaris, N | 4 |
| Charalambidis, G | 1 |
| Ganas, N | 1 |
| Pagou, M | 1 |
| Karabellis, A | 1 |
| Mylonakis, N | 5 |
| Benou, N | 1 |
| Tsikalakis, D | 1 |
| Kosmidis, P | 4 |
| Bradford, TH | 1 |
| Robertson, K | 1 |
| Norman, PF | 1 |
| Meeks, GR | 1 |
| Kymer, PJ | 2 |
| Brown, RE | 2 |
| Lawhorn, CD | 2 |
| Jones, E | 1 |
| Pearce, L | 1 |
| Rust, M | 2 |
| Paxton, LD | 1 |
| McKay, AC | 1 |
| Mirakhur, RK | 1 |
| Gómez-Hospital, JA | 1 |
| Cequier, A | 1 |
| Sala, J | 1 |
| Mauri, J | 1 |
| Catarino, C | 1 |
| Sabaté, M | 1 |
| Barthe, JE | 1 |
| Valerio, L | 1 |
| Jara, F | 1 |
| Esplugas, E | 1 |
| Mecklem, DW | 1 |
| Ohmatsu, H | 1 |
| Eguchi, K | 3 |
| Shinkai, T | 3 |
| Tamura, T | 2 |
| Ohe, Y | 1 |
| Nisio, M | 1 |
| Kunikane, H | 1 |
| Arioka, H | 1 |
| Karato, A | 1 |
| Nakashima, H | 1 |
| Lim, AK | 1 |
| Haron, MR | 1 |
| Yap, TM | 1 |
| Elliott, RH | 1 |
| Graham, SG | 1 |
| Curran, JP | 1 |
| Tomirotti, M | 1 |
| Dimaiuta, M | 1 |
| Confalonieri, M | 1 |
| Scanni, A | 1 |
| Malik, IA | 1 |
| Khan, WA | 1 |
| Qazilbash, M | 1 |
| Ata, E | 1 |
| Butt, A | 1 |
| Khan, MA | 1 |
| Lewis, IH | 2 |
| Campbell, DN | 1 |
| Barrowcliffe, MP | 1 |
| Furst, SR | 1 |
| Rodarte, A | 1 |
| Czeglédi, F | 1 |
| Baki, M | 1 |
| Walder, AD | 1 |
| Aitkenhead, AR | 1 |
| MacEachern, TJ | 1 |
| Spachynski, KA | 1 |
| LeGatt, DF | 1 |
| MacDonald, RN | 2 |
| Babul, N | 3 |
| Darke, AC | 1 |
| Heron, JF | 1 |
| Goedhals, L | 1 |
| Jordaan, JP | 1 |
| Cunningham, J | 1 |
| Cedar, E | 1 |
| Billett, AL | 1 |
| Sallan, SE | 1 |
| Hesketh, PJ | 3 |
| Pater, J | 2 |
| Slamet, L | 1 |
| Zee, B | 1 |
| Osoba, D | 3 |
| Warr, D | 3 |
| Rusthoven, J | 1 |
| Tan, EH | 1 |
| Ang, PT | 1 |
| Khoo, KS | 1 |
| Misra, R | 1 |
| Agarwal, N | 1 |
| Calamandrei, M | 1 |
| Andreuccetti, T | 1 |
| Crescioli, M | 1 |
| Messeri, A | 1 |
| Sarti, A | 1 |
| Sestini, G | 1 |
| Busoni, P | 1 |
| Anderson, H | 1 |
| Thatcher, N | 1 |
| Howell, A | 1 |
| Logan, K | 1 |
| Sage, T | 1 |
| de Bruijn, KM | 2 |
| Saito, H | 2 |
| Shimokata, K | 2 |
| Yamori, S | 1 |
| Kajita, M | 1 |
| Niimi, T | 1 |
| Zbrozek, AS | 2 |
| Cantor, SB | 1 |
| Cardenas, MP | 1 |
| Hill, DP | 1 |
| Rubenstein, EB | 1 |
| Elting, LS | 1 |
| Malins, AF | 1 |
| Field, JM | 1 |
| Nesling, PM | 1 |
| Cooper, GM | 1 |
| Pohjanvirta, R | 1 |
| Unkila, M | 1 |
| Tuomisto, J | 1 |
| Kaufmann, MA | 1 |
| Rosow, C | 1 |
| Schnieper, P | 1 |
| Schneider, M | 1 |
| Fleishman, SB | 1 |
| Lavin, MR | 1 |
| Sattler, M | 1 |
| Szarka, H | 1 |
| Gan, TJ | 1 |
| Collis, R | 1 |
| Hetreed, M | 1 |
| Kris, MG | 5 |
| Phillips, S | 1 |
| Ruggier, R | 1 |
| Hutchinson, SE | 1 |
| Kawashima, T | 1 |
| Wada, T | 1 |
| Morita, N | 1 |
| Ohmata, T | 1 |
| Miyata, K | 1 |
| Sakamoto, T | 1 |
| Hindle, A | 1 |
| Tsukagoshi, S | 1 |
| Ohta, J | 1 |
| Taguchi, T | 1 |
| Raphael, JH | 1 |
| Norton, AC | 1 |
| Sorbe, B | 4 |
| Hallén, C | 4 |
| Frankendal, B | 1 |
| Sorbe, BG | 2 |
| Högberg, T | 1 |
| Glimelius, B | 1 |
| Schmidt, M | 1 |
| Wernstedt, L | 1 |
| Hansen, O | 2 |
| Sörensen, BT | 1 |
| Räisänen, I | 1 |
| van Oosterom, AT | 1 |
| Province, WS | 1 |
| Perrine, GM | 1 |
| Kilgore, JR | 1 |
| Yoshimura, A | 1 |
| Yamano, Y | 1 |
| Gemma, A | 1 |
| Yoshimori, K | 1 |
| Hayashihara, K | 1 |
| Taniguchi, Y | 1 |
| Uematsu, K | 1 |
| Shibuya, M | 1 |
| Kudoh, S | 1 |
| Niitani, H | 1 |
| Cullen, MH | 1 |
| Chevallier, B | 3 |
| Mori, K | 2 |
| Saito, Y | 1 |
| Tominaga, K | 2 |
| Homesley, HD | 1 |
| Hahne, WF | 1 |
| McLees, B | 1 |
| Heck, K | 1 |
| Barrett, RJ | 1 |
| Lentz, SS | 1 |
| Woodlief, L | 1 |
| Lovelace, JV | 1 |
| Levitt, M | 2 |
| Yelle, L | 1 |
| Rayner, HL | 1 |
| Lofters, WS | 1 |
| Perrault, DJ | 1 |
| Wilson, KS | 1 |
| Latreille, J | 3 |
| Potvin, M | 1 |
| Warner, E | 1 |
| Michaloudis, D | 1 |
| O'Keeffe, N | 1 |
| O'Sullivan, K | 1 |
| Healy, TE | 1 |
| Joshi, R | 1 |
| Sivaganesanathan, A | 1 |
| Chang, TC | 1 |
| Hsieh, F | 1 |
| Lai, CH | 1 |
| Tseng, CJ | 1 |
| Cheng, HH | 1 |
| Li, CL | 1 |
| Michael, BJ | 1 |
| Soong, YK | 1 |
| MacCumber, MW | 1 |
| Jaffe, GJ | 1 |
| McCuen, BW | 1 |
| Pfeiffer, P | 1 |
| Madsen, B | 1 |
| Andersen, I | 1 |
| Hansen, B | 1 |
| Mathiesen, B | 1 |
| Gebbia, V | 2 |
| Testa, A | 2 |
| Valenza, R | 1 |
| Cannata, G | 2 |
| Tirrito, ML | 1 |
| Gebbia, N | 2 |
| Cleri, LB | 1 |
| Tyson, LB | 4 |
| Pisters, KM | 1 |
| Clark, RA | 4 |
| Gilbert, CJ | 1 |
| Ohly, KV | 1 |
| Rosner, G | 1 |
| Peters, WP | 1 |
| Jørgensen, M | 1 |
| Victor, MA | 1 |
| Willan, AR | 2 |
| Verweij, J | 2 |
| de Wit, R | 1 |
| de Mulder, PH | 2 |
| Ali-Melkkilä, T | 1 |
| Kanto, J | 1 |
| Katevuo, R | 1 |
| Kitamura, A | 1 |
| Kon, T | 1 |
| Kamiyama, M | 1 |
| Ogawa, R | 1 |
| Güller, R | 1 |
| Reichlin, B | 1 |
| Jost, G | 1 |
| Basade, M | 1 |
| Kulkarni, SS | 1 |
| Dhar, AK | 1 |
| Sastry, PS | 1 |
| Saikia, B | 1 |
| Advani, SH | 1 |
| Lacroix, G | 1 |
| Lessard, MR | 1 |
| Trépanier, CA | 1 |
| Naguib, M | 1 |
| el Bakry, AK | 1 |
| Khoshim, MH | 1 |
| Channa, AB | 1 |
| el Gammal, M | 1 |
| el Gammal, K | 1 |
| Elhattab, YS | 1 |
| Attia, M | 1 |
| Jaroudi, R | 1 |
| Saddique, A | 1 |
| Baines, D | 1 |
| Seifert, L | 1 |
| Watanabe, S | 1 |
| Suarez-Almazor, M | 1 |
| Chen, PP | 1 |
| Chui, PT | 1 |
| Gin, T | 1 |
| Steinbrook, RA | 2 |
| Freiberger, D | 2 |
| Gosnell, JL | 2 |
| Brooks, DC | 1 |
| Watts, SA | 1 |
| Cappelaere, P | 1 |
| Splinter, T | 1 |
| Fabbro, M | 1 |
| Wendling, JL | 1 |
| Cals, L | 1 |
| Catimel, G | 1 |
| Giovannini, M | 1 |
| Khayat, D | 1 |
| Bastit, P | 1 |
| Claverie, N | 1 |
| Stein, DJ | 1 |
| Birnbach, DJ | 1 |
| Danzer, BI | 1 |
| Kuroda, MM | 1 |
| Grunebaum, A | 1 |
| Thys, DM | 1 |
| Suga, S | 2 |
| Iwase, H | 1 |
| Shimada, M | 1 |
| Nishio, Y | 1 |
| Ichihara, T | 1 |
| Ichihara, S | 1 |
| Kusugami, K | 1 |
| Pugh, SC | 1 |
| Jones, NC | 1 |
| Barsoum, LZ | 1 |
| Bliss, A | 1 |
| Pitkänen, MT | 1 |
| Numminen, MK | 1 |
| Tuominen, MK | 1 |
| Rosenberg, PH | 1 |
| Chang, CS | 1 |
| Chen, LT | 1 |
| Huang, SM | 1 |
| Liu, TC | 1 |
| Lin, SF | 1 |
| Chen, TP | 1 |
| Wei, TC | 1 |
| Madej, G | 1 |
| Krzakowski, M | 2 |
| Pawinski, A | 1 |
| Lasota, W | 1 |
| Rogowski, W | 1 |
| Skoneczna, I | 1 |
| Bruntsch, U | 2 |
| Drechsler, S | 2 |
| Eggert, J | 2 |
| Gosse, H | 2 |
| Ukena, D | 2 |
| Imhoff, W | 2 |
| Faerber, L | 2 |
| Otten, J | 1 |
| Hachimi-Idrissi, S | 1 |
| Balduck, N | 1 |
| Maurus, R | 1 |
| Tavorath, R | 1 |
| Regnard, CF | 1 |
| O'Reilly, M | 1 |
| Shende, D | 1 |
| Mandal, NG | 1 |
| Mjahed, K | 1 |
| el Harrar, N | 1 |
| Idali, B | 1 |
| Laouissi, F | 1 |
| Benaguida, M | 1 |
| Amraoui, A | 1 |
| Twycross, R | 1 |
| Ciccarese, G | 1 |
| Alexander, R | 1 |
| Fennelly, M | 1 |
| Polati, E | 1 |
| Verlato, G | 1 |
| Finco, G | 1 |
| Mosaner, W | 1 |
| Grosso, S | 1 |
| Gottin, L | 1 |
| Pinaroli, AM | 1 |
| Ischia, S | 1 |
| Balfour, JA | 1 |
| Goa, KL | 1 |
| Toyooka, H | 5 |
| Studer-Sachsenberg, EM | 1 |
| Piletta, PA | 1 |
| Fathi, M | 1 |
| Saurat, JH | 1 |
| Salomon, D | 1 |
| Ascaso, FJ | 1 |
| Ayala, I | 1 |
| Carbonell, P | 1 |
| Castro, FJ | 1 |
| Palomar, A | 1 |
| Khoo, VS | 1 |
| Rainford, K | 1 |
| Horwich, A | 1 |
| Dearnaley, DP | 1 |
| Grote-Kiehn, J | 1 |
| Bangerter, M | 1 |
| Oehm, C | 1 |
| Mezger, J | 1 |
| Untch, M | 1 |
| Gallmeier, WM | 1 |
| Diemunsch, P | 1 |
| Conseiller, C | 1 |
| Clyti, N | 1 |
| Mamet, JP | 1 |
| Moyle, JT | 1 |
| Aass, N | 1 |
| Håtun, DE | 1 |
| Thoresen, M | 1 |
| Fosså, SD | 1 |
| Saunders, MI | 1 |
| Hoskin, PJ | 1 |
| Pigott, K | 1 |
| Powell, ME | 1 |
| Goodchild, K | 1 |
| Dische, S | 1 |
| Denekamp, J | 1 |
| Stratford, MR | 1 |
| Dennis, MF | 1 |
| Rojas, AM | 1 |
| Stewart, FC | 1 |
| Stoner, JM | 1 |
| Shirey, R | 1 |
| Volpe, P | 1 |
| Monagle, J | 1 |
| Barnes, R | 1 |
| Goodchild, C | 1 |
| Hewitt, M | 1 |
| Saitoh, Y | 2 |
| Morris, RW | 1 |
| Aune, H | 1 |
| Feiss, P | 1 |
| Hanson, A | 1 |
| Hasselstrøm, L | 1 |
| Maltby, JR | 1 |
| Rocke, DA | 1 |
| Rozenberg, B | 1 |
| Cohen, LA | 1 |
| Harper, CM | 1 |
| Barker, JP | 1 |
| Mystakidou, K | 1 |
| Befon, S | 1 |
| Liossi, C | 1 |
| Vlachos, L | 1 |
| MacLaren, R | 1 |
| Shields, CA | 1 |
| Köseoglu, V | 1 |
| Kürekçi, AE | 1 |
| Sarici, U | 1 |
| Atay, AA | 1 |
| Ozcan, O | 1 |
| Sorici, U | 1 |
| Le Jeunne, C | 1 |
| Gómez, JP | 1 |
| Pradalier, A | 1 |
| Titus i Albareda, F | 1 |
| Joffroy, A | 1 |
| Liaño, H | 1 |
| Henry, P | 1 |
| Lainez, JM | 1 |
| Geraud, G | 1 |
| Berto, P | 1 |
| De Angelis, V | 1 |
| Neri, C | 1 |
| Olivieri, A | 1 |
| Plosker, GL | 1 |
| Milne, RJ | 2 |
| Malik, I | 1 |
| Moid, I | 1 |
| Khan, Z | 1 |
| Hussain, M | 1 |
| Kobayashi, N | 1 |
| Mabro, M | 1 |
| Granisétron, PK | 1 |
| Cohen, N | 1 |
| Alon, I | 1 |
| Almoznino-Sarfian, D | 1 |
| Gorelik, O | 1 |
| Chachasvili, S | 1 |
| Litvinjuk, V | 1 |
| Modai, D | 1 |
| Weissgarten, J | 1 |
| Bouaggad, A | 1 |
| Bouderka, MA | 1 |
| Semkaoui, A | 1 |
| Haida, F | 1 |
| Abassi, O | 1 |
| Chung, F | 1 |
| Lane, R | 1 |
| Spraggs, C | 1 |
| McQuade, B | 2 |
| Jacka, M | 1 |
| Luttropp, HH | 1 |
| Alahuta, S | 1 |
| Rocherieux, S | 1 |
| Roy, M | 1 |
| Duvaldestin, P | 1 |
| Curtis, P | 2 |
| Morrow, GR | 1 |
| Hickok, JT | 1 |
| DuBeshter, B | 1 |
| Lipshultz, SE | 1 |
| Lachaine, J | 1 |
| Laurier, C | 1 |
| Langleben, A | 1 |
| Vaillant, L | 1 |
| Somekawa, Y | 1 |
| Belzile, M | 1 |
| Neumann, C | 1 |
| Lara, DR | 1 |
| Busnello, ED | 1 |
| Souza, DO | 1 |
| Norton, J | 1 |
| Roome, C | 1 |
| Thompson, J | 1 |
| Kropp, S | 1 |
| Hauser, U | 1 |
| Emrich, HM | 1 |
| Grohmann, R | 1 |
| Zatman, TF | 1 |
| Hall, JE | 1 |
| Harmer, M | 1 |
| van Der Kleij, FG | 1 |
| de Vries, PA | 1 |
| Stassen, PM | 1 |
| Sprenger, HG | 1 |
| Gans, RO | 1 |
| Ljutić, D | 1 |
| Perković, D | 1 |
| Rumboldt, Z | 1 |
| Bagatin, J | 1 |
| Hozo, I | 1 |
| Pivac, N | 1 |
| Hoogendam, A | 1 |
| Hofmeijer, J | 1 |
| Frijns, CJ | 1 |
| Heeringa, M | 1 |
| Schouten-Tjin a Tsoi, SL | 1 |
| Jansen, PA | 1 |
| Hardy, J | 1 |
| Daly, S | 1 |
| Albertsson, M | 1 |
| Chimontsi-Kypriou, V | 1 |
| Stathopoulos, P | 1 |
| Pihko, H | 1 |
| Mok, TS | 1 |
| Yam, BM | 1 |
| Yung, H | 1 |
| Gibbs, D | 1 |
| Tarsy, D | 2 |
| Parkes, JD | 3 |
| Marsden, CD | 3 |
| Ekert, H | 1 |
| Waters, KD | 1 |
| Jurk, IH | 1 |
| Mobilia, J | 1 |
| Loughnan, P | 1 |
| Klepp, O | 1 |
| Price, P | 1 |
| Debono, A | 1 |
| Rosenthaler, J | 1 |
| Edelstyn, GA | 1 |
| MacRae, KD | 1 |
| MacDonald, FM | 1 |
| Van Eygen, M | 1 |
| Dhondt, F | 1 |
| Heck, E | 1 |
| Ameryckx, L | 2 |
| Van Ravensteyn, H | 2 |
| De Loore, I | 1 |
| Cooke, RD | 1 |
| Comyn, DJ | 1 |
| Ball, RW | 1 |
| Swann, IL | 1 |
| Thompson, EN | 1 |
| Qureshi, K | 1 |
| Lavy, S | 1 |
| Melamed, E | 1 |
| Penchas, S | 1 |
| Takahashi, S | 5 |
| Kondo, H | 1 |
| Kato, N | 1 |
| Holmsen, R | 1 |
| Tsavaris, NB | 2 |
| Diehl, V | 1 |
| Wilan, A | 1 |
| Venner, P | 1 |
| Kaizer, L | 1 |
| Laberge, F | 1 |
| Stewart, D | 1 |
| O'Connell, G | 1 |
| Houghton, LA | 1 |
| Fowler, P | 1 |
| Keene, ON | 1 |
| Read, NW | 1 |
| Fürst, CJ | 1 |
| Johansson, S | 1 |
| Fredrikson, M | 1 |
| Hursti, T | 1 |
| Steineck, G | 1 |
| Peterson, C | 1 |
| Egros, F | 1 |
| Dufour, A | 1 |
| Cazor, J | 1 |
| Dogliotti, L | 1 |
| Antonacci, RA | 1 |
| Pazè, E | 1 |
| Ortega, C | 1 |
| Berruti, A | 1 |
| Faggiuolo, R | 1 |
| Gandara, DR | 1 |
| Harvey, WH | 1 |
| Monaghan, GG | 1 |
| Perez, EA | 1 |
| Stokes, C | 1 |
| Bryson, JC | 1 |
| Finn, AL | 1 |
| Olver, IN | 1 |
| Wolf, M | 2 |
| Laidlaw, C | 1 |
| Bishop, JF | 2 |
| Cooper, IA | 2 |
| Matthews, J | 1 |
| Smith, R | 1 |
| Buchanan, L | 1 |
| Sledge, GW | 1 |
| Einhorn, L | 1 |
| Nagy, C | 1 |
| House, K | 1 |
| Castle, WM | 1 |
| Cunningham, K | 1 |
| Kanarek, BB | 1 |
| Tsaroucha-Noutsou, E | 2 |
| Bacoyannis, C | 3 |
| Valilis, P | 2 |
| Kozatsani-Halividi, D | 2 |
| Tsoutsos, H | 2 |
| Droufakou, S | 1 |
| Wetchler, BV | 1 |
| Russell, D | 1 |
| Kenny, GN | 1 |
| Sands, R | 1 |
| Roberts, JT | 2 |
| Marsh, M | 1 |
| Gill, A | 1 |
| Bakri, YN | 1 |
| Khan, R | 1 |
| Subhi, J | 1 |
| Kawi, Z | 1 |
| Sassi, M | 2 |
| Lupattelli, M | 2 |
| Picciafuoco, M | 5 |
| Boschetti, E | 3 |
| Liu, YC | 1 |
| Kang, HM | 1 |
| Liou, CM | 1 |
| Tso, HS | 1 |
| Saitou, Y | 1 |
| Miyazawa, N | 1 |
| Treen, DC | 1 |
| Downes, TW | 1 |
| Hayes, DH | 1 |
| McKinnon, WM | 1 |
| Lucraft, H | 1 |
| Collis, CH | 1 |
| Adams, M | 1 |
| Upadhyaya, BK | 1 |
| Priestman, S | 1 |
| Heel, RC | 1 |
| De Besi, P | 1 |
| Busnardo, B | 1 |
| Toso, S | 1 |
| Girelli, ME | 1 |
| Nacamulli, D | 1 |
| Simioni, N | 1 |
| Casara, D | 1 |
| Zorat, P | 1 |
| Fiorentino, MV | 1 |
| Louvet, C | 1 |
| Lorange, A | 1 |
| Letendre, F | 1 |
| Beaulieu, R | 1 |
| Pretty, HM | 1 |
| Courchesne, Y | 1 |
| Neemeh, JA | 1 |
| Monte, M | 1 |
| Moreno, I | 1 |
| Rosell, R | 1 |
| Abad-Esteve, A | 1 |
| Barnadas, A | 1 |
| Carles, J | 1 |
| Ribelles, N | 1 |
| Whalley, DG | 1 |
| AlHaddad, S | 1 |
| Khalil, I | 1 |
| Maurer, W | 1 |
| Furgerson, C | 1 |
| Lim, KS | 1 |
| Lim, BL | 1 |
| Tee, CS | 1 |
| Vengadasalam, D | 1 |
| Karvounis, N | 2 |
| Klinaki, A | 1 |
| Roy, P | 1 |
| Patel, NH | 1 |
| Miller, AJ | 1 |
| Hainsworth, J | 1 |
| Harvey, W | 1 |
| Pendergrass, K | 1 |
| Kasimis, B | 1 |
| Oblon, D | 1 |
| Monaghan, G | 1 |
| Gandara, D | 1 |
| Hesketh, P | 1 |
| Khojasteh, A | 1 |
| Harker, G | 1 |
| Marschner, N | 1 |
| Marschner, NW | 1 |
| Adler, M | 1 |
| Nagel, GA | 1 |
| Christmann, D | 1 |
| Fenzl, E | 1 |
| Upadhyaya, B | 1 |
| Campbell, NN | 1 |
| Thomas, AD | 1 |
| Edwards, JN | 1 |
| Herman, JA | 1 |
| Wallace, BK | 1 |
| Pavy, MD | 1 |
| Harrison-Pavy, J | 1 |
| González Barón, M | 1 |
| Chacón, JI | 1 |
| García Girón, C | 1 |
| Ordóñez Gallego, A | 1 |
| García de Paredes, ML | 1 |
| Feliu, J | 1 |
| Zamora, P | 1 |
| Herranz, C | 1 |
| Garrido, P | 1 |
| Artal, A | 1 |
| Francom, M | 1 |
| Zamanis, N | 1 |
| Zinelis, A | 1 |
| Tsoutsos, E | 1 |
| Sarafidou, M | 1 |
| Wilder-Smith, CH | 2 |
| Schimke, J | 2 |
| Osterwalder, B | 2 |
| Patoia, L | 2 |
| Santi, E | 1 |
| Penza, O | 1 |
| Salles, G | 1 |
| Archimbaud, E | 1 |
| Thomas, X | 1 |
| Fiere, D | 1 |
| Kaasa, S | 2 |
| Mella, O | 1 |
| Kvikstad, A | 1 |
| Hannibal, J | 1 |
| Hallas, J | 1 |
| Andersen, E | 1 |
| Laursen, LC | 1 |
| Hansen, M | 1 |
| Adamski, P | 1 |
| Nagai, H | 1 |
| Horiuchi, Y | 1 |
| Kyokane, K | 1 |
| Miwa, Y | 1 |
| Aoki, Y | 1 |
| Yasue, K | 1 |
| Noro, T | 1 |
| Kamikawa, R | 1 |
| Ninomiya, E | 1 |
| Marty, M | 1 |
| Pouillart, P | 1 |
| Scholl, S | 1 |
| Droz, JP | 1 |
| Azab, M | 1 |
| Brion, N | 1 |
| Pujade-Lauraine, E | 2 |
| Paule, B | 1 |
| Paes, D | 2 |
| Bons, J | 2 |
| Bonneterre, J | 1 |
| Metz, R | 1 |
| Fargeot, P | 1 |
| Spielmann, M | 1 |
| Tubiana-Hulin, M | 1 |
| Kvaløy, S | 1 |
| Dicato, MA | 1 |
| Ries, F | 1 |
| Huys, JV | 1 |
| Royer, E | 1 |
| Carruthers, L | 1 |
| Seynaeve, C | 1 |
| Vermorken, JB | 2 |
| van Liessum, PA | 1 |
| Mols-Jevdevic, S | 1 |
| Allman, EL | 1 |
| Beranek, P | 1 |
| Watanabe, A | 1 |
| Horio, Y | 1 |
| Minami, H | 1 |
| Shibagaki, T | 1 |
| Iwahara, T | 1 |
| Sakai, S | 1 |
| Tortorice, PV | 1 |
| O'Connell, MB | 1 |
| Bone, ME | 1 |
| Wilkinson, DJ | 1 |
| Young, JR | 1 |
| McNeil, J | 1 |
| Charlton, S | 1 |
| Gwynne, A | 1 |
| Malone, JM | 1 |
| Christensen, CW | 1 |
| Yashinsky, D | 1 |
| Malviya, VK | 1 |
| Deppe, G | 1 |
| Schuler, L | 1 |
| Naji, P | 1 |
| Midgaard, T | 1 |
| Papaioannou, D | 1 |
| Beldecos, D | 1 |
| Kakoliris, S | 1 |
| Komitsopoulou, P | 1 |
| Karagiaouris, P | 1 |
| Sarmas, J | 1 |
| Tzannou, I | 1 |
| Berndtson, K | 1 |
| Jenkins, M | 1 |
| Metzer, WS | 1 |
| Kori, Y | 1 |
| Koyama, M | 1 |
| Kato, M | 1 |
| Honda, Y | 1 |
| Kawata, Y | 1 |
| Arai, S | 1 |
| Ito, T | 1 |
| Gallardo, J | 1 |
| Fodor, M | 1 |
| Pandit, SK | 1 |
| Kothary, SP | 1 |
| Pandit, UA | 1 |
| Randel, G | 1 |
| Levy, L | 1 |
| Dundee, JW | 3 |
| Ghaly, RG | 1 |
| Bill, KM | 1 |
| Chestnutt, WN | 1 |
| Fitzpatrick, KT | 1 |
| Lynas, AG | 1 |
| Wilder-Smith, C | 1 |
| Vergin, H | 1 |
| Cirrincione, C | 1 |
| Groshen, S | 2 |
| Chestnut, DH | 2 |
| Owen, CL | 2 |
| Geiger, M | 1 |
| Bates, JN | 2 |
| Choi, WW | 2 |
| Ostman, PL | 1 |
| Donati, D | 1 |
| Malacarne, P | 1 |
| Monici, L | 1 |
| Di Costanzo, F | 1 |
| Grunberg, SM | 2 |
| van Groeningen, CJ | 1 |
| Gall, HE | 1 |
| Simons, KA | 1 |
| van Loenen, AC | 1 |
| Knobf, MK | 1 |
| Nauta, J | 1 |
| Pinedo, HM | 1 |
| Buzzi, F | 1 |
| Calabresi, F | 1 |
| Brower, RD | 1 |
| Dreyer, CF | 1 |
| Kent, TA | 1 |
| Hatae, Y | 1 |
| Takeda, T | 1 |
| Nakadate, H | 1 |
| Hatayama, Y | 1 |
| Kishino, T | 1 |
| Ogawa, Y | 1 |
| Canney, PA | 1 |
| Kohl, RL | 2 |
| Cunningham, D | 4 |
| Bradley, CJ | 1 |
| Forrest, GJ | 2 |
| Hutcheon, AW | 2 |
| Adams, L | 1 |
| Sneddon, M | 1 |
| Harding, M | 1 |
| Kerr, DJ | 2 |
| Soukop, M | 2 |
| Kaye, SB | 3 |
| Dodds, LJ | 1 |
| Hollander, H | 1 |
| Golden, J | 1 |
| Mendelson, T | 1 |
| Cortland, D | 1 |
| Leathem, AM | 1 |
| Howden, CW | 1 |
| Madej, TH | 2 |
| Simpson, KH | 2 |
| Ota, K | 1 |
| Crawford, SM | 1 |
| Buckman, R | 1 |
| Umehara, H | 2 |
| Sawamura, N | 3 |
| Kusano, H | 1 |
| Yokoyama, S | 4 |
| Suemasu, K | 2 |
| Minotti, V | 3 |
| Vollmer-Larsen, B | 1 |
| Sonne, N | 1 |
| Evans, C | 1 |
| Gazet, JC | 1 |
| Ford, H | 1 |
| Pople, A | 1 |
| Dearling, J | 1 |
| Chappell, D | 1 |
| Coombes, C | 1 |
| Parashos, PJ | 2 |
| Dugan, WM | 2 |
| Fry, MW | 2 |
| Chen, JT | 1 |
| Hirai, Y | 1 |
| Yagi, H | 1 |
| Katase, K | 1 |
| Shimizu, Y | 1 |
| Nakayama, K | 1 |
| Teshima, H | 1 |
| Hamada, T | 1 |
| Fujimoto, I | 1 |
| Yamuchi, K | 1 |
| Sridhar, KS | 1 |
| Donnelly, E | 1 |
| al-Idrissi, HY | 2 |
| Ibrahim, EM | 2 |
| Abdullah, KA | 1 |
| Ababtain, WA | 1 |
| Boukhary, HA | 1 |
| Macaulay, HM | 1 |
| Fujii, M | 2 |
| Kiura, K | 2 |
| Kamei, H | 1 |
| Okabe, K | 2 |
| Toki, H | 2 |
| Nino, S | 1 |
| Inoue, I | 1 |
| Sasaki, Y | 3 |
| Sakurai, M | 2 |
| Saijo, N | 2 |
| Matthews, JP | 1 |
| Scott, K | 1 |
| Ackland, S | 1 |
| Yuen, K | 1 |
| Morton, C | 1 |
| Hillcoat, BL | 1 |
| Shiu, W | 1 |
| Tsang, V | 1 |
| Lam, YM | 1 |
| Zacharia, A | 1 |
| Martin, WM | 1 |
| Taylor, WB | 2 |
| Simpson, JM | 1 |
| Venning, M | 1 |
| Rogers, J | 1 |
| Grevel, J | 1 |
| Whiting, B | 1 |
| Kelman, AW | 2 |
| Michaud, M | 1 |
| Partington, J | 1 |
| Brenneis, C | 2 |
| Paterson, AH | 1 |
| Kobayashi, H | 1 |
| Miller, CD | 1 |
| Anderson, WG | 1 |
| Ehler, E | 1 |
| Akerley, WL | 1 |
| Bindi, M | 1 |
| Pepi, F | 1 |
| Sebaste, L | 1 |
| Tucci, E | 1 |
| Pirtoli, L | 1 |
| Mathia, WJ | 1 |
| Bell, SK | 1 |
| Leak, WD | 1 |
| Dozono, H | 2 |
| Yasuda, M | 1 |
| Ochiai, K | 1 |
| Tsuruoka, M | 1 |
| Morimoto, O | 1 |
| Sasaki, H | 1 |
| Arihiro, T | 1 |
| Terashima, Y | 1 |
| Schmidt, H | 1 |
| Schmidt, I | 1 |
| Goldsmith, TL | 1 |
| Norton, JA | 1 |
| Young, AB | 1 |
| Tibbs, PA | 1 |
| Dempsey, RJ | 1 |
| Rapp, RP | 1 |
| Anthony, LB | 1 |
| Krozely, MG | 1 |
| Woodward, NJ | 1 |
| Hainsworth, JD | 1 |
| Hande, KR | 1 |
| Brenner, DE | 1 |
| Greco, FA | 1 |
| Burish, TG | 1 |
| Köhler, M | 1 |
| Weigand, W | 1 |
| Saller, R | 1 |
| Hellenbrecht, D | 1 |
| Bühring, M | 1 |
| Hess, H | 1 |
| Desmond, PV | 1 |
| Watson, KJ | 1 |
| Bischoff, AK | 1 |
| Pirovino, M | 1 |
| Ryssel, HJ | 1 |
| Ibrahim, A | 1 |
| Absood, G | 1 |
| Al-Dossary, E | 1 |
| Al-Jammaa, A | 1 |
| Al-Ethan, S | 1 |
| Eliopoulos, A | 1 |
| Rhinehart, SN | 1 |
| Triplett, WC | 1 |
| Minnick, DJ | 1 |
| Tamai, M | 1 |
| Erlichman, C | 1 |
| Pater, JL | 1 |
| Craig, JB | 1 |
| Powell, BL | 1 |
| White, DR | 1 |
| Capizzi, RL | 1 |
| Vandewalker, GE | 1 |
| Spiess, JL | 1 |
| Adelstein, DJ | 1 |
| Hines, JD | 1 |
| Gez, E | 1 |
| Warner-Efraty, E | 1 |
| Ben-Yosef, R | 1 |
| Ben-Baruch, N | 1 |
| Yitzhaki, N | 1 |
| Uziely, B | 1 |
| Brufman, G | 1 |
| Biran, S | 1 |
| Sabates, R | 1 |
| Drew, SJ | 1 |
| Friedman, LS | 1 |
| Weinrauch, LA | 1 |
| D'Elia, JA | 1 |
| Presant, CA | 1 |
| Wiseman, C | 1 |
| Gala, K | 1 |
| Kennedy, P | 1 |
| Bouzaglou, A | 1 |
| Blayney, D | 1 |
| Schindler, J | 1 |
| Rigas, M | 1 |
| Melville, J | 1 |
| Dolan, J | 1 |
| Frustaci, S | 1 |
| Grattoni, E | 1 |
| Tumolo, S | 1 |
| Crivellari, D | 1 |
| Figoli, F | 1 |
| Galligioni, E | 1 |
| Veronesi, A | 1 |
| Tirelli, U | 1 |
| Grigoletto, E | 1 |
| MacDonald, N | 1 |
| Simpson, I | 1 |
| LeGatt, D | 1 |
| Bernardi, M | 1 |
| Trevisani, F | 1 |
| Gasbarrini, G | 1 |
| Niijima, T | 1 |
| Isurugi, K | 1 |
| Akaza, H | 1 |
| Kondo, Y | 1 |
| Kawabe, K | 1 |
| Fujita, K | 1 |
| Koiso, K | 1 |
| Yokoyama, M | 1 |
| Kinoshita, K | 1 |
| Aso, Y | 1 |
| Ruggeri, EM | 1 |
| Caporali, C | 1 |
| Kauste, A | 1 |
| Tuominen, M | 1 |
| Heikkinen, H | 1 |
| Gordin, A | 1 |
| Korttila, K | 1 |
| MacPherson, JS | 1 |
| Smyth, JF | 1 |
| Kodama, N | 1 |
| Furuse, K | 1 |
| Kawahara, M | 1 |
| Arai, R | 1 |
| Tsuruta, S | 1 |
| Hayashi, S | 1 |
| Kiyota, T | 1 |
| Ito, J | 1 |
| Okada, M | 1 |
| Abo, T | 1 |
| Okamoto, Y | 1 |
| Yamashita, T | 1 |
| Takahashi, K | 1 |
| Uribe, M | 1 |
| Ballesteros, A | 1 |
| Strauss, R | 1 |
| Rosales, J | 1 |
| Garza, J | 1 |
| Villalobos, A | 1 |
| Briones, A | 1 |
| Garcia Ramos, G | 1 |
| Jordan, NS | 1 |
| Schauer, PK | 1 |
| Schauer, A | 1 |
| Nightingale, C | 1 |
| Golub, G | 1 |
| Martin, RS | 1 |
| Williams, HM | 1 |
| Funaki, Y | 1 |
| Fujita, J | 2 |
| Futami, H | 2 |
| Yoshioka, S | 1 |
| Waldmann, CS | 1 |
| Verghese, C | 1 |
| Short, SM | 1 |
| Goldhill, DR | 1 |
| Evans, SJ | 1 |
| Funaki, U | 1 |
| Shimizu, E | 1 |
| Pruitt, BT | 1 |
| Justice, RL | 1 |
| Periman, P | 1 |
| Cohen, JL | 1 |
| Joseph, C | 1 |
| Swierz, J | 1 |
| Szutkowski, Z | 1 |
| Nowakowski, W | 1 |
| Gilchrist, NL | 1 |
| Hepplestone, A | 1 |
| Calder, IT | 1 |
| McArdle, CS | 1 |
| Vella, L | 1 |
| Francis, D | 1 |
| Houlton, P | 1 |
| Reynolds, F | 1 |
| Bayliss, EJ | 1 |
| Bohnet, HG | 1 |
| Kato, K | 1 |
| Wolf, AS | 1 |
| Ohmi, K | 1 |
| Jankovic, J | 1 |
| Glass, JP | 1 |
| Allen, JC | 1 |
| Gralla, R | 1 |
| Reilly, L | 1 |
| Kellick, M | 1 |
| Young, C | 1 |
| Liponi, DF | 1 |
| Aasebø, U | 1 |
| Myhr, K | 1 |
| Markman, M | 1 |
| Newman, DR | 1 |
| Hawkins, RS | 1 |
| Benrubi, GI | 1 |
| Norvell, M | 1 |
| Nuss, RC | 1 |
| Robinson, H | 1 |
| Carr, BI | 1 |
| Bertrand, M | 1 |
| Browning, S | 1 |
| Doroshow, JH | 1 |
| Presant, C | 1 |
| Pulone, B | 1 |
| Hill, LR | 1 |
| Roemeling, RV | 1 |
| Christiansen, NP | 1 |
| Hrushesky, WJ | 1 |
| Tropé, C | 1 |
| Danneskiold-Samsøe, P | 1 |
| Hauksson, A | 1 |
| Graham, J | 1 |
| Blackie, RG | 1 |
| McGovern, E | 1 |
| Robinson, MB | 1 |
| Kennett, RP | 1 |
| Harding, AE | 1 |
| Legg, NJ | 1 |
| Clarke, B | 1 |
| Carter, AB | 1 |
| Masterton, G | 1 |
| Schofield, CB | 1 |
| Tait, IB | 1 |
| Palmer, HM | 1 |
| Beardwell, CG | 1 |
| Fry, EN | 1 |
| Assaf, RA | 1 |
| Samuel, IO | 1 |
| Johnson, AG | 1 |
| Middleton, RS | 1 |
| Dobkin, AB | 1 |
| Evers, W | 1 |
| Israel, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| MEtoclopramide, DExamethasone or Axoli (Palonoseton) for the Prevention of Delayed Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy: the MEDEA-trial[NCT02135510] | Phase 3 | 249 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Prevalence and Burden of Nausea and Vomiting in Pregnant Women in Switzerland: Survey Purity 2022[NCT06055192] | 200 participants (Anticipated) | Observational | 2023-09-30 | Not yet recruiting | |||
| Enhanced Recovery at Cesarean Birth to Improve Postoperative Outcomes and Reduce Postoperative Length of Stay[NCT02956616] | Phase 2 | 118 participants (Actual) | Interventional | 2017-09-01 | Completed | ||
| The Effect of Adding Metoclopramide and Ondansetron to a Prophylactic Phenylephrine Infusion for the Management of Nausea and Vomiting Associated With Spinal Anesthesia for Cesarean Section[NCT01216410] | 306 participants (Actual) | Interventional | 2008-12-31 | Completed | |||
| Intravenous Metoclopramide Versus Dexketoprofen Trometamol Versus Metoclopramide+ Dexketoprofen Trometamol in Acute Migraine Attack in the Emergency Department: a Randomized Double-blind Controlled Trial[NCT04252521] | 150 participants (Actual) | Interventional | 2019-07-03 | Completed | |||
| Nasally Inhaled Isopropyl Alcohol Versus Oral Ondansetron for the Treatment of Nausea in the Emergency Department: A Double-Blind Randomized Controlled Trial[NCT02760069] | Phase 4 | 122 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| Phase II Trial Testing the Antiemetic Efficacy of a Single-day Low Dose Aprepitant (or Fosaprepitant) Added to a 5-HT3 Receptor Antagonist Plus Dexamethasone in Patients Receiving Carboplatin[NCT03237611] | Phase 2 | 15 participants (Actual) | Interventional | 2018-10-30 | Terminated (stopped due to Expired IRB approval on 2/11/21) | ||
| Aprepitant in the Prevention of Cisplatin-induced Delayed Emesis: a Double-blind Randomized Trial[NCT00869310] | Phase 3 | 303 participants (Actual) | Interventional | 2009-09-30 | Terminated (stopped due to we terminated the study before enrolling 303/560 due to a slow accrual) | ||
| Isopropyl Alcohol Inhalation as Anti-emetic Therapy in the Emergency Department[NCT04464915] | 0 participants (Actual) | Interventional | 2020-07-31 | Withdrawn (stopped due to Given the COVID-19 pandemic, there has been a temporary suspension of study activities, therefore the study has not yet been initiated.) | |||
| Effect of Ketamine Versus Sevoflurane On The Right Ventricular Pressure During Congenital Pulmonary Stenosis Balloon Dilatation[NCT05582213] | 40 participants (Actual) | Interventional | 2022-10-01 | Completed | |||
| Value of Ondansetron Medication vs Inhaled Isopropyl Therapy in the Emergency Department (VOMIITED)[NCT03125811] | Early Phase 1 | 121 participants (Actual) | Interventional | 2017-07-17 | Completed | ||
| Phase III Prospective Randomized Trial Comparing Ramosetron Versus Ondansetron for Radiotherapy Induced Nausea and Vomiting in the Treatment of Gastrointestinal Cancer[NCT00971399] | Phase 3 | 172 participants (Anticipated) | Interventional | 2009-09-30 | Completed | ||
| Acute Mountain Sickness Treatment: A Double-blind Comparison of Metoclopramide vs. Ibuprofen[NCT01522326] | 300 participants (Anticipated) | Interventional | 2012-03-01 | Completed | |||
| A Randomized, Double Blind, and Placebo-Controlled Trial Comparing Ondansetron, Metoclopramide and Promethazine for the Treatment of Nausea and Vomiting in the Adult Emergency Department.[NCT00655642] | 171 participants (Actual) | Interventional | 2007-03-31 | Terminated (stopped due to Conditional analysis showed observed differences were significantly less than power calculations) | |||
| Comparison of Gastric Volumes by Gastric Ultrasound in Term Parturients Undergoing Scheduled Elective Cesarean Delivery With and Without Metoclopramide[NCT05033041] | Phase 4 | 72 participants (Anticipated) | Interventional | 2021-10-20 | Recruiting | ||
| Randomized Single-Blind Study of Nometex as an Adjunct to Standard Anti-emetics in Ovarian and Advanced Endometrial and Cervical Cancer Patients Who Receive Moderately to Highly Emetogenic Chemotherapy[NCT01980160] | 0 participants (Actual) | Interventional | 2013-11-30 | Withdrawn (stopped due to Did not receive IRB approval from our institution therefore the study was closed.) | |||
| Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.[NCT03606369] | Phase 2/Phase 3 | 560 participants (Anticipated) | Interventional | 2015-11-05 | Recruiting | ||
| Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer[NCT04669132] | Phase 2 | 50 participants (Actual) | Interventional | 2020-12-17 | Completed | ||
| The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis[NCT04169828] | 176 participants (Anticipated) | Interventional | 2019-08-02 | Recruiting | |||
| Optimizing Anesthesia Antiemetic Measures Versus Combination With Dexamethasone or Ondansetron in the Prevention of Postoperative Nausea and Vomiting.[NCT00825071] | Phase 4 | 180 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| A Randomized Controlled Trial of Cesamet(R) (Nabilone) for the Prevention of Postoperative Nausea and Vomiting in Elective Surgery[NCT02115529] | Phase 2 | 331 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| Is Intra-operative Acupuncture Point P6 Stimulation as Effective as Traditional Pharmacotherapy in Reducing Nausea and Vomiting During Cesarean Section With Regional Anesthesia?[NCT02959840] | Phase 4 | 180 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| A Phase III, Randomized, Open-label, Active-controlled, Two-arm, Parallel-design, Interventional Clinical Trial Evaluating the Efficacy and Safety of Ondansetron 8 mg IV/ IM Injection Compared to Metoclopramide 10 mg in the Management of Nausea and Vomiti[NCT05876585] | Phase 3 | 126 participants (Anticipated) | Interventional | 2023-06-30 | Not yet recruiting | ||
| 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence[NCT01549652] | 133 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
| Aromatherapy for Management of Chemotherapy-induced Symptoms[NCT02670941] | Early Phase 1 | 31 participants (Actual) | Interventional | 2016-01-31 | Terminated (stopped due to Slow accrual; Received grant funding for a similar but different study.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients discharged on postoperative Day #2 (NCT02956616)
Timeframe: Until patient's day of hospital discharge or a maximum of one month from cesarean delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Enhanced Recovery | 5 |
| Routine Perioperative Care | 2 |
Postoperative Length of Hospital Stay in Hours from time of surgery (NCT02956616)
Timeframe: Until patient's day of hospital discharge or a maximum of one month from cesarean delivery
| Intervention | Hours (Median) |
|---|---|
| Enhanced Recovery | 73.58 |
| Routine Perioperative Care | 75.50 |
The amount of postoperative pain medication required for each patient in Morphine Milligram Equivalents (NCT02956616)
Timeframe: Until patient's day of hospital discharge or a maximum of one month from cesarean delivery
| Intervention | Morphine Milligram Equivalents (Mean) |
|---|---|
| Enhanced Recovery | 117.16 |
| Routine Perioperative Care | 119.38 |
All patients will be queried regarding whether breastfeeding was initiated after cesarean birth and how soon after birth (NCT02956616)
Timeframe: Until patient's day of hospital discharge or a maximum of one month from cesarean delivery
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Breastfeeding | Bottlefeeding | Both Breastfeeding and Bottlefeeding | |
| Enhanced Recovery | 39 | 4 | 15 |
| Routine Perioperative Care | 29 | 2 | 29 |
Comparison of intraoperative nausea and vomiting between the 3 groups. (NCT01216410)
Timeframe: Intraoperatively
| Intervention | participants (Number) |
|---|---|
| Combination Group | 23 |
| Metoclopramide | 31 |
| Phenylephrine Infusion | 49 |
The number of patients with systolic blood pressure decrease to less than 20 % of baseline intraoperatively (NCT01216410)
Timeframe: Intraoperatively
| Intervention | participants with SBP< 20 % baseline (Number) |
|---|---|
| Combination Group | 16 |
| Metoclopramide | 19 |
| Phenylephrine Infusion | 16 |
(NCT01216410)
Timeframe: 0-24 hrs
| Intervention | participants (Number) |
|---|---|
| Combination Group | 95 |
| Metoclopramide | 93 |
| Phenylephrine Infusion | 97 |
1=very satisfied, 2=somewhat satisfied, 3= neither satisfied nor dissatisfied, 4=somewhat dissatisfied, 5= very dissatisfied. Number of very satisfied subjects posted. (NCT01216410)
Timeframe: 24 h
| Intervention | participants (Number) |
|---|---|
| Combination Group | 94 |
| Metoclopramide | 85 |
| Phenylephrine Infusion | 87 |
(NCT01216410)
Timeframe: 0-2h, 2-6h, 6-24h
| Intervention | participants (Number) | ||
|---|---|---|---|
| 0-2 hrs PONV | 2-6 hrs PONV | 6-24 hrs PONV | |
| Combination Group | 20 | 28 | 22 |
| Metoclopramide | 33 | 35 | 26 |
| Phenylephrine Infusion | 39 | 41 | 22 |
Full Scale Name: Nausea 100-mm visual analogue scale. Scale Construct: Measures nausea as reported by the patient Scale Range: Minimum is 0 (no nausea) to 100 (worst nausea imaginable). These values quantify, on an interval scale anchored at 0, the patient's subjective sensation of nausea. Higher values represent worse outcomes (e.g., more nausea). Patient makes a single vertical mark on a 100 mm horizontal line with 0 at the left and 100 on the right to depict their nausea. (NCT02760069)
Timeframe: 30 minutes post intervention
| Intervention | units on a scale (Mean) |
|---|---|
| Inhaled ISO + Oral Ondansetron | 23 |
| Inhaled ISO + Oral Placebo | 19 |
| Inhaled Placebo + Oral Ondansetron | 42 |
Whether patient required rescue anti-emetics (binary variable). Measured using nurse drug administration record. (NCT02760069)
Timeframe: Study duration (up to 5 hours post intervention)
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled ISO + Oral Ondansetron | 11 |
| Inhaled ISO + Oral Placebo | 10 |
| Inhaled Placebo + Oral Ondansetron | 18 |
Complete control rate of nausea and vomiting is defined as the percentage of patients without episodes of nausea or emesis, or rescue medication administered, during the overall phase of the first carboplatin-based chemotherapy cycle. Data was collected by administration of the MASCC Antiemesis Tool. The MASCC Antiemesis Tool is an eight-item questionnaire administered to patients to assess the occurrence of vomiting and nausea both during the first 24 hours after chemotherapy as well as the occurrence of delayed nausea and vomiting from the day after to 120 hours after chemotherapy. (NCT03237611)
Timeframe: 24 hours following the first cycle of chemotherapy
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Vomiting | Nausea | |
| Low Dose Aprepitant or Fosaprepitant | 11 | 10 |
Complete control rate of nausea and vomiting is defined as the percentage of patients without episodes of nausea or emesis, or rescue medication administered, during the overall phase of the first carboplatin-based chemotherapy cycle. Data was collected by administration of the MASCC Antiemesis Tool. The MASCC Antiemesis Tool is an eight-item questionnaire administered to patients to assess the occurrence of vomiting and nausea both during the first 24 hours after chemotherapy as well as the occurrence of delayed nausea and vomiting from the day after to 120 hours after chemotherapy. (NCT03237611)
Timeframe: From 24 to 120 hours following the first cycle of chemotherapy, approximately 5 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Vomiting | Nausea | |
| Low Dose Aprepitant or Fosaprepitant | 9 | 9 |
Complete control rate of nausea and vomiting is defined as the percentage of patients without episodes of nausea or emesis, or rescue medication administered, during overall phase of the second chemotherapy cycle. Data was collected by administration of the MASCC Antiemesis Tool. The MASCC Antiemesis Tool is an eight-item questionnaire administered to patients to assess the occurrence of vomiting and nausea both during the first 24 hours after chemotherapy as well as the occurrence of delayed nausea and vomiting from the day after to 120 hours after chemotherapy. (NCT03237611)
Timeframe: 24 hours following the second cycle of chemotherapy
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Vomiting | Nausea | |
| Low Dose Aprepitant or Fosaprepitant | 3 | 3 |
Complete control rate of nausea and vomiting is defined as the percentage of patients without episodes of nausea or emesis, or rescue medication administered, during overall phase of the second chemotherapy cycle. Data was collected by administration of the MASCC Antiemesis Tool. The MASCC Antiemesis Tool is an eight-item questionnaire administered to patients to assess the occurrence of vomiting and nausea both during the first 24 hours after chemotherapy as well as the occurrence of delayed nausea and vomiting from the day after to 120 hours after chemotherapy. (NCT03237611)
Timeframe: From 24 to 120 hours following the second cycle of chemotherapy, approximately 5 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Vomiting | Nausea | |
| Low Dose Aprepitant or Fosaprepitant | 3 | 3 |
"Participants independently rated their nausea severity on separate scales at the baseline and 30-minute evaluations to prevent the baseline VAS score from influencing the 30-minute mark. The VAS had the words Least Severe on the left and Most Severe on the right. The possible values range from 0 to 100mm with 0 at the Least Severe extreme and 100 at the Most Severe extreme. Investigators instructed the participant to draw a single vertical line through the point on the 100mm scale that corresponded to their nausea severity at the times of measurement (Baseline and 30 minutes)." (NCT00655642)
Timeframe: Baseline and 30 minute assessments
| Intervention | millimeter (Median) |
|---|---|
| Ondansetron | -22.0 |
| Metoclopramide | -30.0 |
| Promethazine | -29.0 |
| Placebo | -16.0 |
The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea at any point during the surgical procedure in each group. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 44 |
| Metoclopramide, Ondansetron | 14 |
| Acupressure Point P6 Stimulator | 22 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) during stage I. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 33 |
| Metoclopramide, Ondansetron | 7 |
| Acupressure Point P6 Stimulator | 14 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) during stage II. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 12 |
| Metoclopramide, Ondansetron | 6 |
| Acupressure Point P6 Stimulator | 5 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) during stage III. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 16 |
| Metoclopramide, Ondansetron | 8 |
| Acupressure Point P6 Stimulator | 14 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) during stage IV. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 3 |
| Metoclopramide, Ondansetron | 4 |
| Acupressure Point P6 Stimulator | 0 |
Patients are asked their overall anesthetic care satisfaction (0 = Not Satisfied, 10 = Extremely Satisfied). Data are expressed as number of parturients who gave a score of 8 or higher. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 53 |
| Metoclopramide, Ondansetron | 58 |
| Acupressure Point P6 Stimulator | 56 |
Patients are asked their anti-emetic treatment satisfaction (0 = Not Satisfied, 10 = Extremely Satisfied). Data are expressed as number of parturients who gave a score of 8 or higher. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 49 |
| Metoclopramide, Ondansetron | 58 |
| Acupressure Point P6 Stimulator | 55 |
The investigators will perform objective assessments of whether or not the patients have vomited during the procedure. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 27 |
| Metoclopramide, Ondansetron | 10 |
| Acupressure Point P6 Stimulator | 8 |
The investigators will perform objective assessments of whether or not the patients have vomited during stage I. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 20 |
| Metoclopramide, Ondansetron | 5 |
| Acupressure Point P6 Stimulator | 4 |
The investigators will perform objective assessments of whether or not the patients have vomited during stage II. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 10 |
| Metoclopramide, Ondansetron | 1 |
| Acupressure Point P6 Stimulator | 3 |
The investigators will perform objective assessments of whether or not the patients have vomited during stage III. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 9 |
| Metoclopramide, Ondansetron | 4 |
| Acupressure Point P6 Stimulator | 6 |
The investigators will perform objective assessments of whether or not the patients have vomited during stage IV. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 0 |
| Metoclopramide, Ondansetron | 2 |
| Acupressure Point P6 Stimulator | 0 |
The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -0.44 |
The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -2.68 |
The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -2.59 |
The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in BDIS (Ondansetron) | Change in BDIS (Placebo) | |
| Prevention of Physical Dependence | -0.6 | 0.2 |
"Originally developed by Handelsman, the Objective Opioid Withdrawal Scale (OOWS) score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The minimum score of 0 means the patient is not showing any signs of opioid withdrawal. The maximum score of 13 signifies all signs of opioid withdrawal to the largest extent possible.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If deemed necessary by the clinician, participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in OOWS (Ondansetron) | Change in OOWS (Placebo) | |
| Prevention of Opioid Withdrawal | 3.6 | 3.6 |
"Originally developed by Handelsman, the OOWS score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The maximum score is 13 and suggests the patient is showing all signs of opioid withdrawal to the largest extent possible. The minimum score of 0 suggests the patient is not showing any signs of opioid withdrawal.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in OOWS (Ondansetron) | Change in OOWS (Placebo) | |
| Prevention of Physical Dependence | 4.5 | 4.2 |
The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in VAS Score (Ondansetron) | Change in VAS Score (Placebo) | |
| Prevention of Physical Dependence | -2.9 | -2.8 |
The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in RMDI (Ondansetron) | Change in RMDI (Placebo) | |
| Prevention of Physical Dependence | -4.6 | -2.0 |
The Subjective Opioid Withdrawal Score (SOWS) score is calculated as the sum of 16 subjective patient-reported symptom scores rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in SOWS (Ondansetron) | Change in SOWS (Placebo) | |
| Prevention of Opioid Withdrawal | 12.5 | 12.2 |
The SOWS score is composed of 16 subjective symptoms rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in SOWS (Ondansetron) | Change in SOWS (Placebo) | |
| Prevention of Physical Dependence | 16.4 | 12.0 |
Profile of Mood States (POMS) is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in POMS Score (Ondansetron) | Change in POMS Score (Placebo) | |
| Prevention of Opioid Withdrawal | 29.3 | 28.3 |
(Profile of Mood States) POMS is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in POMS (Ondansetron) | Change in POMS (Placebo) | |
| Prevention of Physical Dependence | 36.1 | 29.2 |
66 reviews available for metoclopramide and Nausea
| Article | Year |
|---|---|
Use of metoclopramide in the first trimester and risk of major congenital malformations: A systematic review and meta-analysis.
Topics: Antiemetics; Congenital Abnormalities; Female; Humans; Metoclopramide; Nausea; Odds Ratio; Pregnancy | 2021 |
Prophylactic antiemetics for adults receiving intravenous opioids in the acute care setting.
Topics: Adult; Analgesics, Opioid; Antiemetics; Female; Humans; Male; Metoclopramide; Nausea; Vomiting | 2022 |
The efficacy and safety of metoclopramide in relieving acute migraine attacks compared with other anti-migraine drugs: a systematic review and network meta-analysis of randomized controlled trials.
Topics: Chlorpromazine; Granisetron; Headache; Humans; Ketorolac; Metoclopramide; Migraine Disorders; Nausea | 2023 |
MASCC antiemetics in advanced cancer updated guideline.
Topics: Antiemetics; Humans; Metoclopramide; Nausea; Neoplasms; Vomiting | 2021 |
Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy, or surgery).
Topics: Adrenal Cortex Hormones; Adult; Chlorpromazine; Dexamethasone; Humans; Indoles; Metoclopramide; Naus | 2017 |
Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.
Topics: Adult; Antiemetics; Antineoplastic Agents; Benzodiazepines; Chemoradiotherapy; Dexamethasone; Disord | 2018 |
Aspirin with or without an antiemetic for acute migraine headaches in adults.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Aspirin; Drug Therapy, Combination; Hum | 2013 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; N | 2015 |
Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Agents; Cannabinoids; Chlorpromazine; Dizziness; Domperidone; Eup | 2015 |
Cannabinoid hyperemesis syndrome: a guide for the practising clinician.
Topics: Adult; Antiemetics; Cannabinoids; Cannabis; Disease Management; Dronabinol; Humans; Male; Marijuana | 2015 |
Chemotherapy-induced nausea and vomiting: challenges and opportunities for improved patient outcomes.
Topics: Antiemetics; Antineoplastic Agents; Humans; Metoclopramide; Nausea; Neoplasms; Substance P; Treatmen | 2009 |
[Treatment of tumor therapy-induced nausea and vomiting].
Topics: Anti-Anxiety Agents; Antiemetics; Antineoplastic Agents; Aprepitant; Drug Therapy, Combination; Huma | 2009 |
[Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benchmarking; Dexamethasone; Dose-Response Relations | 1998 |
Antiemetic therapy for nausea and vomiting in the emergency department.
Topics: Antiemetics; Droperidol; Emergency Service, Hospital; Humans; Metoclopramide; Nausea; Ondansetron; P | 2010 |
Antiemetic therapy for nausea and vomiting in the emergency department.
Topics: Antiemetics; Droperidol; Emergency Service, Hospital; Humans; Metoclopramide; Nausea; Ondansetron; P | 2010 |
Antiemetic therapy for nausea and vomiting in the emergency department.
Topics: Antiemetics; Droperidol; Emergency Service, Hospital; Humans; Metoclopramide; Nausea; Ondansetron; P | 2010 |
Antiemetic therapy for nausea and vomiting in the emergency department.
Topics: Antiemetics; Droperidol; Emergency Service, Hospital; Humans; Metoclopramide; Nausea; Ondansetron; P | 2010 |
Acute vomiting in cats: rational treatment selection.
Topics: Acute Disease; Animals; Antiemetics; Cat Diseases; Cats; Chlorpromazine; Diarrhea; Famotidine; Indol | 2010 |
Aspirin with or without an antiemetic for acute migraine headaches in adults.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Aspirin; Drug Therapy, Combination; Hum | 2010 |
Prophylaxis of radiation-induced nausea and vomiting using 5-hydroxytryptamine-3 serotonin receptor antagonists: a systematic review of randomized trials.
Topics: Antiemetics; Humans; Metoclopramide; Nausea; Radiotherapy; Randomized Controlled Trials as Topic; Se | 2012 |
Nausea and vomiting in early pregnancy.
Topics: Acupressure; Administration, Oral; Domperidone; Female; Humans; Metoclopramide; Nausea; Phytotherapy | 2009 |
Review article: Prophylactic metoclopramide for patients receiving intravenous morphine in the emergency setting: a systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Disease; Analgesics, Opioid; Antiemetics; Dopamine Agonists; Emergencies; Humans; Injections, | 2011 |
Metoclopramide for nausea and vomiting prophylaxis during and after Caesarean delivery: a systematic review and meta-analysis.
Topics: Anesthesia, Conduction; Anesthesia, Obstetrical; Antiemetics; Cesarean Section; Female; Humans; Intr | 2012 |
Evolving treatment paradigms for chemotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Humans; Metoclopramide; Nausea; Prochlorperazine; Vomiting | 2012 |
Evolving treatment paradigms for chemotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Humans; Metoclopramide; Nausea; Prochlorperazine; Vomiting | 2012 |
Evolving treatment paradigms for chemotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Humans; Metoclopramide; Nausea; Prochlorperazine; Vomiting | 2012 |
Evolving treatment paradigms for chemotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Humans; Metoclopramide; Nausea; Prochlorperazine; Vomiting | 2012 |
Reviewing the evidence for using continuous subcutaneous metoclopramide and ondansetron to treat nausea & vomiting during pregnancy.
Topics: Antiemetics; Evidence-Based Medicine; Female; Humans; Infusions, Subcutaneous; Metoclopramide; Nause | 2012 |
[Treatment of nausea and vomiting with prokinetics and neuroleptics in palliative care patients : a review].
Topics: Antiemetics; Antipsychotic Agents; Chronic Disease; Domperidone; Dopamine Antagonists; Drug Therapy, | 2012 |
Long-term safety and clinical effectiveness of controlled-release metoclopramide in cancer-associated dyspepsia syndrome: a multicentre evaluation.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anorexia; Antiemetics; Delayed-Action Preparat | 2002 |
Anti-emetics.
Topics: Antiemetics; Domperidone; Dopamine Antagonists; Humans; Metoclopramide; Migraine Disorders; Nausea; | 2001 |
[Effectiveness of anti-emetics for the prophylaxis of cisplatin-induced delayed emesis: a systematic review].
Topics: Adrenal Cortex Hormones; Antiemetics; Antineoplastic Agents; Cisplatin; Drug Therapy, Combination; H | 2004 |
Best evidence topic reports. Metoclopramide versus placebo with opioid.
Topics: Analgesics, Opioid; Antiemetics; Evidence-Based Medicine; Humans; Male; Metoclopramide; Middle Aged; | 2004 |
Antiemetic therapy in patients treated with cisplatin chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Controlled Clinical Trials as Topic; Double-Blind Met | 1989 |
Naproxen sodium/metoclopramide: metoclopramide/naproxen-sodium, MT 100, naproxen-sodium/metoclopramide.
Topics: Animals; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Combinations; Drug Evaluatio | 2006 |
Acute dystonic reaction caused by metoclopramide, versus tetanus.
Topics: Acute Disease; Adult; Antiemetics; Diagnosis, Differential; Dystonia; Female; Humans; Medical Histor | 2007 |
Pharmacologic treatment of chemotherapy-induced nausea and vomiting.
Topics: Adrenal Cortex Hormones; Antiemetics; Antineoplastic Agents; Butyrophenones; Chemoreceptor Cells; Dr | 1984 |
Advances in anti-emetic therapy.
Topics: Antiemetics; Antineoplastic Agents; Chemoreceptor Cells; Clinical Trials as Topic; Dexamethasone; Do | 1984 |
Treatment of nausea and vomiting caused by cancer chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Cannabinoids; Dronabinol; Humans; Metoclopramide; Nausea; Vomiti | 1982 |
Nausea and vomiting.
Topics: Analgesics; Anesthetics; Domperidone; Humans; Metoclopramide; Nausea; Phenothiazines; Piperazines; S | 1984 |
Recent advances in the pharmacologic and behavioral management of chemotherapy-induced emesis.
Topics: Antiemetics; Antineoplastic Agents; Behavior Therapy; Biofeedback, Psychology; Butyrophenones; Canna | 1984 |
Dopamine antagonists in the upper gastrointestinal tract.
Topics: Diabetic Neuropathies; Digestive System; Domperidone; Dopamine Antagonists; Duodenum; Dyspepsia; Eso | 1984 |
Disorders of gastrointestinal motility associated with diabetes mellitus.
Topics: Autonomic Nervous System Diseases; Bethanechol Compounds; Constipation; Diabetes Complications; Diab | 1983 |
Drug therapy. Metoclopramide.
Topics: Dopamine Antagonists; Esophagitis; Gastric Emptying; Gastroesophageal Reflux; Gastrointestinal Motil | 1981 |
[Pharmacological and clinical characteristics of metoclopramide].
Topics: Endocrine Glands; Gastrointestinal Diseases; Gastrointestinal Motility; Humans; Metoclopramide; Musc | 1981 |
Antiemetics in children receiving cancer chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Child; Dexamethasone; Humans; Metoclopramide; Nausea; Neoplasms; | 1994 |
Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Humans; Metoclopramide; Nausea; Neopla | 1994 |
Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Doxorubicin; Female; Granisetron; Huma | 1994 |
Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting.
Topics: Cisplatin; Costs and Cost Analysis; Economics, Pharmaceutical; Humans; Metoclopramide; Nausea; Ondan | 1994 |
Ondansetron: a specific serotonin antagonist for the prevention of chemotherapy-induced vomiting.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Child; Cisplatin; Clinical Trials, Phase I as To | 1994 |
[An outline of 5-HT3 receptor antagonists (2)--In clinical applications].
Topics: Antineoplastic Agents; Granisetron; Humans; Metoclopramide; Nausea; Ondansetron; Serotonin Antagonis | 1993 |
Optimal control of acute cisplatin-induced emesis.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dopamine Antagonists; Humans; Metoclopramide; Nausea; | 1996 |
Postoperative nausea and vomiting in children.
Topics: Anesthetics, Inhalation; Antiemetics; Child; Droperidol; Humans; Incidence; Metoclopramide; Nausea; | 1996 |
Drug treatment of chemotherapy-induced delayed emesis.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Humans; Metoclopramide; Nausea; Neopla | 1996 |
[Recent improvements in antiemetic therapy].
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combination; Granisetron | 1997 |
Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery.
Topics: Administration, Oral; Age Factors; Antiemetics; Dexamethasone; Humans; Indoles; Injections, Intraven | 1997 |
Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy.
Topics: Costs and Cost Analysis; Drug Therapy; Drug Tolerance; Economics, Pharmaceutical; Forecasting; Formu | 1992 |
Metoclopramide.
Topics: Animals; Digestive System; Gastrointestinal Motility; Humans; Metoclopramide; Muscle, Smooth; Nausea | 1979 |
Antiemetic agents.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combination; Humans; Imi | 1992 |
5-HT3 antagonists in postoperative nausea and vomiting.
Topics: Aged; Anesthesia, General; Humans; Male; Metoclopramide; Nausea; Ondansetron; Postoperative Complica | 1992 |
Ondansetron. Therapeutic use as an antiemetic.
Topics: Antiemetics; Antineoplastic Agents; Humans; Imidazoles; Metoclopramide; Nausea; Ondansetron; Radiati | 1991 |
Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; | 1991 |
[Nausea and vomiting during treatment with cytostatics].
Topics: Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Metoclop | 1991 |
Management of chemotherapy-induced nausea and vomiting.
Topics: Adrenal Cortex Hormones; Antiemetics; Antineoplastic Agents; Benzodiazepines; Butyrophenones; Cannab | 1990 |
[Nausea and vomiting induced by chemotherapy: bases to a rational treatment].
Topics: Antiemetics; Antineoplastic Agents; Butyrophenones; Drug Therapy, Combination; Metoclopramide; Nause | 1989 |
Advances in the management of nausea and vomiting induced by non-cisplatin containing chemotherapeutic regimens.
Topics: Adrenal Cortex Hormones; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepine | 1989 |
The control of cancer chemotherapy-induced nausea and vomiting.
Topics: Adrenal Cortex Hormones; Anti-Anxiety Agents; Antiemetics; Antineoplastic Agents; Antipsychotic Agen | 1985 |
Safety and efficacy of antiemetics used to treat nausea and vomiting in pregnancy.
Topics: Antiemetics; Antipsychotic Agents; Dicyclomine; Diphenhydramine; Doxylamine; Drug Combinations; Fema | 1986 |
[Recent advances in the management of chemotherapy-induced emesis].
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Domperidone; Dronabinol; Drug Therapy, | 1986 |
Combination antiemetics for cisplatin chemotherapy.
Topics: Antiemetics; Cisplatin; Dexamethasone; Diphenhydramine; Droperidol; Drug Evaluation; Drug Therapy, C | 1988 |
Metoclopramide--a review.
Topics: Anxiety; Digestive System; Dopamine Antagonists; Drug Interactions; Female; Gastric Emptying; Gastro | 1986 |
[The control of chemotherapy-induced nausea and vomiting].
Topics: Antiemetics; Antineoplastic Agents; Chemoreceptor Cells; Chlorpromazine; Cisplatin; Domperidone; Hum | 1985 |
281 trials available for metoclopramide and Nausea
| Article | Year |
|---|---|
Ondansetron and metoclopramide as second-line antiemetics in women with nausea and vomiting in pregnancy: the EMPOWER pilot factorial RCT.
Topics: Antiemetics; Cost-Benefit Analysis; Female; Humans; Metoclopramide; Nausea; Ondansetron; Pregnancy; | 2021 |
Ondansetron in dogs with nausea associated with vestibular disease: A double-blinded, randomized placebo-controlled crossover study.
Topics: Animals; Antiemetics; Arginine Vasopressin; Cross-Over Studies; Dog Diseases; Dogs; Double-Blind Met | 2022 |
The efficacy of prophylactic metoclopramide in preventing nausea and vomiting in patients with acute pain treated with intravenous tramadol: a randomized double-blinded, placebo-controlled trial.
Topics: Acute Pain; Analgesics, Opioid; Antiemetics; Double-Blind Method; Humans; Metoclopramide; Nausea; Tr | 2023 |
Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial.
Topics: Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Double-Blind Method; Humans; Male; Metoclop | 2021 |
Effect of metoclopramide on nausea and emesis in dogs premedicated with morphine and dexmedetomidine.
Topics: Analgesics, Opioid; Animals; Antiemetics; Dexmedetomidine; Dogs; Dopamine Antagonists; Female; Male; | 2018 |
Can granisetron injection used as primary prophylaxis improve the control of nausea and vomiting with low- emetogenic chemotherapy?
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Female; G | 2013 |
Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cardiotonic Agents; Cesarean Section; Drug Therapy, Combinat | 2013 |
Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cardiotonic Agents; Cesarean Section; Drug Therapy, Combinat | 2013 |
Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cardiotonic Agents; Cesarean Section; Drug Therapy, Combinat | 2013 |
Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Cardiotonic Agents; Cesarean Section; Drug Therapy, Combinat | 2013 |
Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Benztropine; Camptoth | 2013 |
Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo.
Topics: Adult; Aged; Antiemetics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Middle | 2014 |
Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo.
Topics: Adult; Aged; Antiemetics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Middle | 2014 |
Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo.
Topics: Adult; Aged; Antiemetics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Middle | 2014 |
Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo.
Topics: Adult; Aged; Antiemetics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Middle | 2014 |
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.
Topics: Activities of Daily Living; Administration, Intravenous; Administration, Oral; Adolescent; Adult; Ag | 2015 |
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.
Topics: Activities of Daily Living; Administration, Intravenous; Administration, Oral; Adolescent; Adult; Ag | 2015 |
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.
Topics: Activities of Daily Living; Administration, Intravenous; Administration, Oral; Adolescent; Adult; Ag | 2015 |
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.
Topics: Activities of Daily Living; Administration, Intravenous; Administration, Oral; Adolescent; Adult; Ag | 2015 |
The Effect of Intravenous Dexamethasone on the Nausea Accompanying Vestibular Neuritis: A Preliminary Study.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Dexamethasone; Dizziness; Female; Human | 2015 |
Treatment in carbon monoxide poisoning patients with headache: a prospective, multicenter, double-blind, controlled clinical trial.
Topics: Adult; Analgesics; Carbon Monoxide Poisoning; Carboxyhemoglobin; Combined Modality Therapy; Dipyrone | 2016 |
A comparison between maropitant and metoclopramide for the prevention of morphine-induced nausea and vomiting in dogs.
Topics: Analgesics, Opioid; Animals; Antiemetics; Dog Diseases; Dogs; Female; Hysterectomy; Male; Metoclopra | 2017 |
Metoclopramide as intermittent and continuous infusions in critically ill patients: a pilot randomized clinical trial.
Topics: Adult; Aged; Antiemetics; Critical Illness; Drug Administration Schedule; Energy Intake; Enteral Nut | 2017 |
Pretreatment of patients requiring oral contrast abdominal computed tomography with antiemetics: a randomized controlled trial of efficacy.
Topics: Administration, Oral; Adult; Analysis of Variance; Antiemetics; Chi-Square Distribution; Contrast Me | 2009 |
Ondansetron vs. metoclopramide for the prevention of nausea and vomiting after gynecologic surgery.
Topics: Adult; Aged; Antiemetics; Double-Blind Method; Female; Gynecologic Surgical Procedures; Humans; Meto | 2008 |
A randomized trial of diphenhydramine as prophylaxis against metoclopramide-induced akathisia in nauseated emergency department patients.
Topics: Adult; Aged; Akathisia, Drug-Induced; Antiemetics; Diphenhydramine; Dopamine Antagonists; Double-Bli | 2009 |
Antiemetic activity of megestrol acetate in patients receiving chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Drug Therapy | 2011 |
A randomized, placebo-controlled trial of ondansetron, metoclopramide, and promethazine in adults.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Humans; Male; Metoclop | 2011 |
A randomized, placebo-controlled trial of ondansetron, metoclopramide, and promethazine in adults.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Humans; Male; Metoclop | 2011 |
A randomized, placebo-controlled trial of ondansetron, metoclopramide, and promethazine in adults.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Humans; Male; Metoclop | 2011 |
A randomized, placebo-controlled trial of ondansetron, metoclopramide, and promethazine in adults.
Topics: Adult; Antiemetics; Double-Blind Method; Emergency Service, Hospital; Female; Humans; Male; Metoclop | 2011 |
A trial of midazolam vs diphenhydramine in prophylaxis of metoclopramide-induced akathisia.
Topics: Adult; Akathisia, Drug-Induced; Antiemetics; Diphenhydramine; Double-Blind Method; Female; Humans; H | 2012 |
Slow infusion metoclopramide does not affect the improvement rate of nausea while reducing akathisia and sedation incidence.
Topics: Adult; Akathisia, Drug-Induced; Antiemetics; Deep Sedation; Double-Blind Method; Female; Humans; Inf | 2012 |
Randomized, double-blinded, placebo-controlled trial of ondansetron plus dexamethasone with or without metoclopramide as antiemetic prophylaxis in patients receiving high-dose cisplatin in medical practice.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Dose-Response Relationship, Drug; Doub | 2012 |
Comparing the efficacy of prophylactic p6 acupressure, ondansetron, metoclopramide and placebo in the prevention of vomiting and nausea after strabismus surgery.
Topics: Acupressure; Adolescent; Adult; Antiemetics; Child; Combined Modality Therapy; Double-Blind Method; | 2011 |
Tropisetron versus metoclopramide for the treatment of nausea and vomiting in the emergency department: A randomized, double-blinded, clinical trial.
Topics: Adult; Aged; Antiemetics; Double-Blind Method; Emergency Medical Services; Emergency Service, Hospit | 2011 |
Comparing the effects of ginger and metoclopramide on the treatment of pregnancy nausea.
Topics: Adult; Antiemetics; Double-Blind Method; Female; Humans; Metoclopramide; Nausea; Placebos; Pregnancy | 2011 |
The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Cis | 2013 |
Long-term safety and clinical effectiveness of controlled-release metoclopramide in cancer-associated dyspepsia syndrome: a multicentre evaluation.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anorexia; Antiemetics; Delayed-Action Preparat | 2002 |
Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.
Topics: Administration, Oral; Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols | 2002 |
Metoclopramide pretreatment attenuates emergency contraceptive-associated nausea.
Topics: Adult; Antiemetics; Contraceptives, Oral, Combined; Contraceptives, Postcoital; Double-Blind Method; | 2003 |
A comparison of granisetron, droperidol, and metoclopramide in the treatment of established nausea and vomiting after breast surgery: a double-blind, randomized, controlled trial.
Topics: Adult; Aged; Anesthesia, General; Antiemetics; Double-Blind Method; Droperidol; Female; Granisetron; | 2003 |
Comparison of three outpatient regimens in the management of nausea and vomiting in pregnancy.
Topics: Adult; Antiemetics; Drug Therapy, Combination; Female; Humans; Hyperemesis Gravidarum; Metoclopramid | 2003 |
Intermediate dose metoclopramide is not more effective than standard dose metoclopramide for patients who present to the emergency department with nausea and vomiting: a pilot study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Dose-Response Relationship, Drug; Emergency | 2004 |
Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Chronic Disease; Dexamethasone; D | 2004 |
Effectiveness of pre-emptive metoclopramide infusion in alleviating pain, discomfort and nausea associated with nasogastric tube insertion: a randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Double-Blind Method; Female; Gagging; Human | 2005 |
Antiemetics in the ED: a randomized controlled trial comparing 3 common agents.
Topics: Adult; Antiemetics; Droperidol; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; M | 2006 |
Use of a prophylactic antiemetic with morphine in acute pain: randomised controlled trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Antiemetics; Female; | 2006 |
Betamethasone does not prevent nausea and vomiting induced by the dopamine-agonist apomorphine.
Topics: Adult; Apomorphine; Betamethasone; Dopamine Agonists; Dopamine Antagonists; Female; Glucocorticoids; | 2006 |
Ondansetron, metoclopramid, dexamethason, and their combinations compared for the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: a prospective randomized study.
Topics: Adult; Aged; Antiemetics; Cholecystectomy, Laparoscopic; Dexamethasone; Drug Therapy, Combination; F | 2006 |
Contribution to the treatment of nausea and emesis induced by chemotherapy in children and adolescents with osteosarcoma.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Bone Neoplasms; Child; Dimenhydrinate; Female; Grani | 2006 |
Skipping day 2 antiemetic medications may improve chemotherapy induced delayed nausea and vomiting control: results of two pilot phase II trials.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antiemetics; Antineoplastic Combined Chemotherapy Pro | 2007 |
Advances in anti-emetic therapy.
Topics: Antiemetics; Antineoplastic Agents; Chemoreceptor Cells; Clinical Trials as Topic; Dexamethasone; Do | 1984 |
The antiemetic activity of tetrahydrocannabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Double-Blind Method; Dronabinol; Human | 1980 |
Antiemetics for patients treated with antitumor chemotherapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Cisplatin; Cyclizine; Dronabinol; Drug Therapy, Combination; F | 1980 |
Nabilone and high-dose metoclopramide: anti-emetics for cancer chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Double-Blind Method; Dronabinol; Human | 1984 |
[Metoclopramide in the prevention of postoperative nausea and vomiting].
Topics: Adolescent; Adult; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Metocloprami | 1983 |
Improved control of chemotherapy-induced emesis by the addition of dexamethasone to metoclopramide in patients resistant to metoclopramide.
Topics: Adult; Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone; Double-Blind Method; Drug Syn | 1983 |
[Domperidone and metoclopramide in the prevention of postoperative nausea and vomiting].
Topics: Abortion, Induced; Adolescent; Adult; Clinical Trials as Topic; Domperidone; Double-Blind Method; Fe | 1983 |
Nausea and vomiting during spinal anaesthesia. Effect of metoclopramide and domperidone: a double-blind trial.
Topics: Aged; Anesthesia, Spinal; Blood Pressure; Clinical Trials as Topic; Domperidone; Double-Blind Method | 1984 |
Randomized open cross-over trial between metoclopramide (MCP) and dexamethazone (DXM) for the prevention of cisplatin-induced nausea and vomiting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cl | 1984 |
Metoclopramide and chemotherapy-induced emesis.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Diazepam; Drug Therapy, Combination; Humans; Metocl | 1984 |
Low-dose metoclopramide versus methylprednisolone in controlling chemotherapy induced nausea and vomiting.
Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Female; Humans; Male; Methylprednisolo | 1984 |
Dexamethasone and high dose metoclopramide: efficacy in controlling cisplatin induced nausea and vomiting.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Humans; Metoc | 1984 |
Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide.
Topics: Adult; Aged; Antiemetics; Basal Ganglia Diseases; Cisplatin; Dexamethasone; Double-Blind Method; Dru | 1984 |
[Alizapride in a double-blind trial with metoclopramide in nausea and vomiting caused by radiotherapy].
Topics: Adolescent; Adult; Aged; Antiemetics; Appetite; Double-Blind Method; Female; Humans; Male; Metoclopr | 1983 |
[Domperidone as an anti-emetic in antineoplastic chemotherapy].
Topics: Aged; Antineoplastic Agents; Benzimidazoles; Clinical Trials as Topic; Domperidone; Female; Gastroin | 1981 |
Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Cisplatin; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Metoclo | 1981 |
[Study of cipropride in the treatment of digestive disorders induced by anticancer chemotherapy. Double-blind study using metoclopramide].
Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Double-Blind Method; Female; Humans; M | 1981 |
Intravenous metoclopramide. An effective antiemetic in cancer chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Drug Therapy, Combination; | 1982 |
Metoclopramide in the reduction of nausea and vomiting associated with combined chemotherapy.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Hum | 1982 |
Reduction of postoperative vomiting by preoperative administration of oral metoclopramide.
Topics: Adolescent; Adult; Double-Blind Method; Female; Gastrointestinal Motility; Humans; Intraoperative Ca | 1980 |
Metoclopramide therapy in fifty-five patients with delayed gastric emptying.
Topics: Adolescent; Adult; Aged; Diabetes Complications; Drainage; Female; Gastric Emptying; Humans; Male; M | 1980 |
Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis.
Topics: Administration, Oral; Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child | 1995 |
The efficacy of prophylactic ondansetron, droperidol, perphenazine, and metoclopramide in the prevention of nausea and vomiting after major gynecologic surgery.
Topics: Akathisia, Drug-Induced; Consciousness; Double-Blind Method; Droperidol; Female; Humans; Hypotension | 1995 |
Antiemetic efficacy of a droperidol-morphine combination in patient-controlled analgesia.
Topics: Adolescent; Adult; Analgesia, Patient-Controlled; Dose-Response Relationship, Drug; Double-Blind Met | 1995 |
Prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy. A prospective randomized study of metoclopramide and transdermal hyoscine.
Topics: Administration, Cutaneous; Adult; Aged; Cholecystectomy, Laparoscopic; Dizziness; Female; Humans; In | 1995 |
Ondansetron in chemotherapy-induced emesis. Our experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female; Genital Neoplas | 1995 |
Ondansetron compared with ondansetron plus metoclopramide in the prevention of cisplatin-induced emesis.
Topics: Adult; Aged; Cisplatin; Double-Blind Method; Drug Therapy, Combination; Eating; Female; Humans; Male | 1994 |
Ondansetron versus metoclopramide as antiemetic treatment during cisplatin-based chemotherapy. A prospective study with special regard to regard to electrolyte imbalance.
Topics: Adult; Aged; Cisplatin; Drug Therapy, Combination; Female; Humans; Male; Metoclopramide; Middle Aged | 1995 |
Reduction of pain and nausea after laparoscopic sterilization with bupivacaine, metoclopramide, scopolamine, ketorolac, and gastric suctioning.
Topics: Analgesics, Non-Narcotic; Bupivacaine; Combined Modality Therapy; Female; Humans; Ketorolac; Laparos | 1995 |
The effects of oral droperidol versus oral metoclopramide versus both oral droperidol and metoclopramide on postoperative vomiting when used as a premedicant for strabismus surgery.
Topics: Administration, Oral; Adolescent; Ambulatory Surgical Procedures; Anesthesia Recovery Period; Child; | 1995 |
[Intravenous administration of ondansetron vs. metoclopramide for the prophylaxis of postoperative nausea and vomiting].
Topics: Adult; Double-Blind Method; Female; Genital Diseases, Female; Humans; Injections, Intravenous; Metoc | 1995 |
Prevention of nausea and vomiting after day case gynaecological laparoscopy. A comparison of ondansetron, droperidol, metoclopramide and placebo.
Topics: Adult; Ambulatory Surgical Procedures; Anesthesia, General; Double-Blind Method; Droperidol; Female; | 1995 |
[The mechanism producing nausea during ventriculography performed with ioxaglate: the implications of a randomized study].
Topics: Administration, Oral; Diazepam; Drug Therapy, Combination; Electrocardiography; Female; Gated Blood- | 1994 |
Propofol injection pain: comparing the addition of lignocaine or metoclopramide.
Topics: Adult; Anesthesia Recovery Period; Anesthesia, Intravenous; Blood Pressure; Extrapyramidal Tracts; F | 1994 |
A randomized cross-over study of high-dose metoclopramide plus dexamethasone versus granisetron plus dexamethasone in patients receiving chemotherapy with high-dose cisplatin.
Topics: Adult; Aged; Cisplatin; Cross-Over Studies; Dexamethasone; Drug Therapy, Combination; Female; Granis | 1994 |
Ondansetron against metoclopramide/dexamethasone--a comparative study.
Topics: Adult; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Male; Metoclopramide; Mi | 1994 |
Sustained release metoclopramide for prophylaxis of post-operative nausea and vomiting.
Topics: Administration, Oral; Adult; Delayed-Action Preparations; Double-Blind Method; Elective Surgical Pro | 1994 |
Efficacy and tolerability of nasally administered compared to parenterally administered metoclopramide in the symptomatic treatment of chemotherapy-induced emesis in cancer outpatients. A controlled clinical study.
Topics: Administration, Intranasal; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; | 1994 |
Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial.
Topics: Adult; Cisplatin; Clemastine; Dexamethasone; Drug Therapy, Combination; Female; Humans; Lorazepam; M | 1995 |
Effect of nabilone on nausea and vomiting after total abdominal hysterectomy.
Topics: Adult; Aged; Antiemetics; Double-Blind Method; Dronabinol; Drug Administration Schedule; Female; Hum | 1994 |
Prophylactic antiemetic treatment with ondansetron in children undergoing tonsillectomy.
Topics: Acetaminophen; Antiemetics; Child; Child, Preschool; Double-Blind Method; Droperidol; Female; Humans | 1994 |
[Nausea and vomiting in cytostatic therapy of melanoma patients with the use of metoclopramide and corticosteroid or ondansetron].
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Huma | 1994 |
Antiemetic efficacy of metoclopramide when included in a patient-controlled analgesia infusion.
Topics: Adult; Aged; Analgesia, Patient-Controlled; Double-Blind Method; Female; Gynecology; Humans; Metoclo | 1994 |
Comparison of the efficacy, safety, and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer.
Topics: Chronic Disease; Delayed-Action Preparations; Double-Blind Method; Humans; Metoclopramide; Nausea; N | 1994 |
Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles. Italian Group for Antiemetic Research.
Topics: Acute Disease; Chi-Square Distribution; Cisplatin; Dexamethasone; Diphenhydramine; Drug Therapy, Com | 1994 |
Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group.
Topics: Administration, Oral; Adult; Aged; Chi-Square Distribution; Cisplatin; Constipation; Dexamethasone; | 1994 |
Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer. Italian Group for Antiemetic Research.
Topics: Adult; Aged; Aged, 80 and over; Cisplatin; Dexamethasone; Diphenhydramine; Drug Combinations; Drug T | 1994 |
Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Doxorubicin; Female; Granisetron; Huma | 1994 |
Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide.
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Constipation; Cyclophosphamide; Epirubicin; Fem | 1994 |
[Effects of ondansetron and metoclopramide on postoperative nausea and vomiting after epidural anesthesia in children].
Topics: Anesthesia, Epidural; Child; Child, Preschool; Female; Humans; Male; Metoclopramide; Nausea; Ondanse | 1994 |
Tropisetron compared with a metoclopramide-based regimen in the prevention of chemotherapy-induced nausea and vomiting.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Femal | 1994 |
Continuous infusion versus intermittent short infusion of metoclopramide for cisplatin-induced acute emesis.
Topics: Acute Disease; Adult; Aged; Chi-Square Distribution; Cisplatin; Female; Humans; Infusions, Intraveno | 1994 |
Nausea and vomiting after gynaecological laparoscopy: comparison of premedication with oral ondansetron, metoclopramide and placebo.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Anesthesia, General; Female; Gynecology; Humans; | 1994 |
Prophylactic antiemetic therapy with patient-controlled analgesia: a double-blind, placebo-controlled comparison of droperidol, metoclopramide, and tropisetron.
Topics: Analgesia, Patient-Controlled; Antiemetics; Double-Blind Method; Droperidol; Elective Surgical Proce | 1994 |
Double-blind comparison of ondansetron, droperidol and saline in the prevention of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia, Epidural; Anesthesia, General; Double-Blind | 1994 |
Zingiber officinale (ginger)--an antiemetic for day case surgery.
Topics: Adult; Ambulatory Surgical Procedures; Antiemetics; Double-Blind Method; Female; Humans; Metoclopram | 1993 |
[Clinical effects of granisetron and methylprednisolone against nausea, vomiting and anorexia induced by cisplatin].
Topics: Adult; Aged; Anorexia; Cisplatin; Domperidone; Drug Therapy, Combination; Female; Granisetron; Human | 1993 |
Antiemetic efficacy of prophylactic ondansetron in laparoscopic surgery: randomized, double-blind comparison with metoclopramide.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Anesthesia, General; Double-Blind Method; Female; | 1993 |
An open, randomized study to compare the efficacy and tolerability of tropisetron with that of a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Drug Administration Schedule; Female; Genita | 1994 |
A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Female; Humans; Indoles; Male; Metoclopramid | 1994 |
Comparison of intermittent ondansetron versus continuous infusion metoclopramide used with standard combination antiemetics in control of acute nausea induced by cisplatin chemotherapy.
Topics: Adult; Aged; Antiemetics; Cisplatin; Costs and Cost Analysis; Dexamethasone; Diphenhydramine; Drug A | 1993 |
[An early phase II trial combining cisplatin and carboplatin in advanced non-small cell lung cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-S | 1993 |
Mitomycin, ifosfamide, and cisplatin in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Non-Small-Cell | 1993 |
The control of acute cisplatin-induced emesis--a comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone. Granisetron Study Group.
Topics: Blood Pressure; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Granisetron; Humans; In | 1993 |
Antiemetic efficacy of alprazolam in the combination of metoclopramide plus methylprednisolone. Double-blind randomized crossover study in patients with cisplatin-induced emesis.
Topics: Adult; Aged; Alprazolam; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non | 1993 |
Randomized comparison of the antiemetic efficacy of a serotonin type 3 receptor antagonist (MDL 72,222) with a high-dose metoclopramide regimen.
Topics: Adult; Aged; Antiemetics; Cisplatin; Diphenhydramine; Drug Therapy, Combination; Female; Genital Neo | 1993 |
Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophospha | 1993 |
Postoperative nausea and vomiting: a comparison of anti-emetic drugs used alone or in combination.
Topics: Adult; Antiemetics; Double-Blind Method; Droperidol; Drug Combinations; Humans; Metoclopramide; Naus | 1993 |
Tiapride versus metoclopramide: comparison after minor gynaecological surgery.
Topics: Abortion, Incomplete; Abortion, Missed; Adolescent; Adult; Dilatation and Curettage; Double-Blind Me | 1993 |
Comparison of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Cross-Over Studies; Drug Therapy, Combin | 1996 |
Sustained-release metoclopramide plus methylprednisolone versus placebo plus methylprednisolone as antiemetic prophylaxis during non-cisplatin chemotherapy. A randomized double-blind cross-over trial.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplas | 1996 |
Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Cisplatin; Drug Therapy, Combination; Female; Granis | 1995 |
Oral combination antiemetics in patients with small cell lung cancer receiving cisplatin or cyclophosphamide plus doxorubicin.
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Sm | 1995 |
Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation.
Topics: Adult; Antiemetics; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combine | 1995 |
Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemot | 1996 |
Tropisetron and metoclopramide in the prevention of postoperative nausea and vomiting. A comparative, placebo controlled study in patients undergoing ophthalmic surgery.
Topics: Adolescent; Adult; Aged; Anesthesia, General; Antiemetics; Double-Blind Method; Female; Humans; Indo | 1996 |
[Colonic preparation with sodium phosphate. Prospective, randomized, placebo-controlled double blind study with various antiemetics].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Cathartics; Cisapride | 1996 |
Comparison of dexamethasone and metoclopramide as antiemetics in children receiving cancer chemotherapy.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cr | 1996 |
Treatment of postoperative nausea and vomiting: comparison of propofol, droperidol and metoclopramide.
Topics: Adult; Antiemetics; Double-Blind Method; Droperidol; Female; Humans; Male; Metoclopramide; Middle Ag | 1996 |
Prophylactic antiemetic therapy with ondansetron, tropisetron, granisetron and metoclopramide in patients undergoing laparoscopic cholecystectomy: a randomized, double-blind comparison with placebo.
Topics: Adult; Aged; Antiemetics; Cholecystectomy, Laparoscopic; Double-Blind Method; Female; Granisetron; H | 1996 |
Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen.
Topics: Aged; Antiemetics; Antineoplastic Agents; Female; Humans; Male; Metoclopramide; Nausea; Neoplasms; R | 1996 |
Comparison of ondansetron and metoclopramide for the prevention of post-operative nausea and vomiting after major gynaecological surgery.
Topics: Adolescent; Adult; Analgesics, Opioid; Antiemetics; Double-Blind Method; Female; Humans; Hysterectom | 1996 |
Prophylactic antiemetics for laparoscopic cholecystectomy: ondansetron versus droperidol plus metoclopramide.
Topics: Adrenergic Agonists; Adult; Antiemetics; Atropine; Chemoprevention; Cholecystectomy, Laparoscopic; C | 1996 |
A randomized double-blinded comparison of metoclopramide, ondansetron and cyclizine in day-case laparoscopy.
Topics: Adult; Ambulatory Surgical Procedures; Anesthesia, Inhalation; Anesthesia, Intravenous; Anesthetics, | 1996 |
Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Com | 1997 |
A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.
Topics: Acute Disease; Alcoholism; Antiemetics; Antineoplastic Agents; Basal Ganglia Diseases; Cisplatin; Do | 1997 |
Acupressure versus intravenous metoclopramide to prevent nausea and vomiting during spinal anesthesia for cesarean section.
Topics: Acupressure; Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Antiemetics; Cesarean Section; Doub | 1997 |
Neoadjuvant chemotherapy in scirrhous cancer of the stomach using uracil and tegafur and cisplatin.
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy | 1996 |
A comparison of prophylactic ondansetron and metoclopramide administration in patients undergoing major neurosurgical procedures.
Topics: Antiemetics; Double-Blind Method; Female; Humans; Male; Metoclopramide; Middle Aged; Nausea; Neurosu | 1996 |
Comparison of metoclopramide and ondansetron for the prevention of nausea and vomiting after intrathecal morphine.
Topics: Aged; Analgesics, Opioid; Antiemetics; Blood Pressure; Double-Blind Method; Female; Hip; Humans; Inj | 1997 |
A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis.
Topics: Adult; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Dopamine Antagonists; Double-Bl | 1994 |
Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Dopamine Antagonists; Drug Therapy, | 1994 |
Prevention of emesis by tropisetron (Navoban) in children receiving cytotoxic therapy for solid malignancies.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Dopamine Antagonists; Femal | 1994 |
Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Dopamine Antagonists; Drug Therapy, | 1994 |
Efficacy of ondansetron and metoclopramide for preventing postoperative emesis following strabismus surgery in children.
Topics: Age Distribution; Antiemetics; Child; Child, Preschool; Double-Blind Method; Female; Humans; Infant; | 1997 |
[Does oral ondansetron reduce the incidence of nausea and vomiting after surgery for strabismus in children?].
Topics: Administration, Oral; Adolescent; Antiemetics; Child; Female; Humans; Male; Metoclopramide; Nausea; | 1996 |
Comparison of ondansetron, metoclopramide and placebo as premedicants to reduce nausea and vomiting after major surgery.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Double-Blind Method; Female; Humans; Male; | 1997 |
Ondansetron versus metoclopramide in the treatment of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Age Factors; Aged; Anesthesia Recovery Period; Anesthetics, Intravenous; Antiemet | 1997 |
Prevention of PONV with granisetron, droperidol and metoclopramide in female patients with history of motion sickness.
Topics: Adult; Antiemetics; Double-Blind Method; Droperidol; Female; Granisetron; Humans; Metoclopramide; Mi | 1997 |
Prophylactic intravenous ondansetron in patients undergoing cataract extraction under general anesthesia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia, General; Antiemetics; Cataract Extraction; C | 1997 |
The effect of antiemetics and reduced radiation fields on acute gastrointestinal morbidity of adjuvant radiotherapy in stage I seminoma of the testis: a randomized pilot study.
Topics: Acute Disease; Adult; Antiemetics; Diarrhea; Gastrointestinal Diseases; Humans; Lymphatic Metastasis | 1997 |
Comparison of three tropisetron-containing antiemetic regimens in the prophylaxis of acute and delayed chemotherapy-induced emesis and nausea.
Topics: Acute Disease; Adult; Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Administration S | 1997 |
Ondansetron compared with metoclopramide in the treatment of established postoperative nausea and vomiting. The French Ondansetron Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia, General; Antiemetics; Double-Blind Method; F | 1997 |
Prophylactic use of tropisetron or metoclopramide during adjuvant abdominal radiotherapy of seminoma stage I: a randomised, open trial in 23 patients.
Topics: Adult; Antiemetics; Dose-Response Relationship, Drug; Humans; Indoles; Male; Metoclopramide; Nausea; | 1997 |
Accelerated radiotherapy, carbogen and nicotinamide (ARCON) in locally advanced head and neck cancer: a feasibility study.
Topics: Administration, Oral; Aerosols; Antiemetics; Carbon Dioxide; Disease-Free Survival; Dose Fractionati | 1997 |
Ondansetron dose response curve in high-risk pediatric patients.
Topics: Adenoidectomy; Antiemetics; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Blind | 1997 |
Ondansetron is not superior to moderate dose metoclopramide in the prevention of post-operative nausea and vomiting after minor gynaecological surgery.
Topics: Adult; Antiemetics; Dilatation and Curettage; Double-Blind Method; Female; Gynecologic Surgical Proc | 1997 |
Prevention of nausea and vomiting in female patients undergoing breast surgery: a comparison with granisetron, droperidol, metoclopramide and placebo.
Topics: Adult; Antiemetics; Breast Neoplasms; Double-Blind Method; Droperidol; Female; Granisetron; Humans; | 1998 |
Prevention of PONV with granisetron, droperidol or metoclopramide in patients with postoperative emesis.
Topics: Adult; Double-Blind Method; Droperidol; Female; Gastrointestinal Agents; Granisetron; Humans; Metocl | 1998 |
International, multicentre, placebo-controlled study to evaluate the effectiveness of ondansetron vs. metoclopramide in the prevention of post-operative nausea and vomiting.
Topics: Adolescent; Adult; Anesthesia, General; Antiemetics; Double-Blind Method; Female; Gynecologic Surgic | 1998 |
Anti-emetic efficacy of prophylactic granisetron, droperidol and metoclopramide in the prevention of nausea and vomiting after laparoscopic cholecystectomy: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Antiemetics; Cholecystectomy, Laparoscopic; Double-Blind Method; Droperidol; Female; Gr | 1998 |
Prevention of postoperative nausea and vomiting in female patients during menstruation: comparison of droperidol, metoclopramide and granisetron.
Topics: Adult; Antiemetics; Double-Blind Method; Droperidol; Female; Granisetron; Gynecologic Surgical Proce | 1998 |
Comparison of the efficacy and safety of tropisetron, metoclopramide, and chlorpromazine in the treatment of emesis associated with far advanced cancer.
Topics: Adult; Aged; Antiemetics; Chlorpromazine; Dexamethasone; Drug Therapy, Combination; Female; Humans; | 1998 |
Prophylactic antiemetics for laparoscopic cholecystectomy: a comparison of perphenazine, droperidol plus ondansetron, and droperidol plus metoclopramide.
Topics: Adult; Aged; Antiemetics; Cholecystectomy, Laparoscopic; Double-Blind Method; Droperidol; Female; Hu | 1998 |
Comparison of the efficacy and side-effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy: a prospective randomized study.
Topics: Antiemetics; Antineoplastic Agents; Child; Diphenhydramine; Drug Therapy, Combination; Female; Human | 1998 |
Comparative efficacy and safety of calcium carbasalate plus metoclopramide versus ergotamine tartrate plus caffeine in the treatment of acute migraine attacks.
Topics: Abdominal Pain; Adolescent; Adult; Aged; Analgesics; Aspirin; Caffeine; Double-Blind Method; Drug Th | 1999 |
Prospective randomized comparison of tropisetron with and without dexamethasone against high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting.
Topics: Acute Disease; Adult; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Co | 1999 |
Granisetron, droperidol, and metoclopramide for preventing postoperative nausea and vomiting after thyroidectomy.
Topics: Adult; Antiemetics; Double-Blind Method; Droperidol; Female; Granisetron; Humans; Metoclopramide; Mi | 1999 |
[Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Breast Neoplasms; Drug Therapy, Combination; Female; | 1999 |
Sulpiride versus metoclopramide in nononcologic patients with vomiting or nausea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Dose-Response Relationship, Drug; Double-Bl | 1999 |
[Postoperative nausea and vomiting after laparoscopic cholecystectomy].
Topics: Adult; Antiemetics; Cholecystectomy, Laparoscopic; Humans; Metoclopramide; Middle Aged; Nausea; Post | 1999 |
Ondansetron is more effective than metoclopramide for the treatment of opioid-induced emesis in post-surgical adult patients. Ondansetron OIE Post-Surgical Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Antiemetics; Double-Blind Method; Fe | 1999 |
Changes in clinical measures of autonomic nervous system function related to cancer chemotherapy-induced nausea.
Topics: Aged; Antiemetics; Antineoplastic Agents; Autonomic Nervous System; Blood Pressure; Carboplatin; Cis | 1999 |
Granisetron, droperidol, and metoclopramide for the treatment of established postoperative nausea and vomiting in women undergoing gynecologic surgery.
Topics: Adult; Anesthesia, General; Antiemetics; Double-Blind Method; Droperidol; Female; Granisetron; Gynec | 2000 |
A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer.
Topics: Aged; Antiemetics; Chronic Disease; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; M | 2000 |
Prophylactic metoclopramide is unnecessary with intravenous analgesia in the ED.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesia; Analgesics, Opioid; Antiemetics; Double-Blind | 2000 |
Gastric residual volume in children: a study comparing efficiency of erythromycin and metoclopramide as prokinetic agents.
Topics: Administration, Oral; Adolescent; Antiemetics; Child; Child, Preschool; Double-Blind Method; Erythro | 2001 |
A pilot study of the use of progressive muscle relaxation training in the management of post-chemotherapy nausea and vomiting.
Topics: Adult; Antiemetics; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Breast Neoplasms; Cost | 2000 |
Comparison of ondansetron with metoclopramide in the symptomatic relief of uremia-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Metoclopram | 2002 |
A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Antiemetics; Double-Blind Method; Female; Humans | 2002 |
Letter: Metoclopramide in parkinsonism.
Topics: Clinical Trials as Topic; Humans; Levodopa; Metoclopramide; Nausea; Parkinson Disease; Promethazine; | 1975 |
Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol.
Topics: Antiemetics; Antineoplastic Agents; Child; Clinical Trials as Topic; Double-Blind Method; Dronabinol | 1979 |
Plasma bromocriptine levels, clinical and growth hormone responses in Parkinsonism.
Topics: Aged; Blood Pressure; Bromocriptine; Clinical Trials as Topic; Female; Growth Hormone; Humans; Male; | 1978 |
Improvement of life quality in cancer patients undergoing chemotherapy.
Topics: Alopecia; Antineoplastic Agents; Bone Marrow Diseases; Breast Neoplasms; Clinical Trials as Topic; C | 1979 |
A double-blind comparison of domperidone and metoclopramide suppositories in the treatment of nausea and vomiting in children.
Topics: Antiemetics; Benzimidazoles; Child; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; | 1979 |
Domperidone drops in the symptomatic treatment of chronic paediatric vomiting and regurgitation. A comparison with metoclopramide.
Topics: Antiemetics; Benzimidazoles; Child; Child, Preschool; Chronic Disease; Clinical Trials as Topic; Dou | 1979 |
Prevention of postoperative nausea and vomiting by domperidone: A double-blind randomized study using domperidone, metoclopramide and a placebo.
Topics: Adult; Anesthesia, Inhalation; Anesthesia, Intravenous; Anesthesia, Obstetrical; Benzimidazoles; Cli | 1979 |
Domperidone or metoclopramide in preventing chemotherapeutically induced nausea and vomiting.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Benzimidazoles; Child; Child, Preschool; Female; Hum | 1979 |
Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Drug Evaluation; Drug Interactions; Drug Therapy, Combina | 1975 |
Fractionated chemotherapy--granisetron or conventional antiemetics? The Granisetron Study Group.
Topics: Adult; Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Administration Schedule; Drug Therapy | 1992 |
A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. An NCI Canada Clinical Trials Group Phase III Trial.
Topics: Antiemetics; Cisplatin; Dexamethasone; Diphenhydramine; Double-Blind Method; Drug Therapy, Combinati | 1992 |
Effect of sumatriptan, a new selective 5HT1-like agonist, on liquid gastric emptying in man.
Topics: Adult; Double-Blind Method; Fats; Gamma Cameras; Gastric Emptying; Half-Life; Humans; Indoles; Infus | 1992 |
Three years' experience with tropisetron in the control of nausea and vomiting in cisplatin-treated patients.
Topics: Adult; Aged; Antiemetics; Cisplatin; Female; Humans; Indoles; Lorazepam; Male; Metoclopramide; Middl | 1992 |
The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Double-Blind Method; Female; Humans; Imidazo | 1992 |
A randomised double-blind study of high-dose intravenous prochlorperazine versus high-dose metoclopramide as antiemetics for cancer chemotherapy.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Cisplatin; Female; H | 1992 |
Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy.
Topics: Adolescent; Adult; Cisplatin; Double-Blind Method; Humans; Injections, Intravenous; Male; Metoclopra | 1992 |
Antiemetic efficacy of high-dose metoclopramide and dexamethasone in patients receiving cisplatin chemotherapy: a randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Dose-Response | 1992 |
Antiemetic activity of two different high doses and schedules of metoclopramide in dacarbazine-treated cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dexamethasone; Diphenhydramine; Double- | 1992 |
Comparison of antiemetic effect among ephedrine, droperidol and metoclopramide in pediatric inguinal hernioplasty.
Topics: Antiemetics; Child; Child, Preschool; Droperidol; Drug Evaluation; Ephedrine; Hernia, Inguinal; Huma | 1992 |
Comparison of continuous and intermittent bolus infusions of metoclopramide during 5-day continuous intravenous infusion with cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 1991 |
Outpatient cholecystectomy simulated in an inpatient population.
Topics: Abdomen; Adult; Age Factors; Aged; Aged, 80 and over; Ambulatory Surgical Procedures; Analgesics; An | 1991 |
Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation.
Topics: Abdomen; Adolescent; Adult; Aged; Antiemetics; Double-Blind Method; Female; Humans; Imidazoles; Male | 1990 |
Randomized trial for the control of acute vomiting in cisplatin-treated patients: high-dose metoclopramide with dexamethasone and lorazepam as adjuncts versus high-dose alizapride plus dexamethasone and lorazepam. Study of the incidence of delayed emesis.
Topics: Antiemetics; Cisplatin; Dexamethasone; Humans; Lorazepam; Metoclopramide; Nausea; Prospective Studie | 1991 |
Metoclopramide does not decrease the incidence of nausea and vomiting after alfentanil for outpatient anaesthesia.
Topics: Adult; Alfentanil; Ambulatory Surgical Procedures; Anesthesia, Inhalation; Anesthesia, Intravenous; | 1991 |
Nausea and vomiting after termination of pregnancy as day surgery cases: comparison of 3 different doses of droperidol and metoclopramide as anti-emetic prophylaxis.
Topics: Abortion, Induced; Adult; Ambulatory Surgical Procedures; Dose-Response Relationship, Drug; Droperid | 1991 |
A comparison of controlled release metoclopramide and domperidone in the treatment of nausea and vomiting.
Topics: Delayed-Action Preparations; Domperidone; Double-Blind Method; Female; Humans; Male; Metoclopramide; | 1991 |
A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Female; Humans; Imidazoles; Injections, Intr | 1991 |
Double-blind crossover trial of single vs. divided dose of metoclopramide in a combined regimen for treatment of cisplatin-induced emesis.
Topics: Cisplatin; Dexamethasone; Diphenhydramine; Double-Blind Method; Drug Administration Schedule; Drug T | 1991 |
Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; | 1991 |
The final assessment of a randomized double-blind comparative study of ondansetron vs. metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation.
Topics: Abdominal Neoplasms; Adult; Aged; Antiemetics; Double-Blind Method; Humans; Imidazoles; Metocloprami | 1991 |
Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide.
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Double-Blind Method; Epirubicin; Female; Humans; Im | 1991 |
Does propofol have an anti-emetic effect? A prospective study of the anti-emetic effect of propofol following laparoscopy.
Topics: Adult; Antiemetics; Blood Pressure; Female; Humans; Laparoscopy; Metoclopramide; Nausea; Postoperati | 1991 |
Comparison of patient-controlled and nurse-controlled antiemetic therapy in patients receiving chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Analgesia, Patient-Controlled; Antineoplastic Agents; Diphenhydramin | 1991 |
Antiemetic regimens in outpatients receiving cisplatin and non-cisplatin chemotherapy. A randomized trial comparing high-dose metoclopramide plus methylprednisolone with and without lorazepam.
Topics: Antineoplastic Agents; Cisplatin; Drug Therapy, Combination; Female; Humans; Lorazepam; Male; Methyl | 1991 |
Diphenhydramine for nausea and vomiting related to cancer chemotherapy with cisplatin.
Topics: Adult; Aged; Antiemetics; Cisplatin; Diphenhydramine; Drug Therapy, Combination; Female; Humans; Mal | 1991 |
Cinnarizine for prevention of nausea and vomiting during platin chemotherapy.
Topics: Adult; Aged; Carboplatin; Cinnarizine; Cisplatin; Combined Modality Therapy; Female; Humans; Lorazep | 1991 |
Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study.
Topics: Cisplatin; Dexamethasone; Female; Humans; Male; Metoclopramide; Middle Aged; Nausea; Sex Factors; Vo | 1991 |
Antiemetic activity of high-dose methylprednisolone associated with continuous-infusion metoclopramide and oral alprazolam during multiple-day chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alprazolam; Antineoplastic Combined Chemotherapy Protoco | 1991 |
High-dose metoclopramide + lorazepam versus low-dose metoclopramide + lorazepam + dehydrobenzperidol in the treatment of cisplatin-induced nausea and vomiting.
Topics: Adult; Aged; Cisplatin; Double-Blind Method; Droperidol; Drug Therapy, Combination; Female; Humans; | 1991 |
Betamethasone-dixyrazine versus betamethasone-metoclopramide as antiemetic treatment of cisplatin-doxorubicin-induced nausea in ovarian carcinoma patients.
Topics: Activities of Daily Living; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Betamethaso | 1991 |
Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.
Topics: Adult; Aged; Antiemetics; Cisplatin; Double-Blind Method; Drug Tolerance; Female; Humans; Imidazoles | 1990 |
A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Brea | 1990 |
A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; | 1990 |
Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.
Topics: Adult; Aged; Antiemetics; Cisplatin; Double-Blind Method; Female; Humans; Imidazoles; Male; Metoclop | 1990 |
Ginger root--a new antiemetic. The effect of ginger root on postoperative nausea and vomiting after major gynaecological surgery.
Topics: Adolescent; Adult; Aged; Analgesics; Antiemetics; Double-Blind Method; Female; Genital Diseases, Fem | 1990 |
Prochlorperazine and transdermal scopolamine added to a metoclopramide antiemetic regimen. A controlled comparison.
Topics: Administration, Cutaneous; Cisplatin; Female; Genital Neoplasms, Female; Humans; Infusions, Intraven | 1990 |
Comparison of antiemetic activity of chloropromazine and high doses of metoclopramide in cisplatin-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorpromazine; Cisplatin; Drug Adminis | 1990 |
Dose-response study of droperidol and metoclopramide as antiemetics for outpatient anesthesia.
Topics: Administration, Oral; Adult; Ambulatory Surgical Procedures; Antiemetics; Dose-Response Relationship | 1989 |
Comparison of intermittent versus continuous infusion metoclopramide in control of acute nausea induced by cisplatin chemotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Dexamethasone; Diphenhydramine; Dr | 1989 |
Antiemetic treatment of chemotherapy-induced nausea in ovarian carcinoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antipsychotic Agents; Betamethasone; Cisplatin; Clin | 1989 |
Effect of stimulation of the P6 antiemetic point on postoperative nausea and vomiting.
Topics: Acupuncture Points; Acupuncture Therapy; Adolescent; Adult; Anesthesia, General; Cyclizine; Electroa | 1989 |
Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.
Topics: Adult; Aged; Antiemetics; Cisplatin; Clinical Trials as Topic; Dexamethasone; Double-Blind Method; D | 1989 |
Dose-ranging antiemetic trial of high-dose oral metoclopramide.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Clinical Trials as Topic; Diphenhydramine; Drug | 1989 |
Metoclopramide versus droperidol for prevention of nausea and vomiting during epidural anesthesia for cesarean section.
Topics: Adult; Akathisia, Drug-Induced; Anesthesia, Epidural; Anesthesia, Obstetrical; Cesarean Section; Dou | 1989 |
Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research
Topics: Age Factors; Antiemetics; Cisplatin; Dexamethasone; Diphenhydramine; Drug Administration Schedule; D | 1989 |
Comparison of two different high doses of metoclopramide in the prevention of chemotherapy-induced emesis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Do | 1989 |
Antiemetic activity of high-dose metoclopramide combined with methylprednisolone versus metoclopramide alone in dacarbazine-treated cancer patients. A randomized double-blind study of the Italian Oncology Group for Clinical Research.
Topics: Dacarbazine; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methylprednisolon | 1989 |
A double-blind randomised cross-over comparison of nabilone and metoclopramide in the control of radiation-induced nausea.
Topics: Antiemetics; Clinical Trials as Topic; Double-Blind Method; Dronabinol; Female; Humans; Male; Metocl | 1987 |
A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues.
Topics: Adolescent; Adult; Aged; Antiemetics; Cisplatin; Clinical Trials as Topic; Dexamethasone; Dronabinol | 1988 |
Comparison of the use of domperidone, droperidol and metoclopramide in the prevention of nausea and vomiting following major gynaecological surgery.
Topics: Abdomen; Adult; Antiemetics; Clinical Trials as Topic; Domperidone; Droperidol; Female; Humans; Hyst | 1986 |
Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study.
Topics: Antiemetics; Cisplatin; Double-Blind Method; Dronabinol; Humans; Metoclopramide; Nausea | 1986 |
[Randomized controlled study of high-dose metoclopramide and dexamethasone in the prevention of CDDP-induced emesis].
Topics: Adult; Aged; Anorexia; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Dexamethasone; Dr | 1986 |
Betamethasone-dixyrazine versus metoclopramide as antiemetic treatment in cancer chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Betamethasone; Clinical Trials as Topic; Double-Blind Method; Hu | 1988 |
A prospective randomized double-blind crossover study comparing the antiemetic activity of alizapride and metoclopramide in patients receiving cisplatin chemotherapy.
Topics: Adult; Aged; Antiemetics; Cisplatin; Clinical Trials as Topic; Double-Blind Method; Female; Humans; | 1988 |
[The effect of metoclopramide on postoperative nausea and vomiting].
Topics: Abortion, Therapeutic; Adolescent; Adult; Clinical Trials as Topic; Double-Blind Method; Female; Hum | 1988 |
Comparison of antiemetic efficacy of domperidone, metoclopramide, and dexamethasone in patients receiving outpatient chemotherapy regimens.
Topics: Adult; Aged; Ambulatory Care; Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Dexameth | 1987 |
Continuous infusion metoclopramide: clinical trials, pharmacokinetic considerations and cost-effectiveness.
Topics: Cisplatin; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Infusions, Intravenous; Metoclop | 1987 |
[Effect of medical vagotomy on the CDDP induced nausea and vomiting evaluated by the chemotherapy-vomiting time (CV time)].
Topics: Acetaminophen; Adult; Cisplatin; Female; Humans; Metoclopramide; Middle Aged; Nausea; Ovarian Neopla | 1988 |
A double-blind trial comparing antiemetic efficacy and toxicity of metoclopramide versus methylprednisolone versus domperidone in patients receiving doxorubicin chemotherapy alone or in combination with other antiblastic agents.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Domperidone; Double-Blind Method; Doxor | 1988 |
Antiemetic efficacy of high-dose dexamethasone: randomized, double-blind, crossover study with a combination of dexamethasone, metoclopramide and diphenhydramine.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone; Diphenhydra | 1988 |
[Antiemetic effects of combinations of metoclopramide, droperidol and dexamethasone for the prevention of cisplatin-induced gastro-intestinal toxicity: a randomized crossover trial].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as | 1987 |
Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1987 |
[A randomized controlled trial of acute and delayed cisplatin-induced emesis with metoclopramide, dexamethasone and prochlorperazine].
Topics: Adult; Aged; Cisplatin; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Female; | 1987 |
Randomized, double-blind, cross-over study comparing prochlorperazine and lorazepam with high-dose metoclopramide and lorazepam for the control of emesis in patients receiving cytotoxic chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Com | 1987 |
A randomised cross-over trial comparing low-dose metoclopramide and chlorpromazine with high-dose metoclopramide in Chinese patients with advanced cancer receiving cisplatinum and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorpromazine; Cisplatin; Clinical Tri | 1987 |
High-dose metoclopramide by infusion: a double-blind study of plasma concentration-effect relationships in patients receiving cancer chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Doub | 1987 |
[The effect of metoclopramide, dexamethasone and antihistamine in the prevention of PAC chemotherapy-induced emesis].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; D | 1988 |
Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized study.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclopho | 1988 |
Antiemetic effect of oral versus intravenous metoclopramide in patients receiving cisplatin: a randomized, double-blind trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 1986 |
[Prevention of nausea and emesis during cytostatic therapy. Antiemetic efficacy of high-dosage oral metoclopramide without and with prednisone].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cis | 1986 |
Enhancement of the antiemetic action of metoclopramide against cisplatin-induced emesis by transdermal electrical nerve stimulation.
Topics: Adult; Aged; Cisplatin; Clinical Trials as Topic; Double-Blind Method; Electric Stimulation; Female; | 1986 |
The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective, randomized, double-blind trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Do | 1986 |
Antiemetic efficacy of high-dose dexamethasone: randomized, double-blind, crossover study with high-dose metoclopramide in patients receiving cancer chemotherapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone | 1986 |
The value of dexamethasone when added to combination drug therapy in the prevention of cisplatin-induced nausea and vomiting, evaluated by time-lapse video technology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Dexamethasone; | 1986 |
Comparison of the use of domperidone, droperidol and metoclopramide in the prevention of nausea and vomiting following gynaecological surgery in day cases.
Topics: Adolescent; Adult; Aged; Ambulatory Surgical Procedures; Antiemetics; Clinical Trials as Topic; Dila | 1986 |
[Randomized crossover trial of the antiemetic effects obtained with metoclopramide and droperidol versus those obtained with metoclopramide, droperidol and methylprednisolone in patients receiving cis-platinum chemotherapy].
Topics: Aged; Cisplatin; Clinical Trials as Topic; Droperidol; Drug Therapy, Combination; Female; Humans; Lu | 1986 |
Superiority of methylprednisolone sodium succinate over low dose metoclopramide hydrochloride in the prevention of nausea and vomiting produced by cancer chemotherapy.
Topics: Antineoplastic Agents; Anxiety; Gastrointestinal Diseases; Humans; Methylprednisolone; Methylprednis | 1986 |
Antiemetic therapy in patients treated with high-dose cytosine arabinoside.
Topics: Adolescent; Adult; Aged; Basal Ganglia Diseases; Clinical Trials as Topic; Cytarabine; Drug Therapy, | 1987 |
Metoclopramide as prophylaxis for nausea and vomiting induced by fluorescein.
Topics: Female; Fluorescein Angiography; Humans; Male; Metoclopramide; Middle Aged; Nausea; Vomiting | 1987 |
Randomized crossover antiemetic study in cisplatin-treated patients. Comparison between high-dose i.v. metoclopramide and high-dose i.v. dexamethasone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Female; Human | 1986 |
[Randomized cross-over study on the effects of methylprednisolone, metoclopramide and droperidol on the control of nausea and vomiting associated with cis-platinum chemotherapy].
Topics: Adult; Aged; Cisplatin; Droperidol; Drug Administration Schedule; Female; Humans; Male; Methylpredni | 1986 |
Droperidol, alizapride and metoclopramide in the prevention and treatment of post-operative emetic sequelae.
Topics: Adolescent; Adult; Droperidol; Drug Evaluation; Female; Humans; Intraoperative Care; Metoclopramide; | 1986 |
Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin.
Topics: Adult; Aged; Cisplatin; Female; Humans; Infusions, Parenteral; Male; Metoclopramide; Middle Aged; Na | 1986 |
[Anti-emetic treatment with metoclopramide and other drugs during CDDP therapy].
Topics: Aged; Cisplatin; Dexamethasone; Female; Humans; Lorazepam; Lung Neoplasms; Male; Metoclopramide; Mid | 1987 |
Successful administration of metoclopramide for the treatment of nausea in patients with advanced liver disease. A double-blind controlled trial.
Topics: Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Female; Gastroesophageal Reflux; Hep | 1985 |
The effect of administration rate on cisplatin-induced emesis.
Topics: Adult; Aged; Cisplatin; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; | 1985 |
[Randomized control study of high-dose metoclopramide in the prevention of CDDP-induced emesis].
Topics: Adult; Aged; Cisplatin; Clinical Trials as Topic; Female; Humans; Infusions, Parenteral; Male; Metoc | 1985 |
The evaluation of domperidone and metoclopramide as antiemetics in day care abortion patients.
Topics: Abortion, Therapeutic; Adolescent; Adult; Anesthesia, General; Anesthesia, Obstetrical; Clinical Tri | 1985 |
Comparative evaluation of two outpatient antiemetic regimens for cancer chemotherapy.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone; Humans; Metoclopramide; Nausea; Neop | 1985 |
Clinical pharmacokinetics of high-dose metoclopramide in cancer patients receiving cisplatin therapy.
Topics: Adult; Aged; Cisplatin; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Female; | 1985 |
[Metoclopramide in the prevention of nausea and vomiting caused by cytostatics].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Female; Humans; Mal | 1985 |
Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Cisplatin; Clinical Trials as | 1985 |
Randomised trial of intravenous high dose metoclopramide and intramuscular chlorpromazine in controlling nausea and vomiting induced by cytotoxic drugs.
Topics: Chlorpromazine; Cisplatin; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Injections | 1985 |
Comparison of the antiemetics metoclopramide and promethazine in labour.
Topics: Clinical Trials as Topic; Consciousness; Double-Blind Method; Female; Humans; Meperidine; Metoclopra | 1985 |
[Randomized controlled study of high-dose metoclopramide (2 mg/kg x 4:H) vs moderate-dose metoclopramide (1 mg/kg x 4:M) in the prevention of CDDP-induced emesis].
Topics: Aged; Cisplatin; Drug Administration Schedule; Female; Humans; Metoclopramide; Middle Aged; Nausea; | 1986 |
High-dose intravenous metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind crossover comparison of antiemetic efficacy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; | 1985 |
The use of methylprednisolone and metoclopramide in control of emesis in patients receiving cis-platinum.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Double-Blind Me | 1985 |
A comparison of the antiemetic efficacy of prochlorperazine and metoclopramide for the treatment of cisplatin-induced emesis: a prospective, randomized, double-blind study.
Topics: Adolescent; Adult; Aged; Cisplatin; Double-Blind Method; Drug Administration Schedule; Drug Evaluati | 1985 |
Metoclopramide and drinking before general anaesthesia.
Topics: Adolescent; Adult; Anesthesia, General; Child; Drinking; Female; Gastrointestinal Motility; Humans; | 1974 |
Flatulent dyspepsia.
Topics: Clinical Trials as Topic; Dyspepsia; Female; Flatulence; Gastroesophageal Reflux; Heartburn; Humans; | 1973 |
Double-blind evaluation of metoclopramide (MK 745, Sinemet), trimethobenzamide (Tigan), and a placebo as postanaesthetic anti-emetics following methoxyflurane anaesthesia.
Topics: Adult; Anesthesia, Inhalation; Antiemetics; Benzamides; Clinical Trials as Topic; Double-Blind Metho | 1968 |
191 other studies available for metoclopramide and Nausea
| Article | Year |
|---|---|
Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis.
Topics: Animals; Antiemetics; Benzamides; Catalepsy; Chemical Phenomena; Chemistry; Cisplatin; Dogs; Dopamin | 1988 |
Area postrema syndrome caused by medullary infarction.
Topics: Area Postrema; Female; Humans; Infarction; Metoclopramide; Nausea; Ondansetron; Syndrome; Vomiting | 2022 |
Peripheral N-methyl-D-aspartate receptor activation contributes to monosodium glutamate-induced headache but not nausea behaviours in rats.
Topics: Amino Acids; Animals; Aspartic Acid; Female; Glutamic Acid; Headache; Kynurenic Acid; Male; Metoclop | 2022 |
Reply to: Olanzapine: Sancho Panza for clinicians who care for patients with advanced cancer.
Topics: Antiemetics; Humans; Male; Metoclopramide; Nausea; Neoplasms; Olanzapine; Vomiting | 2020 |
Olanzapine versus Metoclopramide for Treatment of Nausea and Vomiting in Advanced Cancer Patients with Incomplete Malignant Bowel Obstruction.
Topics: Antiemetics; Double-Blind Method; Humans; Metoclopramide; Nausea; Neoplasms; Olanzapine; Vomiting | 2020 |
Pregnancy outcome following in-utero exposure to ondansetron: A prospective comparative observational study.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Antiemetics; Child; Child, Preschool; Female; Heart | 2021 |
Comparison of efficacy dimenhydrinate and metoclopramide in the treatment of nausea due to vertigo; a randomized study.
Topics: Adolescent; Adult; Aged; Antiemetics; Dimenhydrinate; Double-Blind Method; Emergency Service, Hospit | 2021 |
Controversies in Gastroparesis: Discussing the Sticky Points.
Topics: Abdominal Pain; Antiemetics; Chronic Disease; Diabetes Complications; Diagnosis, Differential; Diagn | 2021 |
Metoclopramide induced pheochromocytoma crisis.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Adult; Antiemetics; Emergency Medical Services; Female; Head | 2018 |
The Management of Nausea at the End of Life.
Topics: Analgesics, Opioid; Antiemetics; Antineoplastic Agents; Humans; Metoclopramide; Nausea; Serotonin An | 2018 |
The nature of nausea: prevalence, etiology, and treatment in patients with advanced cancer not receiving antineoplastic treatment.
Topics: Adrenal Cortex Hormones; Adult; Age Factors; Aged; Aged, 80 and over; Antiemetics; Female; Humans; M | 2019 |
Prophylactic use of antiemetics for prevention of opioid-induced nausea and vomiting: a survey about Italian physicians' practice.
Topics: Adrenal Cortex Hormones; Adult; Analgesics, Opioid; Antiemetics; Antipsychotic Agents; Cross-Section | 2019 |
Women's perspectives on the management and consequences of hyperemesis gravidarum - a descriptive interview study.
Topics: Abortion, Induced; Activities of Daily Living; Adult; Antiemetics; Attitude; Cross-Sectional Studies | 2019 |
New evidence for concern over the risk of birth defects from medications for nausea and vomitting of pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Antiemetics; Cohort Studies; Dicyclomine; Doxylamine; Drug Combi | 2019 |
Suppression of lithium chloride-induced conditioned gaping (a model of nausea-induced behaviour) in rats (using the taste reactivity test) with metoclopramide is enhanced by cannabidiolic acid.
Topics: Animals; Antiemetics; Cannabinoids; Conditioning, Psychological; Lithium Chloride; Male; Metoclopram | 2013 |
Formulation and evaluation of metoclopramide solid lipid nanoparticles for rectal suppository.
Topics: Administration, Rectal; Animals; Antiemetics; Delayed-Action Preparations; Dopamine Antagonists; Dru | 2013 |
Cost-effectiveness analysis of granisetron-based versus standard antiemetic regimens in low-emetogenic chemotherapy: a hospital-based perspective from Malaysia.
Topics: Antiemetics; Antineoplastic Agents; Cost-Benefit Analysis; Dexamethasone; Drug Therapy, Combination; | 2013 |
Drug treatment of adults with nausea and vomiting in primary care.
Topics: Adult; Antiemetics; Domperidone; Droperidol; Female; Histamine Antagonists; Humans; Male; Metoclopra | 2014 |
Prescribing for nausea in palliative care: a cross-sectional national survey of Australian palliative medicine doctors.
Topics: Adult; Antiemetics; Australia; Cross-Sectional Studies; Female; Haloperidol; Humans; Male; Metoclopr | 2014 |
Neither ondansetron nor metoclopramide reduced nausea and vomiting in the emergency department.
Topics: Antiemetics; Emergency Service, Hospital; Female; Humans; Male; Metoclopramide; Nausea; Ondansetron; | 2014 |
Metoclopramide-induced facial and palatopharyngeal myoclonus.
Topics: Antiemetics; Facial Muscles; Female; Humans; Metoclopramide; Middle Aged; Myoclonus; Nausea; Palatal | 2015 |
Prophylactic Use of Antiemetics for Prevention of Opioid-Induced Nausea and Vomiting: A Questionnaire Survey among Japanese Physicians.
Topics: Analgesics, Opioid; Antiemetics; Benzodiazepines; Chemoprevention; Domperidone; Health Care Surveys; | 2015 |
[Phytotherapy for control of nausea and vomiting].
Topics: Drug Recalls; Drug Substitution; Humans; Metoclopramide; Nausea; Phytotherapy; Plant Extracts; Plant | 2015 |
Preventing and alleviating patients' symptoms of nausea and vomiting while in the care of the ambulance service - a qualitative study.
Topics: Ambulances; Antiemetics; Emergency Medical Services; Female; Humans; Male; Metoclopramide; Nausea; O | 2016 |
Delayed nausea and vomiting from carboplatin doublet chemotherapy.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Lora | 2016 |
Oligoantiemesis or Inadequate Prescription of Antiemetics in the Emergency Department: A Local and National Perspective.
Topics: Adult; Antiemetics; Emergency Service, Hospital; Female; Humans; Logistic Models; Male; Metocloprami | 2016 |
Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer.
Topics: Adult; Aged; Antiemetics; Benzimidazoles; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Female; F | 2009 |
The safety of metoclopramide use in the first trimester of pregnancy.
Topics: Abnormalities, Drug-Induced; Antiemetics; Cohort Studies; Female; Fetus; Humans; Infant, Low Birth W | 2009 |
Circulatory collapse in a patient with gastrinoma after metoclopramide administration.
Topics: Adolescent; Dopamine Antagonists; Gastrinoma; Humans; Male; Metoclopramide; Nausea; Pancreatic Neopl | 2009 |
Nausea and vomiting in advanced cancer.
Topics: Algorithms; Antiemetics; Causality; Decision Trees; Drug Therapy, Combination; Evidence-Based Medici | 2010 |
Use of antiemetics in the management of chemotherapy-related nausea and vomiting in current UK practice.
Topics: Antiemetics; Antineoplastic Agents; Dexamethasone; Dopamine Antagonists; Health Care Surveys; Humans | 2011 |
Treatment and assessment of emergency department nausea and vomiting in Australasia: a survey of anti-emetic management.
Topics: Antiemetics; Australia; Clinical Protocols; Cross-Sectional Studies; Dopamine Antagonists; Emergency | 2011 |
Treatment of severe nausea and vomiting of pregnancy with subcutaneous medications.
Topics: Adolescent; Adult; Antiemetics; Female; Home Infusion Therapy; Humans; Infusions, Subcutaneous; Meto | 2011 |
Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Casse | 2011 |
Strategic pain management: the identification and development of the IAHPC opioid essential prescription package.
Topics: Analgesics, Opioid; Antiemetics; Clinical Protocols; Constipation; Delphi Technique; Dioctyl Sulfosu | 2012 |
[Acute respiratory failure after metoclopramide for methemoglobinemia - a rare and potentially life-threatening side effect].
Topics: Aged, 80 and over; Antiemetics; Female; Humans; Methemoglobinemia; Metoclopramide; Nausea; Respirato | 2012 |
Impact of data by Fujii and colleagues on the meta-analysis of metoclopramide for antiemetic prophylaxis in women undergoing Caesarean delivery under neuraxial anaesthesia.
Topics: Anesthesia, Obstetrical; Anesthesia, Spinal; Antiemetics; Cesarean Section; Female; Humans; Intraope | 2012 |
Is there an association between PONV and chemotherapy-induced nausea and vomiting?
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Betamethasone; Breast Neoplasms; | 2013 |
Alternatives to rehydration during hypodermoclysis.
Topics: Analgesics, Opioid; Fluid Therapy; Humans; Infusions, Parenteral; Metoclopramide; Nausea; Pain; Pall | 2002 |
Strategies in the treatment of migraine.
Topics: Analgesics; Antiemetics; Aspirin; Complementary Therapies; Humans; Lysine; Metoclopramide; Migraine | 2002 |
Metoclopramide for nausea and vomiting of pregnancy: a prospective multicenter international study.
Topics: Adolescent; Adult; Antiemetics; Brazil; Canada; Case-Control Studies; Congenital Abnormalities; Dopa | 2002 |
Low incidence of nausea and vomiting with intravenous opiate analgesia in the ED.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Antiemetics; Double-Blind Method; Em | 2002 |
[With evidence-based phytotherapy. Takes away gastric and intestinal irritation].
Topics: Antiemetics; Cisapride; Clinical Trials as Topic; Dopamine Antagonists; Evidence-Based Medicine; Gas | 2003 |
Challenges in palliative care research: one experience.
Topics: Antiemetics; Attitude of Health Personnel; Diphenhydramine; Drug Combinations; Ethics Committees, Re | 2004 |
Efficacy of intravenous diphenhydramine versus intravenous DHE-45 in the treatment of severe migraine headache.
Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Antiemetics; Dihydroergotamine; Diphenhydramine; | 2005 |
[Effect of steroid on antiemetic for side effect of anticancer chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dexamethasone; Drug Administration S | 2005 |
Unsteady, unfocused, and unable to hear.
Topics: Adolescent; Cognition Disorders; Combined Modality Therapy; Female; Fluid Therapy; Gait Disorders, N | 2005 |
Tolerability of the compound ABHR in hospice patients.
Topics: Aged; Antiemetics; Cohort Studies; Diphenhydramine; Drug Combinations; Female; Haloperidol; Hospice | 2005 |
[Relationship between neurotransmitter blood noradrenalin and nausea/emesis after chemotherapy for lung cancer].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Catecholamines; Cisplatin; Docetaxel; D | 2006 |
Antiemetics in the ED: a randomized controlled trial comparing 3 common agents.
Topics: Antiemetics; Droperidol; Emergency Service, Hospital; Humans; Metoclopramide; Nausea; Prochlorperazi | 2006 |
Anaphylaxis during treatment of nausea and vomiting: IgE-mediated metoclopramide allergy.
Topics: Adult; Anaphylaxis; Diagnosis, Differential; Drug Hypersensitivity; Female; Humans; Immunoglobulin E | 2006 |
A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis.
Topics: Adolescent; Antiemetics; Diphenhydramine; Dopamine Antagonists; Dystonia; Female; Fundoplication; Hi | 2006 |
Persistent generalized anxiety after brief exposure to the dopamine antagonist metoclopramide.
Topics: Adult; Agoraphobia; Antiemetics; Dopamine Antagonists; Female; Gastrointestinal Diseases; Humans; Me | 2007 |
Metoclopramide: extrapyramidal symptoms in children.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Child; Humans; Metoclopramide; Nausea; Netherlands; Vo | 2007 |
Pain and nausea in malignant pheochromocytoma: a pharmacological minefield.
Topics: Adrenal Gland Neoplasms; Analgesics, Opioid; Antiemetics; Fatal Outcome; Female; Humans; Lymphatic M | 2008 |
Management of chemotherapy-induced nausea and emesis.
Topics: Adrenal Cortex Hormones; Antiemetics; Antineoplastic Agents; Butyrophenones; Cannabinoids; Histamine | 1983 |
[Phase I study of alizapride in cancer patients treated with cisplatin].
Topics: Adult; Aged; Antiemetics; Cisplatin; Drug Evaluation; Female; Humans; Hypotension, Orthostatic; Male | 1983 |
An initial evaluation of Nabilone in the control of radiotherapy-induced nausea and vomiting.
Topics: Adult; Antiemetics; Dronabinol; Female; Humans; Male; Metoclopramide; Middle Aged; Nausea; Radiother | 1984 |
Randomized crossover study of the antiemetic activity of levonantradol and metoclopramide in cancer patients receiving chemotherapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Drug Therapy, Combination; Female; Huma | 1984 |
[A new solution for orthograde intestinal lavage].
Topics: Colonic Diseases; Humans; Intubation, Gastrointestinal; Metoclopramide; Nausea; Polyethylene Glycols | 1984 |
Control of cancer chemotherapy-induced nausea and vomiting.
Topics: Antineoplastic Agents; Butyrophenones; Cannabinoids; Drug Therapy, Combination; Glucocorticoids; Hum | 1984 |
Prolonged metoclopramide-induced dyskinetic reaction.
Topics: Acute Disease; Adult; Benztropine; Female; Humans; Metoclopramide; Movement Disorders; Nausea; Time | 1984 |
Metoclopramide in chemotherapy-induced nausea and vomiting.
Topics: Adult; Cisplatin; Female; Humans; Metoclopramide; Nausea | 1984 |
Effective control of chemotherapy-induced nausea and vomiting with oral prednisone and metoclopramide.
Topics: Administration, Oral; Adult; Cisplatin; Dose-Response Relationship, Drug; Drug Therapy, Combination; | 1984 |
Comparison of methylprednisolone and metoclopramide in the prophylactic treatment of cis-platin-induced nausea and vomiting.
Topics: Adult; Aged; Cisplatin; Drug Evaluation; Female; Humans; Male; Methylprednisolone; Metoclopramide; M | 1984 |
[Gastrointestinal disturbance by cancer chemotherapy--recent progress in antiemetic regimens].
Topics: Adult; Aged; Animals; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Domper | 1984 |
Cyclophosphamide, methotrexate, and 5-FU (CMF)-induced nausea and vomiting: a controlled study with high-dose metoclopramide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 1984 |
Metoclopramide: a brief review.
Topics: Drug Interactions; Humans; Metoclopramide; Nausea; Vomiting | 1983 |
Metoclopramide therapy for chemotherapy -- induced nausea and vomiting.
Topics: Antineoplastic Agents; Humans; Metoclopramide; Nausea; Vomiting | 1983 |
Continuous infusion of high-dose metoclopramide for the prevention of nausea and vomiting in patients receiving cancer chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Infusions, Parenteral; Male; Metoclopramide; Mid | 1983 |
High dose metoclopramide-preliminary pharmacokinetic studies.
Topics: Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Humans; Kinetics; Metoclopramide; Mid | 1983 |
Metoclopramide.
Topics: Animals; Atropine; Cat Diseases; Cats; Central Nervous System; Digestive System; Dog Diseases; Dogs; | 1983 |
Metoclopramide. A review of antiemetic trials.
Topics: Antiemetics; Cisplatin; Humans; Metoclopramide; Nausea | 1983 |
Oral metoclopramide and cisplatin chemotherapy.
Topics: Administration, Oral; Cisplatin; Female; Humans; Male; Metoclopramide; Middle Aged; Nausea | 1983 |
Side effects of metoclopramide as an antiemetic in childhood cancer chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Dystonia; Female; Humans; Male; Metoclopramide; Nau | 1984 |
Intravenous metoclopramide: prevention of chemotherapy-induced nausea and vomiting. A preliminary evaluation.
Topics: Antineoplastic Agents; Diarrhea; Drug Administration Schedule; Drug Evaluation; Humans; Infusions, P | 1984 |
Gastric emptying in patients with diabetes mellitus.
Topics: Adult; Diabetes Mellitus, Type 1; Female; Food; Gastric Emptying; Humans; Male; Metoclopramide; Midd | 1984 |
Chronic intestinal pseudo-obstruction.
Topics: Adult; Aged; Celiac Disease; Chronic Disease; Female; Humans; Intestinal Obstruction; Intestinal Pse | 1981 |
High dose metoclopramide as an antiemetic for patients receiving chemotherapy with cis-platinum.
Topics: Adult; Cisplatin; Drug Evaluation; Humans; Metoclopramide; Nausea; Neoplasms; Vomiting | 1982 |
High-dose metoclopramide in cancer chemotherapy-induced nausea and vomiting.
Topics: Antineoplastic Agents; Female; Humans; Male; Metoclopramide; Middle Aged; Nausea; Vomiting | 1982 |
[High dose metoclopramide during cancer chemotherapy. Phase II study in 80 consecutive patients].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Drug Evaluation; Drug Therapy, Combination; Female; | 1982 |
Metoclopramide as an antiemetic.
Topics: Antiemetics; Cisplatin; Humans; Metoclopramide; Nausea | 1981 |
A comparison of droperidol and metoclopramide in the treatment of nausea and vomiting during cis-platinum polichemotherapy in ovarian carcinoma.
Topics: Antineoplastic Agents; Cisplatin; Droperidol; Drug Therapy, Combination; Female; Humans; Metoclopram | 1981 |
High-dose metoclopramide for chemotherapy-induced nausea and vomiting.
Topics: Antineoplastic Agents; Humans; Metoclopramide; Nausea; Vomiting | 1981 |
A double blind study of metoclopramide in the treatment of migraine attacks.
Topics: Acetaminophen; Adolescent; Adult; Aged; Diazepam; Double-Blind Method; Drug Therapy, Combination; Fe | 1980 |
Interim analyses in 2 x 2 crossover trials.
Topics: Antiemetics; Antineoplastic Agents; Biometry; Clinical Trials as Topic; Cross-Over Studies; Humans; | 1995 |
Cost-effectiveness analysis of antiemetic therapy for ambulatory surgery.
Topics: Ambulatory Surgical Procedures; Antiemetics; Cost-Benefit Analysis; Costs and Cost Analysis; Droperi | 1995 |
Nausea and vomiting in fractionated radiotherapy: a prospective on-demand trial of tropisetron rescue for non-responders to metoclopramide.
Topics: Abdominal Neoplasms; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Child; Female; Humans; | 1995 |
On the relationship between nausea and vomiting in patients undergoing chemotherapy. Italian Group for Antiemetic Research.
Topics: Antiemetics; Cisplatin; Confounding Factors, Epidemiologic; Dexamethasone; Diphenhydramine; Factor A | 1994 |
Effective control of cisplatin induced emesis by combination drug regimen.
Topics: Adult; Cisplatin; Dexamethasone; Drug Administration Schedule; Drug Combinations; Female; Follow-Up | 1994 |
Pharmacoeconomic analyses: whose perspective counts and costs the most?
Topics: Adult; Cisplatin; Cost-Benefit Analysis; Decision Trees; Drug Evaluation; Humans; Metoclopramide; Na | 1994 |
Cost-effectiveness, not cost containment.
Topics: Cisplatin; Cost Control; Cost-Benefit Analysis; Drug Evaluation; Humans; Metoclopramide; Nausea; Ond | 1994 |
TCDD-induced hypophagia is not explained by nausea.
Topics: Animals; Antiemetics; Benzamides; Body Weight; Eating; Energy Metabolism; Female; Kaolin; Male; Meto | 1994 |
Antiemetic-induced akathisia in cancer patients receiving chemotherapy.
Topics: Akathisia, Drug-Induced; Antineoplastic Agents; Drug Therapy, Combination; Female; Humans; Male; Met | 1994 |
Ondansetron versus metoclopramide and droperidol: an unfair comparison.
Topics: Anesthesiology; Droperidol; Humans; Metoclopramide; Nausea; Ondansetron; Postoperative Complications | 1993 |
[Postoperative anti-emetic effects of low dose droperidol].
Topics: Adult; Droperidol; Female; Genital Diseases, Female; Humans; Metoclopramide; Middle Aged; Nausea; Po | 1993 |
Treatment of migraine headache after ocular surgery with intravenous metoclopramide hydrochloride.
Topics: Adult; Cataract Extraction; Dopamine Antagonists; Female; Humans; Injections, Intravenous; Lenses, I | 1996 |
Design considerations in crossover trials with a single interim analysis and serial patient entry.
Topics: Antineoplastic Agents; Biometry; Clinical Trials as Topic; Cross-Over Studies; Humans; Linear Models | 1996 |
Menstrual stage influences postoperative nausea and vomiting following epidural buprenorphine.
Topics: Adult; Analgesia, Epidural; Analgesics, Opioid; Anesthesia, Epidural; Anesthetics, Local; Antiemetic | 1996 |
Controlling the toxicity of palliative radiotherapy: the role of 5-HT3 antagonists.
Topics: Antiemetics; Clinical Trials as Topic; Dopamine Antagonists; Humans; Metoclopramide; Nausea; Neoplas | 1996 |
Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Epirubicin; Female; Hu | 1996 |
Prophylactic antiemetics for laparoscopic cholecystectomy: ondansetron versus droperidol plus metoclopramide.
Topics: Antiemetics; Cholecystectomy, Laparoscopic; Droperidol; Drug Therapy, Combination; Humans; Metoclopr | 1997 |
Comparison of intravenous granisetron with metoclopramide plus dexamethasone in the prevention of nausea and vomiting associated with emetogenic cytotoxic chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Dexamethasone; Female; Granisetron; Humans; Injections, Intraven | 1997 |
Re: Metoclopramide for chronic nausea.
Topics: Antiemetics; Humans; Metoclopramide; Nausea; Neoplasms | 1997 |
Re: Metoclopramide for chronic nausea.
Topics: Antiemetics; Chronic Disease; Humans; Metoclopramide; Nausea | 1997 |
Influence of metoclopramide on the pharmacokinetics of 8-methoxypsoralen.
Topics: Administration, Oral; Adult; Age Factors; Antiemetics; Area Under Curve; Biological Availability; Ch | 1997 |
Correct choice of anti-emetic.
Topics: Antiemetics; Humans; Metoclopramide; Nausea; Ondansetron; Postoperative Complications; Vomiting | 1997 |
Ondansetron compared with metoclopramide in the treatment of PONV.
Topics: Antiemetics; Drug Therapy, Combination; Humans; Metoclopramide; Nausea; Ondansetron; Postoperative C | 1998 |
Respiratory failure following oral administration of metoclopramide.
Topics: Administration, Oral; Adult; Antiemetics; Female; Humans; Metoclopramide; Nausea; Respiratory Insuff | 1998 |
Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy.
Topics: Chemotherapy, Adjuvant; Cisplatin; Costs and Cost Analysis; Dexamethasone; Diphenhydramine; Dose-Res | 1994 |
Radiation-induced emesis: a prospective observational multicenter Italian trial. The Italian Group for Antiemetic Research in Radiotherapy.
Topics: Adult; Antiemetics; Domperidone; Drug Administration Schedule; Female; Humans; Incidence; Indoles; M | 1999 |
Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer.
Topics: Antiemetics; Antineoplastic Agents; Breast Neoplasms; Canada; Cost-Benefit Analysis; Humans; Metoclo | 1999 |
Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Italian Group for Antiemetic Research.
Topics: Adult; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combination; Huma | 2000 |
Ondansetron rather than metoclopramide for bupropion-induced nausea.
Topics: Adult; Antiemetics; Bupropion; Depressive Disorder; Drug Interactions; Female; Humans; Metoclopramid | 2001 |
Laryngeal dystonia in psychiatry.
Topics: Adolescent; Benztropine; Dopamine Agonists; Dopamine Antagonists; Dystonia; Female; Humans; Laryngea | 2001 |
Pre-emptive metoclopramide and ondansetron for nausea and vomiting associated with iloprost infusions.
Topics: Aged; Antiemetics; Humans; Iloprost; Infusions, Intravenous; Male; Metoclopramide; Nausea; Ondansetr | 2001 |
Metoclopramide-related pisa syndrome in clozapine treatment.
Topics: Clozapine; Dopamine Antagonists; Dyskinesia, Drug-Induced; Female; Humans; Metoclopramide; Middle Ag | 2001 |
Acute dystonia due to metoclopramide: increased risk in AIDS.
Topics: Abdominal Pain; Acquired Immunodeficiency Syndrome; Acute Disease; Adult; Antiemetics; Dystonia; Fol | 2002 |
[Severe parkinsonism due to metoclopramide in a patient with polypharmacy].
Topics: Aged; Antiemetics; Antitubercular Agents; Dopamine Antagonists; Dose-Response Relationship, Drug; Fe | 2002 |
[Cervical dystonia].
Topics: Antiemetics; Child; Humans; Male; Metoclopramide; Nausea; Torticollis | 1999 |
An analysis of the antiemetic protection of metoclopramide plus dexamethasone in Chinese patients receiving moderately high emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; China; Cyclophosphamide; Dexamet | 2002 |
Diseases of the alimentary system; Nausea and vomiting.
Topics: Antiemetics; Female; Histamine H1 Antagonists; Humans; Metoclopramide; Motion Sickness; Nausea; Phen | 1976 |
[Cytostatic treatment and nausea-suppressing agents].
Topics: Antiemetics; Antineoplastic Agents; Humans; Metoclopramide; Nausea; Neoplasms; Prochlorperazine | 1979 |
Tardive dyskinesia associated with metoclopramide.
Topics: Dyskinesia, Drug-Induced; Humans; Male; Metoclopramide; Middle Aged; Nausea; Substance Withdrawal Sy | 1978 |
Effect of l-5-hydroxytryptophan on brain monoamine metabolism and evaluation of its clinical effect in depressed patients.
Topics: 5-Hydroxytryptophan; Adjustment Disorders; Adult; Aged; Blood Platelets; Brain; Depression; Female; | 1975 |
[L-dopa-decarboxylase inhibitor combination preparation (Sinemet) in parkinsonism and syndromes imitating parkinsonism. 1 year's experience with 34 patients].
Topics: Aged; Drug Combinations; Female; Humans; Levodopa; Male; Metoclopramide; Middle Aged; Nausea; Parkin | 1976 |
Diphenhydramine for nausea and vomiting related to cancer chemotherapy with cisplatin.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Diphenhydramine; Drug Therapy, Combination; Female; Humans; M | 1992 |
Control of cisplatin induced emesis--a multidisciplinary intervention strategy.
Topics: Adult; Aged; Biperiden; Cisplatin; Female; Humans; Lorazepam; Metoclopramide; Middle Aged; Nausea; O | 1992 |
Continuous versus intermittent infusion of high-dose metoclopramide in prevention of cisplatin-induced emesis.
Topics: Cisplatin; Drug Administration Schedule; Humans; Metoclopramide; Nausea | 1992 |
Ondansetron is not associated with vascular adverse events, thrombocytopenia or renal failure.
Topics: Acute Kidney Injury; Cisplatin; Humans; Metoclopramide; Nausea; Neoplasms; Ondansetron; Thrombocytop | 1992 |
Postoperative nausea and vomiting in day-case surgery.
Topics: Ambulatory Surgical Procedures; Child; Droperidol; Female; Humans; Male; Metoclopramide; Nausea; Pos | 1992 |
Low dose ondansetron and dexamethasone: a cost effective alternative to high dose metoclopramide/dexamethasone/lorazepam in the prevention of acute cisplatin induced emesis.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Cost-Benefit Analysis; Dexamethasone; Female | 1992 |
Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy.
Topics: Adenocarcinoma; Antiemetics; Female; Humans; Metoclopramide; Middle Aged; Nausea; Neuroleptic Malign | 1992 |
Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer.
Topics: Adenocarcinoma; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Betamethas | 1991 |
Acute and delayed emesis after cisplatin-based regimen: description and prevention.
Topics: Acute Disease; Antiemetics; Cisplatin; Dexamethasone; Dose-Response Relationship, Drug; Humans; Lora | 1991 |
Antiemetic efficacy of alprazolam in carboplatin-induced emesis.
Topics: Administration, Oral; Aged; Alprazolam; Carboplatin; Drug Therapy, Combination; Female; Humans; Infu | 1991 |
Compounding nausea aid.
Topics: Benztropine; Chemistry, Pharmaceutical; Dexamethasone; Diphenhydramine; Drug Combinations; Drug Comp | 1991 |
Antiemetic suppositories.
Topics: Administration, Rectal; Dexamethasone; Diphenhydramine; Drug Combinations; Humans; Metoclopramide; N | 1991 |
[Treatment of nausea and vomiting induced by a 24-hour i.v. infusion of cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Drug Therapy, Combination; | 1990 |
[A combined anti-emesis therapy of oral prednisolone and alprazolam for cisplatin-induced delayed emesis].
Topics: Administration, Oral; Adult; Aged; Alprazolam; Antineoplastic Combined Chemotherapy Protocols; Carci | 1990 |
A pilot study of metoclopramide, dexamethasone, diphenhydramine and lorazepam in prevention of nausea and vomiting in cisplatin-treated male patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Diphenhydramine; Drug Eval | 1990 |
A nursing narrative.
Topics: Acute Disease; Adult; Humans; Male; Metoclopramide; Nausea; Pancreatitis; Seizures; Vomiting | 1990 |
Patient-controlled antiemesis for cancer chemotherapy-induced nausea and vomiting.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Agents; Droperidol; Evaluation Studies as Topic; Huma | 1990 |
[Trial with a new anti-nausea regime].
Topics: Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Humans; Metoclopramide | 1990 |
Metoclopramide and exercise-induced nausea.
Topics: Adult; Exercise; Humans; Male; Metoclopramide; Nausea | 1990 |
Avoidance of metoclopramide for the treatment of clozapine-induced nausea.
Topics: Clozapine; Dibenzazepines; Dyskinesia, Drug-Induced; Humans; Metoclopramide; Nausea; Parkinson Disea | 1990 |
[Clinical study of chemotherapy (PPM therapy) with cisplatin, peplomycin and mitomycin C in squamous cell lung cancer].
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcin | 1986 |
Suitability of long-acting metoclopramide for prophylaxis of chemotherapy-induced delayed nausea and vomiting.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Humans; Metoclopramide; Nausea; Neoplas | 1989 |
Neuroleptic malignant syndrome in a child treated with metoclopramide for chemotherapy-related nausea.
Topics: Child, Preschool; Humans; Male; Metoclopramide; Nausea; Neuroleptic Malignant Syndrome | 1989 |
[The antiemetic effect and clinical evaluation of metoclopramide alone and combined with betamethasone in children with malignant tumor].
Topics: Adolescent; Adrenal Cortex; Antineoplastic Agents; Betamethasone; Child; Child, Preschool; Drug Eval | 1989 |
Hormonal responses of metoclopramide-treated subjects experiencing nausea or emesis during parabolic flight.
Topics: Adrenocorticotropic Hormone; Adult; Arginine Vasopressin; Epinephrine; Humans; Metoclopramide; Motio | 1987 |
Nabilone and other antiemetics for cancer patients.
Topics: Antiemetics; Antineoplastic Agents; Butyrophenones; Dronabinol; Drug Therapy, Combination; Glucocort | 1988 |
Extrapyramidal symptoms in AIDS patients given low-dose metoclopramide or chlorpromazine.
Topics: Acquired Immunodeficiency Syndrome; Basal Ganglia Diseases; Chlorpromazine; Drug Administration Sche | 1985 |
Treatment of common minor ailments.
Topics: Acetaminophen; Antacids; Antiemetics; Aspirin; Dyspepsia; Female; Heartburn; Histamine H1 Antagonist | 1986 |
Domperidone: an alternative to metoclopramide.
Topics: Acute Disease; Adolescent; Adult; Child; Domperidone; Humans; Metoclopramide; Nausea; Vomiting | 1988 |
Continuous subcutaneous infusion: flexible option in symptom control.
Topics: Anxiety; Female; Haloperidol; Humans; Infusion Pumps; Infusions, Parenteral; Metoclopramide; Middle | 1988 |
Population analysis of the pharmacokinetic variability of high-dose metoclopramide in cancer patients.
Topics: Antineoplastic Agents; Humans; Metoclopramide; Nausea; Neoplasms; Software | 1988 |
Continuous subcutaneous (CS) infusion of metoclopramide (MCP) using a plastic disposable infusor for the treatment of chemotherapy-induced emesis.
Topics: Adult; Antineoplastic Agents; Disposable Equipment; Female; Humans; Infusion Pumps; Infusions, Paren | 1988 |
Silent regurgitation in day case gynaecological patients.
Topics: Adult; Ambulatory Surgical Procedures; Female; Gastroesophageal Reflux; Genital Diseases, Female; Hu | 1988 |
Oral metoclopramide with or without diphenhydramine: potential for prevention of late nausea and vomiting induced by cisplatin.
Topics: Adolescent; Adult; Age Factors; Aged; Cisplatin; Diphenhydramine; Female; Humans; Male; Metocloprami | 1988 |
Combination of glucagon and low-dose metoclopramide in management of cisplatin-induced nausea and vomiting.
Topics: Cisplatin; Drug Therapy, Combination; Glucagon; Humans; Metoclopramide; Nausea; Vomiting | 1988 |
Effects of preoperative metoclopramide and droperidol on postoperative nausea and vomiting in ambulatory surgery patients.
Topics: Adult; Ambulatory Surgical Procedures; Droperidol; Female; Humans; Metoclopramide; Nausea; Postopera | 1988 |
[The prevention of CDDP-induced emesis with a combination regimen including metoclopramide, dexamethasone, droperidol and diphenhydramine].
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dex | 1987 |
[Dyskinetic syndrome following the use of metoclopramide].
Topics: Adolescent; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Feeding and Eating Disorders | 1986 |
Safety and antiemetic effects of metoclopramide in metrizamide myelography.
Topics: Adult; Double-Blind Method; Female; Humans; Male; Metoclopramide; Metrizamide; Myelography; Nausea; | 1987 |
Administration of metoclopramide for prevention of nausea and vomiting during epidural anesthesia for elective cesarean section.
Topics: Anesthesia, Epidural; Cesarean Section; Female; Fentanyl; Gestational Age; Humans; Metoclopramide; M | 1987 |
Evaluation of ethanol as an antiemetic in patients receiving cisplatin.
Topics: Cisplatin; Ethanol; Female; Humans; Infusions, Intravenous; Male; Metoclopramide; Nausea; Neoplasms; | 1987 |
High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplati | 1987 |
Metoclopramide-induced neuroleptic malignant syndrome.
Topics: Adult; Diabetes Mellitus, Type 1; Female; Humans; Metoclopramide; Nausea; Neuroleptic Malignant Synd | 1987 |
Antiemetic effects of metoclopramide (M) continuous infusion (CI): safety, efficacy, patient preference, and cost reduction.
Topics: Cisplatin; Humans; Infusions, Intravenous; Metoclopramide; Nausea; Neoplasms; Vomiting | 1987 |
Metoclopramide infusion with a disposable portable pump.
Topics: Humans; Infusions, Parenteral; Metoclopramide; Nausea | 1986 |
Metoclopramide administration in advanced liver disease.
Topics: Dyskinesia, Drug-Induced; Hepatic Encephalopathy; Humans; Liver Diseases; Metoclopramide; Nausea | 1986 |
Maintenance of antiemetic effect of a metoclopramide-dexamethasone combination during subsequent cisplatin courses.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Drug Combinations; Female; Humans; Male; Metoclopramide; Midd | 1986 |
[Experimental study on the control of cisplatin-induced emesis in dogs].
Topics: Analysis of Variance; Animals; Cisplatin; Dogs; Metoclopramide; Nausea; Vagotomy; Vomiting | 1987 |
Failure of metoclopramide to control emesis or nausea due to stressful angular or linear acceleration.
Topics: Acceleration; Adult; Coriolis Force; Humans; Metoclopramide; Motion Sickness; Nausea; Space Flight | 1987 |
Metoclopramide versus chlorpromazine in controlling nausea and vomiting induced by cytotoxic drugs.
Topics: Chlorpromazine; Humans; Metoclopramide; Nausea; Vomiting | 1985 |
Treatment of hyperprolactinemic amenorrhea with Metergoline.
Topics: Adenoma; Adult; Amenorrhea; Ergolines; Female; Humans; Hyperprolactinemia; Metergoline; Metocloprami | 1986 |
Metoclopramide-induced phantom dyskinesia.
Topics: Amputation, Surgical; Breast Neoplasms; Dyskinesia, Drug-Induced; Female; Humans; Mastectomy; Metocl | 1985 |
Metoclopramide: dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy.
Topics: Adolescent; Adult; Akathisia, Drug-Induced; Antineoplastic Agents; Basal Ganglia Diseases; Child; Di | 1985 |
[Cisplatin drug therapy. Antiemetic treatment. Experiences with the use of high-dose metoclopramide combined with chlopromazine and prochlorperazine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorpromazine; Cisplatin; Dose-Response Relat | 1985 |
Parkinsonism following i.v. administration of high-dose metoclopramide used as an antiemetic agent during cancer chemotherapy.
Topics: Abdominal Neoplasms; Adenocarcinoma; Aged; Cisplatin; Female; Humans; Metoclopramide; Nausea; Ovaria | 1985 |
Lack of antiemetic effect of high-dose metoclopramide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female; Humans; | 1985 |
High-dose metoclopramide in the treatment of cis-platinum induced emesis. A dose-finding study.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Genital Neoplasms, Fem | 1985 |
The relationship between steady state metoclopramide levels and control of emesis during treatment with cis-platinum.
Topics: Cisplatin; Humans; Kinetics; Metoclopramide; Nausea; Vomiting | 1985 |
Neuroleptic malignant syndrome associated with metoclopramide.
Topics: Humans; Male; Metoclopramide; Middle Aged; Nausea; Neuroleptic Malignant Syndrome | 1985 |
Letter: Pyridoxine contraindicated in parkinsonism.
Topics: Dihydroxyphenylalanine; Drug Antagonism; Humans; Metoclopramide; Nausea; Parkinson Disease; Pyridoxi | 1973 |
Triple tetracycline ('Deteclo') as a single dose oral treatment of uncomplicated gonorrhoea in the male.
Topics: Administration, Oral; Adolescent; Adult; Chlortetracycline; Demeclocycline; Diarrhea; Drug Combinati | 1973 |
Hyperthyroidism presenting with acute abdominal symptoms.
Topics: Abdomen, Acute; Adult; Antacids; Body Weight; Carbimazole; Colic; Diarrhea; Female; Goiter; Hemateme | 1974 |
Studies of drugs given before anaesthesia. XXIV: Metocloramide with morphine and pethidine.
Topics: Adult; Anxiety; Female; Humans; Infant, Newborn; Meperidine; Metoclopramide; Morphine; Nausea; Prean | 1974 |
The premedicant and anti-emetic action of metoclopramide.
Topics: Atropine; Diazepam; Female; Humans; Hypnotics and Sedatives; Meperidine; Metoclopramide; Nausea; Pre | 1973 |
The use of metoclopramide in the elderly.
Topics: Aged; Digitalis; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Geriatrics; Hiccup; Humans; | 1973 |